melarsoprol profile

Melarsoprol is an arsenic-containing drug used to treat the late-stage, neurological form of African trypanosomiasis (sleeping sickness) caused by Trypanosoma brucei gambiense. It is synthesized through a complex multi-step process involving the reaction of 4-amino-phenylarsonic acid with 3-hydroxypropanal in the presence of hydrochloric acid and sodium chloride. Melarsoprol exhibits trypanocidal activity by inhibiting the enzyme trypanothione reductase, which is essential for the survival of Trypanosoma brucei. The drug has been effective in treating late-stage sleeping sickness, but it can cause severe side effects, including encephalopathy, coma, and death. Due to its toxicity, melarsoprol is typically reserved for cases where other treatments have failed. The high toxicity of melarsoprol has led to research efforts aimed at developing safer and more effective trypanocidal drugs. Research on melarsoprol focuses on understanding its mechanism of action, developing safer analogs, and exploring potential alternative treatments for African trypanosomiasis.'

Melarsoprol: Arsenical used in trypanosomiases. It may cause fatal encephalopathy and other undesirable side effects. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	10311
CHEMBL ID	166
CHEBI ID	6729
SCHEMBL ID	61707
MeSH ID	M0013318

Synonym
chebi:6729 ,
CHEMBL166
melarsoprolum
unii-zf3786q2e8
zf3786q2e8 ,
1,3,2-dithiarsolane-4-methanol, 2-(4-((4,6-diamino-1,3,5-triazin-2-yl)amino)phenyl)-
2-(p-(4,6-diamino-s-triazin-2-ylamino)phenyl)-1,3,2-dithiarsolane-4-methanol
melarsoprol [inn:ban:dcf]
einecs 207-793-4
melarsoprolum [inn-latin]
rp 3854
2-[4-{(4,6-diamino-1,3,5-triazin-2-yl)amino}phenyl]-1,3,2-dithiarsolan-e-4-methanol
[2-[4-[(4,6-diamino-1,3,5-triazin-2-yl)amino]phenyl]-1,3,2-dithiarsolan-4-yl]methanol
494-79-1
melarsoprol
C08001
D00832
melarsoprol (inn)
mel b (tn)
arsobal
specia
rp-3854
mel b
SCHEMBL61707
DB12864
(2-{4-[(4,6-diamino-1,3,5-triazin-2-yl)amino]phenyl}-1,3,2-dithiarsolan-4-yl)methanol
DTXSID90862033
Q419753
(2-(4-((4,6-diamino-1,3,5-triazin-2-yl)amino)phenyl)-1,3,2-dithiarsolan-4-yl)methanol
melarsoprol [mart.]
melarsoprol [mi]
melarsoprol [who-dd]
melarsoprol [inn]
AKOS040752991

Excerpt	Reference	Relevance
"Melarsoprol (MEL) is an arsenic-containing drug, and has been applied in the treatment of human African trypanosomiasis at the late stage."	( Delivery of melarsoprol using folate-targeted PEGylated cyclodextrin-based nanoparticles for hepatocellular carcinoma. Guo, J; Han, S; Li, Y; Li, YN; O'Driscoll, CM; Shi, X; Shi, Y; Sun, D; Wang, L; Yang, L; Zou, Y, 2023)	2.01

Excerpt	Reference	Relevance
"Melarsoprol has been used for many decades."	( Cost-effectiveness analysis of alternative treatments of African gambiense trypanosomiasis in Uganda. Carrín, G; Cattand, PD; Evans, D; Kuzoe, FA; Politi, C, )	0.85

Excerpt	Reference	Relevance
"Melarsoprol treatment was undertaken."	( Polysomnography as a diagnosis and post-treatment follow-up tool in human African trypanosomiasis: a case study in an infant. Bandzouzi, B; Bouteille, B; Buguet, A; Cespuglio, R; Mpandzou, G; Ngampo, S; Vincendeau, P, 2011)	1.09
"Melarsoprol treatment was feared for its side effects."	( Drug toxicity and cost as barriers to community participation in HAT control in the Democratic Republic of Congo. Boelaert, M; Kande Betu Ku Mesu, V; Lefèvre, P; Lubanza, S; Lutumba, P; Robays, J; Van der Stuyft, P, 2007)	1.06
"Treatment with melarsoprol in two cases and eflornithine in one case led to complete recovery."	( [Sleeping sickness in children at Bobo-Dioulasso Hospital Center: apropos of 3 cases]. Bonkoungou, P; Millogo, A; Nacro, B; Sanou, M; Tall, F; Traoré, H; Traoré, S, 1999)	0.64

Excerpt	Reference	Relevance
"The authors consider evident similarities of toxic effects in the treatment of human african trypanosomiasis with Arsobal, and those in the treatment of syphilis with arsenobenzole derivatives."	( [Adrenaline in the prevention and treatment of adverse effects of arsobal therapy. Apropos of 776 cases of human African trypanosomiasis caused by T. gambiense in the Health Service of Fontem (U.R. Cameroon)]. Cramet, B; Sina, GC; Suh Bandu, M; Triolo, N, )	0.13
"2 and experienced significantly fewer cutaneous and neurological adverse effects than did patients who were treated with melarsoprol in 2001 and 2002 (n = 708)."	( Eflornithine is safer than melarsoprol for the treatment of second-stage Trypanosoma brucei gambiense human African trypanosomiasis. Bovier, PA; Chappuis, F; Meussen, A; Stietenroth, K; Udayraj, N, 2005)	0.83
"Less toxic drugs, lowering financial barriers and improving confidentiality would have considerable impact on the participation in population screening for HAT."	( Drug toxicity and cost as barriers to community participation in HAT control in the Democratic Republic of Congo. Boelaert, M; Kande Betu Ku Mesu, V; Lefèvre, P; Lubanza, S; Lutumba, P; Robays, J; Van der Stuyft, P, 2007)	0.34

Excerpt	Reference	Relevance
" The 'terminal' elimination rate constant could be determined in six patients and subsequent kinetic calculations showed a three to fourfold variation in plasma clearance and 'terminal' half-life (median 1126 (range 553-2036) ml min-1 and 265 (107-446) h, respectively)."	( Pharmacokinetics and adverse reactions after a single dose of pentamidine in patients with Trypanosoma gambiense sleeping sickness. Bronner, U; Doua, F; Ericsson, O; Gustafsson, LL; Miézan, T; Rais, M; Rombo, L, 1995)	0.29
" The results of this study are compared with recent pharmacokinetic data from human patients, and discussed in the context of the problem of relapses and reactive encephalopathy occurring after treatment of sleeping sickness."	( Pharmacokinetics of melarsoprol in uninfected vervet monkeys. Auma, JE; Brun, R; Burri, C; Burudi, EM; Onyango, JD, 1994)	0.61
" Mean terminal elimination half-life of melarsoprol was about 35 h, volume of distribution was about 100 l and total clearance was about 50 ml/min."	( Pharmacokinetic properties of the trypanocidal drug melarsoprol. Baltz, T; Brun, R; Burri, C; Doua, F; Giroud, C; Welker, HA, )	0.65
" As a large number of patients refractory to melarsoprol treatment was recently reported from northern Uganda and northern Angola, we investigated in northern Angola whether interpatient pharmacokinetic differences influence the outcome of melarsoprol treatment."	( Pharmacokinetic investigations in patients from northern Angola refractory to melarsoprol treatment. Burri, C; Keiser, J, 2001)	0.8

Excerpt	Reference	Relevance
" Susceptibility patterns of sensitive and resistant parasites were evaluated against calcium antagonists of several chemical classes (verapamil, cyproheptidine, desipramine and chlopromazine), alone and in combination with suramin, diminazene aceturate or melarsen oxide cyteamine."	( Trypanocidal resistance in Trypanosoma evansi in vitro: effects of verapamil, cyproheptidine, desipramine and chlorpromazine alone and in combination with trypanocides. Anene, BM; Anika, SM; Chukwu, CC; Ross, CA, 1996)	0.29
" This megazol gel, when used in combination with melarsoprol (3."	( Topical chemotherapy for experimental African trypanosomiasis with cerebral involvement: the use of melarsoprol combined with the 5-nitroimidazole, megazol. Chauvière, G; Jennings, FW; Murray, M; Viode, C, 1996)	0.76
" When these gels are used in combination with melarsoprol gel they are capable of curing experimental murine CNS-trypanosomiasis with a one-day treatment."	( Topical chemotherapy for experimental murine African CNS-trypanosomiasis: the successful use of the arsenical, melarsoprol, combined with the 5-nitroimidazoles, fexinidazole or MK-436. Atouguia, JM; Jennings, FW; Murray, M, 1996)	0.76

Excerpt	Reference	Relevance
" The aim of our work was to develop melarsoprol-cyclodextrin complexes in order to improve the tolerability and the bioavailability of melarsoprol."	( Melarsoprol-cyclodextrins inclusion complexes. Astier, A; Fries, I; Gibaud, S; Mutzenhardt, P; Zirar, SB, 2005)	2.05
" These complexes increase the oral bioavailability of melarsoprol making them effective orally and both curative and nontoxic in doses that are equivalent to those of intravenous melarsoprol."	( An alternative form of melarsoprol in sleeping sickness. Kennedy, PG, 2012)	0.94
" The 7-nitroquinoxalin-2-one and 5-nitroindazole scaffold derivatives 58 and 35, respectively, are particularly interesting because of their established oral bioavailability in mice."	( Discovery of nitroheterocycles active against African trypanosomes. In vitro screening and preliminary SAR studies. Arán, VJ; Dardonville, C; Kaiser, M, 2012)	0.38
" Our compound optimization that has led to synthesis of several potent 4-anilinoquinazolines, including NEU617, 23a, a highly potent, orally bioavailable inhibitor of trypanosome replication."	( Kinase scaffold repurposing for neglected disease drug discovery: discovery of an efficacious, lapatinib-derived lead compound for trypanosomiasis. Behera, R; Edwards, P; Guyett, PJ; Karver, CE; Mensa-Wilmot, K; Patel, G; Pollastri, MP; Roncal, NE; Sullenberger, C, 2013)	0.39

Excerpt	Relevance	Reference
" Optimum dosage and duration of therapy, modes of administration and potential for large scale use are discussed."	( Advances in sleeping sickness therapy. Van Nieuwenhove, S, 1992)	0.28
" A (donor) mouse, infected for 28 days, is dosed with a drug, or combination of drugs, and samples of blood, cerebral cortex, choroid plexus and lining of ventricle are injected into clean (recipient) mice."	( Screening compounds for sleeping sickness therapy without relapse. Ormerod, WE; Raseroka, BH, 1988)	0.27
" Two other goats appeared to be cured with this dosage of suramin but later developed abnormal central nervous system (CNS) signs and parasitaemia."	( Experimental infection of goats with Trypanosoma brucei ssp. and effects of treatment with suramin and Mel-B. Chumo, DA; Muriithi, RM; Mwangi, J; Reardon, MJ; Towett, S; Wellde, BT, 1989)	0.28
" The prolonged elimination of pentamidine seems inconsistent with the present recommended dosage regimen of pentamidine for treatment of trypanosomiasis of 7 to 10 parenteral doses given once daily or every second day."	( Pharmacokinetics and adverse reactions after a single dose of pentamidine in patients with Trypanosoma gambiense sleeping sickness. Bronner, U; Doua, F; Ericsson, O; Gustafsson, LL; Miézan, T; Rais, M; Rombo, L, 1995)	0.29
" The remaining animal in this group, that displayed persistent antigenaemia, had been treated with a sub-curative drug dosage level."	( Trypanosoma brucei rhodesiense: use of an antigen detection enzyme immunoassay for evaluation of response to chemotherapy in infected vervet monkeys (Cercopithecus aethiops). Gichuki, CW; Nantulya, VM; Sayer, PD, 1994)	0.29
" Dose-response experiments with melarsoprol (10(-7) to 10(-9) mol/L) were performed over 96 hours."	( Comparative activity of melarsoprol and arsenic trioxide in chronic B-cell leukemia lines. Gabrilove, JL; Jakubowski, A; König, A; Pandolfi, PP; Rivi, R; Warrell, RP; Wrazel, L, 1997)	0.89
" The higher frequency of relapses in 1994 to 1997 was associated with an incremental dosage regimen of melarsoprol."	( Trypanosomiasis relapse after melarsoprol therapy, Democratic Republic of Congo, 1982-2001. Mpia, B; Pépin, J, 2005)	0.83
" injections separated by 1-week intervals, but with graded dosing (1."	( Randomized controlled trial of three regimens of melarsoprol in the treatment of Trypanosoma brucei gambiense trypanosomiasis. Mpia, B; Pépin, J, 2006)	0.59
" rhodesiense in vivo, curing three of four infected mice dosed intraperitoneally at 5 mg/kg x 4 days."	( Synthesis and antiprotozoal activities of dicationic bis(phenoxymethyl)benzenes, bis(phenoxymethyl)naphthalenes, and bis(benzyloxy)naphthalenes. Bakunov, SA; Bakunova, SM; Barzcz, T; Brun, R; Chen, H; Jones, SK; Kumar, EV; Patrick, DA; Tidwell, RR; Wenzler, T; Werbovetz, KA, 2009)	0.35
" A combination chemotherapy, eflornithine alongside nifurtimox, has been introduced to decrease the time frame and overall dosing of eflornithine and reducing the risk of drug resistance emerging."	( Potential new drugs for human African trypanosomiasis: some progress at last. Barrett, MP, 2010)	0.36
" The introduction of the combination of nifurtimox and eflornithine (NECT) has accelerated the shift from melarsoprol to the best treatment available, due to reduced dosage and treatment time for eflornithine that has significantly lessened the cost and improved the burden of logistics encountered during treatment and distribution."	( Update on field use of the available drugs for the chemotherapy of human African trypanosomiasis. Diarra, A; Franco, J; Jannin, J; Postigo, JA; Simarro, PP, 2012)	0.59
" 28DAP010 showed efficacy similar to that of DB829 in dose-response studies in mouse models of first- and second-stage African sleeping sickness."	( In vitro and in vivo evaluation of 28DAP010, a novel diamidine for treatment of second-stage African sleeping sickness. Boykin, DW; Braissant, O; Brun, R; Ismail, MA; Patrick, DA; Tidwell, RR; Wang, MZ; Wenzler, T; Yang, S, 2014)	0.4
"We have shown that drug dose-response can be evaluated using bioluminescence imaging and confirmed quantification of tissue parasite load using qPCR."	( A sensitive and reproducible in vivo imaging mouse model for evaluation of drugs against late-stage human African trypanosomiasis. Bradley, B; Burrell-Saward, H; Croft, SL; Rodgers, J; Ward, TH, 2015)	0.42
"Current treatments for Human African Trypanosomiasis (HAT) are limited in their application, have undesirable dosing regimens and unsatisfactory toxicities highlighting the need for the development of a safer drug pipeline."	( Design, synthesis and antitrypanosomal activities of 2,6-disubstituted-4,5,7-trifluorobenzothiophenes. Arroo, RRJ; Bhambra, AS; Burrell-Saward, H; Edgar, M; Elsegood, MRJ; Krystof, V; Li, Y; Weaver, GW; Yardley, V, 2016)	0.43

Class	Description
triazines	Compounds based on a triazine skeleton.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (378)

Assay ID	Title	Year	Journal	Article
AID473009	Inhibition of Plasmodium falciparum recombinant falcipain-2 using Cbz-Leu-Arg-AMC as substrate by standard fluorescence assay	2010	Journal of medicinal chemistry, Mar-11, Volume: 53, Issue:5	Michael acceptor based antiplasmodial and antitrypanosomal cysteine protease inhibitors with unusual amino acids.
AID445251	Antitrypanosomal activity against Trypanosoma brucei rhodesiense STIB900 after 70 hrs by alamar blue assay	2010	Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1	Synthesis and antiprotozoal activity of cationic 1,4-diphenyl-1H-1,2,3-triazoles.
AID562497	Ratio of IC50 for Trypanosoma brucei brucei AT1KO to IC50 for Trypanosoma brucei brucei BS221	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	New treatment option for second-stage African sleeping sickness: in vitro and in vivo efficacy of aza analogs of DB289.
AID432043	Antitrypanosomal activity against Trypanosoma brucei rhodesiense STIB900	2009	European journal of medicinal chemistry, Sep, Volume: 44, Issue:9	Synthesis and antiprotozoal activities of dicationic bis(phenoxymethyl)benzenes, bis(phenoxymethyl)naphthalenes, and bis(benzyloxy)naphthalenes.
AID1653744	Cytotoxicity against rat L6 cells assessed as reduction in cell viability measured after 72 hrs by Alamar blue based inverted microscopy analysis	2020	Bioorganic & medicinal chemistry, 01-01, Volume: 28, Issue:1	Synthesis, in-vitro antiprotozoal activity and molecular docking study of isothiocyanate derivatives.
AID252603	In vivo antitrypanosomal activity at a dose of 4*1 mg/kg, i.p., in mice infected with Trypanosoma brucei brucei STIB 795 strain; 2/4	2005	Journal of medicinal chemistry, Aug-25, Volume: 48, Issue:17	Design and synthesis of a series of melamine-based nitroheterocycles with activity against Trypanosomatid parasites.
AID441748	Selectivity index, ratio of IC50 for rat L6 cells to IC50 for bloodstream Trypanosoma brucei rhodesiense STIB 900	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Antitrypanosomal activity of 1,2-dihydroquinolin-6-ols and their ester derivatives.
AID1298167	Selectivity index, ratio of IC50 for rat L6 cells to IC50 for Trypanosoma brucei rhodesiense STIB900	2016	Bioorganic & medicinal chemistry, 06-01, Volume: 24, Issue:11	Synthesis of novel amide and urea derivatives of thiazol-2-ethylamines and their activity against Trypanosoma brucei rhodesiense.
AID401637	Antitrypanosomal activity against Trypanosoma brucei rhodesiense	2005	Journal of natural products, May, Volume: 68, Issue:5	Isoneocryptolepine, a synthetic indoloquinoline alkaloid, as an antiplasmodial lead compound.
AID274293	Antiprotozoal activity against Trypanosoma brucei rhodesiense STIB900	2006	Bioorganic & medicinal chemistry letters, Oct-15, Volume: 16, Issue:20	Antiprotozoal activities of new bis-chlorophenyl derivatives of bicyclic octanes and aza-nonanes.
AID690543	Antiprotozoal activity against Trypanosoma brucei rhodesiense bloodstream forms	2012	Bioorganic & medicinal chemistry letters, Oct-01, Volume: 22, Issue:19	2-Alkynoic fatty acids inhibit topoisomerase IB from Leishmania donovani.
AID341603	Antileishmanial activity against Leishmania donovani MHOM-ET-67/L82 amastigotes by axenic assay	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Peroxide bond-dependent antiplasmodial specificity of artemisinin and OZ277 (RBx11160).
AID1143877	Antimicrobial activity against trypomastigote stage of Trypanosoma brucei rhodesiense STIB900 infected in rat L6 cells after 96 hrs by Alamar Blue assay	2014	European journal of medicinal chemistry, Jun-23, Volume: 81	Antiprotozoal activity and DNA binding of N-substituted N-phenylbenzamide and 1,3-diphenylurea bisguanidines.
AID595451	Antiparasitic activity against bloodstream form of Trypanosoma brucei rhodesiense STIB 900 after 72 hrs by microplate reader assay	2011	Journal of natural products, Apr-25, Volume: 74, Issue:4	Didemnidines A and B, indole spermidine alkaloids from the New Zealand ascidian Didemnum sp.
AID213470	In vitro antitrypanosomal activity against Trypanosoma brucei rhodesiense	2004	Journal of medicinal chemistry, Apr-22, Volume: 47, Issue:9	Bisguanidine, bis(2-aminoimidazoline), and polyamine derivatives as potent and selective chemotherapeutic agents against Trypanosoma brucei rhodesiense. Synthesis and in vitro evaluation.
AID1163239	Metabolic stability in mouse liver microsomes assessed as compound remaining after 15 mins by UPLC analysis	2014	Bioorganic & medicinal chemistry, Oct-01, Volume: 22, Issue:19	From human immunodeficiency virus non-nucleoside reverse transcriptase inhibitors to potent and selective antitrypanosomal compounds.
AID756886	Cytotoxicity against rat L6 cells after 72 hrs by Alamar Blue assay	2013	Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13	Synthesis and antiprotozoal activity of dicationic m-terphenyl and 1,3-dipyridylbenzene derivatives.
AID1614005	Antiprotozoal activity against Trypanosoma brucei rhodesiense STIB900 trypomastigotes after 72 hrs by Alamar Blue dye-based fluorometric analysis	2019	Journal of medicinal chemistry, 02-14, Volume: 62, Issue:3	Design, Synthesis, and Biological Evaluation of New 1-(Aryl-1 H-pyrrolyl)(phenyl)methyl-1 H-imidazole Derivatives as Antiprotozoal Agents.
AID378569	Antitrypanosomal activity against Trypanosoma brucei rhodesiense trypomastigotes	2005	Journal of natural products, Mar, Volume: 68, Issue:3	Ambigol C and 2,4-dichlorobenzoic acid, natural products produced by the terrestrial cyanobacterium Fischerella ambigua.
AID1193503	Selectivity index, ratio of IC50 for rat L6 cells to IC50 for bloodstream forms of Trypanosoma brucei rhodesiense STIB 900	2015	Bioorganic & medicinal chemistry, Apr-01, Volume: 23, Issue:7	Anti-trypanosomal cadinanes synthesized by transannular cyclization of the natural sesquiterpene lactone nobilin.
AID336752	Antitrypanosomal activity against Trypanosoma brucei rhodesiense KETRI 243 isolate after 48 hrs	2003	Journal of natural products, Mar, Volume: 66, Issue:3	Trypanocidal diarylheptanoids from Aframomum letestuianum.
AID1480088	Antitrypanosomal activity against bloodstream form of Trypanosoma brucei rhodesiense STIB 900 assessed as parasite growth inhibition after 48 hrs by Alamar blue assay	2018	Journal of medicinal chemistry, 04-26, Volume: 61, Issue:8	2 H-1,2,3-Triazole-Based Dipeptidyl Nitriles: Potent, Selective, and Trypanocidal Rhodesain Inhibitors by Structure-Based Design.
AID389449	Cytotoxicity against rat L6 cells	2008	Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21	Synthesis and antiprotozoal activity of cationic 2-phenylbenzofurans.
AID1193547	Selectivity index, ratio of CC50 for rat L6 cells to IC50 for Trypanosoma brucei rhodesiense STIB900	2015	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 25, Issue:7	Synthesis of 3-azabicyclo[3.2.2]nonanes and their antiprotozoal activities.
AID341599	Antiplasmodial activity against Plasmodium falciparum K1	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Peroxide bond-dependent antiplasmodial specificity of artemisinin and OZ277 (RBx11160).
AID1079933	Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID1336733	Selectivity index, ratio of IC50 for rat L6 cells to IC50 for Trypanosoma brucei rhodesiense STIB900 bloodstream forms	2017	Bioorganic & medicinal chemistry, 02-01, Volume: 25, Issue:3	New derivatives of 7-chloroquinolin-4-amine with antiprotozoal activity.
AID644365	Antiprotozoal activity against Trypanosoma brucei rhodesiense STIB900 trypomastigotes after 72 hrs by alamar blue assay	2012	Bioorganic & medicinal chemistry, Feb-15, Volume: 20, Issue:4	Synthesis and antimalarial and antituberculosis activities of a series of natural and unnatural 4-methoxy-6-styryl-pyran-2-ones, dihydro analogues and photo-dimers.
AID1156608	Antiparasitic activity against Trypanosoma brucei rhodesiense STIB900 trypomastigotes after 3 days by Alamar blue assay	2014	European journal of medicinal chemistry, Aug-18, Volume: 83	Synthesis and antiparasitic activity of new bis-arylimidamides: DB766 analogs modified in the terminal groups.
AID372439	Antitrypanosomal activity against tbat1 knockout Trypanosoma cruzi BS221 infected in mouse macrophage by reporter dye assay	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	2,N6-disubstituted adenosine analogs with antitrypanosomal and antimalarial activities.
AID497468	Trypanocidal activity against Trypanosoma brucei rhodesiense STIB 900 after 72 hrs	2010	Journal of natural products, Aug-27, Volume: 73, Issue:8	Antiprotozoal steroidal saponins from the marine sponge Pandaros acanthifolium.
AID1480086	Antitrypanosomal activity against bloodstream form of Trypanosoma brucei rhodesiense STIB 900 assessed as parasite growth inhibition after 16 hrs by Alamar blue assay	2018	Journal of medicinal chemistry, 04-26, Volume: 61, Issue:8	2 H-1,2,3-Triazole-Based Dipeptidyl Nitriles: Potent, Selective, and Trypanocidal Rhodesain Inhibitors by Structure-Based Design.
AID1193502	Cytotoxicity against rat L6 cells	2015	Bioorganic & medicinal chemistry, Apr-01, Volume: 23, Issue:7	Anti-trypanosomal cadinanes synthesized by transannular cyclization of the natural sesquiterpene lactone nobilin.
AID1336732	Antitrypanosomal activity against Trypanosoma brucei rhodesiense STIB900 bloodstream forms isolated from patient after 70 hrs by microplate alamar blue assay	2017	Bioorganic & medicinal chemistry, 02-01, Volume: 25, Issue:3	New derivatives of 7-chloroquinolin-4-amine with antiprotozoal activity.
AID418754	Antitrypanosomal activity against Trypanosoma brucei rhodesiense STIB900 trypomastigotes infected in NMRI mouse assessed as survival and aparasitemic condition at 8 mg/kg, ip administered from day 3 to day 6 postinfection measured after 60 days postinfect	2009	Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7	Structure-activity study of pentamidine analogues as antiprotozoal agents.
AID677563	Antitrypanosomal activity against Trypanosoma brucei rhodesiense STIB 900 trypomastigotes	2012	Journal of medicinal chemistry, Jun-14, Volume: 55, Issue:11	Novel 3-nitro-1H-1,2,4-triazole-based amides and sulfonamides as potential antitrypanosomal agents.
AID303261	Antiparasitic activity against Trypanosoma brucei rhodesiense STIB900 in blood	2007	Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23	Synthesis and evaluation of antiparasitic activities of new 4-[5-(4-phenoxyphenyl)-2H-pyrazol-3-yl]morpholine derivatives.
AID1776165	Antitrypanosomal activity against bloodstream form of Trypanosoma brucei rhodesiense STIB900 assessed as inhibition of parasite growth incubated for 72 hrs by Alamar blue dye-based fluorometric analysis	2021	Journal of natural products, 04-23, Volume: 84, Issue:4	Spirombandakamine A
AID248819	Inhibitory concentration in vitro against blood stream Trypanosoma brucei rhodesiense incubated for 72 hr at 37 degree C	2005	Journal of medicinal chemistry, Aug-25, Volume: 48, Issue:17	Design and synthesis of a series of melamine-based nitroheterocycles with activity against Trypanosomatid parasites.
AID404599	Selectivity index, Ratio of IC50 for L6 cells to IC50 for Trypanosoma brucei rhodesiense STIB 9	2008	Bioorganic & medicinal chemistry, Jun-15, Volume: 16, Issue:12	Novel azabicyclo[3.2.2]nonane derivatives and their activities against Plasmodium falciparum K1 and Trypanosoma brucei rhodesiense.
AID756887	Antiprotozoal activity against Trypanosoma brucei rhodesiense STIB900 infected in NMRI mouse assessed as reduction of parasitemia relapse at 5 mg/kg, ip qd for 4 days	2013	Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13	Synthesis and antiprotozoal activity of dicationic m-terphenyl and 1,3-dipyridylbenzene derivatives.
AID333758	Antitrypanosomal activity against Trypanosoma brucei rhodesiense	2004	Journal of natural products, Dec, Volume: 67, Issue:12	Ancistrobenomine a, the first naphthylisoquinoline oxygenated at Me-3, and related 5,1'-coupled alkaloids, from the "new" plant species ancistrocladusbenomensis.
AID765725	Antitrypanosomal activity against Trypanosoma brucei rhodesiense STIB900 after 72 hrs by Alamar blue assay	2013	European journal of medicinal chemistry, Sep, Volume: 67	Synthesis and antiprotozoal activities of benzyl phenyl ether diamidine derivatives.
AID1578098	Antitrypanosomal activity against Trypanosoma brucei rhodesiense	2019	Bioorganic & medicinal chemistry letters, 10-15, Volume: 29, Issue:20	Antiprotozoal alkaloid principles of the plant family Amaryllidaceae.
AID1480084	Antitrypanosomal activity against bloodstream form of Trypanosoma brucei rhodesiense STIB 900 assessed as parasite growth inhibition after 2 hrs by Alamar blue assay	2018	Journal of medicinal chemistry, 04-26, Volume: 61, Issue:8	2 H-1,2,3-Triazole-Based Dipeptidyl Nitriles: Potent, Selective, and Trypanocidal Rhodesain Inhibitors by Structure-Based Design.
AID1713354	Antiprotozoal activity against Trypanosoma brucei rhodesiense STIB900 trypomastigotes by alamar blue staining-based fluorometric analysis	2016	European journal of medicinal chemistry, Nov-10, Volume: 123	Nitrotriazole-based acetamides and propanamides with broad spectrum antitrypanosomal activity.
AID475980	Cytotoxicity against rat L6 cells	2010	Bioorganic & medicinal chemistry, Apr-01, Volume: 18, Issue:7	Assessing the trypanocidal potential of natural and semi-synthetic diketopiperazines from two deep water marine-derived fungi.
AID1501229	Antiprotozoal activity against blood stream form of Trypanosoma brucei rhodesiense STIB900 after 72 hrs by alamar blue assay	2017	Journal of natural products, 09-22, Volume: 80, Issue:9	Antiprotozoal Linear Furanosesterterpenoids from the Marine Sponge Ircinia oros.
AID389450	Antitrypanosomal activity against Trypanosoma brucei rhodesiense STIB 900 bloodstream trypomastigotes	2008	Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21	Synthesis and antiprotozoal activity of cationic 2-phenylbenzofurans.
AID748437	Antitrypanosomal activity against Trypanosoma brucei rhodesiense STIB 900 trypomastigotes after 72 hrs by Alamar blue assay	2013	ACS medicinal chemistry letters, Jun-13, Volume: 4, Issue:6	New Promising Compounds with in Vitro Nanomolar Activity against Trypanosoma cruzi.
AID274295	Antiprotozoal activity against chloroquine-, pyrimethamine-resistant Plasmodium falciparum K1	2006	Bioorganic & medicinal chemistry letters, Oct-15, Volume: 16, Issue:20	Antiprotozoal activities of new bis-chlorophenyl derivatives of bicyclic octanes and aza-nonanes.
AID1196797	Antitrypanosomal activity against trypomastigote stage of Trypanosoma brucei rhodesiense STIB 900 assessed as parasite growth inhibition after 72 hrs by Alamar Blue assay	2015	Journal of medicinal chemistry, Feb-12, Volume: 58, Issue:3	Novel 3-nitrotriazole-based amides and carbinols as bifunctional antichagasic agents.
AID433913	Antitrypanosomal activity against Trypanosoma brucei rhodesiense STIB 900 after 72 hrs by alamar blue based microplate assay	2009	European journal of medicinal chemistry, Sep, Volume: 44, Issue:9	Synthesis of a series of N6-substituted adenosines with activity against trypanosomatid parasites.
AID419759	Antitrypanosomal activity against bloodstream Trypanosoma brucei rhodesiense STIB900 infected in NMRI mouse assessed as parasite free mouse survival at 2 mg/kg, ip administered for 4 consecutive days from day 3 to 6 postinfection measured up to 60 days	2009	Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15	Synthesis and antiprotozoal activity of pyridyl analogues of pentamidine.
AID1156609	Selectivity index, ratio of IC50 for rat L6 cells to IC50 for Trypanosoma brucei rhodesiense STIB900 trypomastigotes	2014	European journal of medicinal chemistry, Aug-18, Volume: 83	Synthesis and antiparasitic activity of new bis-arylimidamides: DB766 analogs modified in the terminal groups.
AID1163232	Cytotoxicity against human MRC5 SV2 cells assessed as reduction in cell growth after 72 hrs	2014	Bioorganic & medicinal chemistry, Oct-01, Volume: 22, Issue:19	From human immunodeficiency virus non-nucleoside reverse transcriptase inhibitors to potent and selective antitrypanosomal compounds.
AID214465	50% antitrypanosomal activity against Trypanosoma rhodesiense	2002	Journal of medicinal chemistry, Jul-04, Volume: 45, Issue:14	Lepadins D-F: antiplasmodial and antitrypanosomal decahydroquinoline derivatives from the tropical marine tunicate Didemnum sp.
AID635852	Antitrypanosomal activity against bloodstream form of Trypanosoma brucei rhodesiense STIB 900 after 70 hrs by resazurin-based spectrophotometric assay	2011	Bioorganic & medicinal chemistry, Dec-15, Volume: 19, Issue:24	Bis(oxyphenylene)benzimidazoles: a novel class of anti-Plasmodium falciparum agents.
AID215328	Evaluated in vitro for antitrypanosomal activity against Trypanosoma brucei	2002	Bioorganic & medicinal chemistry letters, Dec-16, Volume: 12, Issue:24	Antitrypanosomal activities and cytotoxicity of 5-nitro-2-furancarbohydrazides.
AID264014	Cytotoxicity against J774.1 cell line after 48 hrs	2006	Bioorganic & medicinal chemistry letters, May-15, Volume: 16, Issue:10	Aziridine-2,3-dicarboxylate inhibitors targeting the major cysteine protease of Trypanosoma brucei as lead trypanocidal agents.
AID1483953	Antiprotozoal activity against patient derived Trypanosoma brucei rhodesiense STIB 900 bloodstream form after 72 hrs by Alamar Blue assay	2017	Journal of natural products, 02-24, Volume: 80, Issue:2	Dioncophyllines C
AID253516	In vitro inhibitory concentration against blood stream Trypanosoma brucei brucei AT1 wild type incubated for 72 h at 37 degree C	2005	Journal of medicinal chemistry, Aug-25, Volume: 48, Issue:17	Design and synthesis of a series of melamine-based nitroheterocycles with activity against Trypanosomatid parasites.
AID235941	In vivo antitrypanosomal activity at a dose of 4*8 mg/kg, i.p., in mice infected with Trypanosoma brucei rhodesiense STIB 900 strain, measured as cured/infected; 4/4	2005	Journal of medicinal chemistry, Aug-25, Volume: 48, Issue:17	Design and synthesis of a series of melamine-based nitroheterocycles with activity against Trypanosomatid parasites.
AID1578097	Antitrypanosomal activity against Leishmania donovani	2019	Bioorganic & medicinal chemistry letters, 10-15, Volume: 29, Issue:20	Antiprotozoal alkaloid principles of the plant family Amaryllidaceae.
AID341606	Antimicrobial activity against Babesia divergens 1903B	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Peroxide bond-dependent antiplasmodial specificity of artemisinin and OZ277 (RBx11160).
AID1578095	Antitrypanosomal activity against Trypanosoma cruzi after 48 hrs by [3H]-hypoxanthine incorporation assay	2019	Bioorganic & medicinal chemistry letters, 10-15, Volume: 29, Issue:20	Antiprotozoal alkaloid principles of the plant family Amaryllidaceae.
AID286669	Antitrypanosomal activity against Trypanosoma brucei rhodesiense	2007	Journal of medicinal chemistry, May-17, Volume: 50, Issue:10	Synthesis and in vitro antiprotozoal activities of dicationic 3,5-diphenylisoxazoles.
AID597077	Antiparasitic activity against Trypanosoma brucei rhodesiense STIB 900 bloodstream form after 72 hrs by microplate fluorimetry	2011	Journal of natural products, Apr-25, Volume: 74, Issue:4	Antiparasitic compounds from Cupania cinerea with activities against Plasmodium falciparum and Trypanosoma brucei rhodesiense.
AID1306906	Selectivity index, ratio of IC50 for rat L6 cells to IC50 for Trypanosoma brucei rhodesiense STIB 900 bloodstream forms	2016	Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16	Antiprotozoal activity of bicycles featuring a dimethylamino group at their bridgehead.
AID322077	Cytotoxicity against human HL60 cells	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Bis-acridines as lead antiparasitic agents: structure-activity analysis of a discrete compound library in vitro.
AID1079931	Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID303244	Antitrypanosomal activity against Trypanosoma brucei rhodesiense STIB900	2007	Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23	Synthesis and in vitro antiprotozoal activity of bisbenzofuran cations.
AID1062627	Cytotoxicity against rat L6 cells assessed as cell viability after 70 hrs by Alamar blue assay	2014	Bioorganic & medicinal chemistry, Jan-01, Volume: 22, Issue:1	Antiprotozoal activity of dicationic 3,5-diphenylisoxazoles, their prodrugs and aza-analogues.
AID1612294	Antitrypanosomal activity against Trypanosoma brucei rhodesiense STIB900 bloodstream forms after 72 hrs by Alamar blue staining-based fluorometric analysis	2018	Journal of natural products, 10-26, Volume: 81, Issue:10	Methionine-Containing Rhabdopeptide/Xenortide-like Peptides from Heterologous Expression of the Biosynthetic Gene Cluster kj12ABC in Escherichia coli.
AID341602	Antitrypanosomal activity against Trypanosoma cruzi Tulahuen C4	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Peroxide bond-dependent antiplasmodial specificity of artemisinin and OZ277 (RBx11160).
AID419754	Selectivity index, ratio of IC50 for rat L6 cells to IC50 for bloodstream Trypanosoma brucei rhodesiense STIB900	2009	Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15	Synthesis and antiprotozoal activity of pyridyl analogues of pentamidine.
AID562491	Antitrypanosomal activity against Trypanosoma brucei brucei AT1KO by Alamar blue assay	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	New treatment option for second-stage African sleeping sickness: in vitro and in vivo efficacy of aza analogs of DB289.
AID300098	Selectivity index, ratio of IC50 for rat L6 cells to IC50 for Trypanosoma brucei rhodesiense	2007	Bioorganic & medicinal chemistry, Aug-15, Volume: 15, Issue:16	Bicyclo[2.2.2]octyl esters of dialkylamino acids as antiprotozoals.
AID1079943	Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID274299	Survival of NMRI mouse infected with Trypanosoma brucei brucei at 0.5 mg/kg, ip	2006	Bioorganic & medicinal chemistry letters, Oct-15, Volume: 16, Issue:20	Antiprotozoal activities of new bis-chlorophenyl derivatives of bicyclic octanes and aza-nonanes.
AID432059	Antitrypanosomal activity against Trypanosoma brucei rhodesiense STIB900 infected NMRI mouse assessed mean survival time at 4 mg/kg, ip dosed for 4 days	2009	European journal of medicinal chemistry, Sep, Volume: 44, Issue:9	Synthesis and antiprotozoal activities of dicationic bis(phenoxymethyl)benzenes, bis(phenoxymethyl)naphthalenes, and bis(benzyloxy)naphthalenes.
AID1068803	Antitrypanosomal activity against Trypanosoma brucei rhodesiense STIB900 assessed as parasite growth inhibition after 70 hrs by Alamar blue assay	2014	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 24, Issue:3	Activity of diimidazoline amides against African trypanosomiasis.
AID322076	Antimicrobial activity against Trypanosoma brucei brucei clone 427-221a after 48 hrs	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Bis-acridines as lead antiparasitic agents: structure-activity analysis of a discrete compound library in vitro.
AID1240950	Toxicity in late-stage human african trypanosomiasis patient assessed as mortality rate following 10-day schedule	2015	Journal of medicinal chemistry, Sep-10, Volume: 58, Issue:17	6-Arylpyrazine-2-carboxamides: A New Core for Trypanosoma brucei Inhibitors.
AID562487	Antitrypanosomal activity against Trypanosoma brucei gambiense K03048 by Alamar blue assay	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	New treatment option for second-stage African sleeping sickness: in vitro and in vivo efficacy of aza analogs of DB289.
AID596419	Antiparasitic activity against Trypanosoma brucei rhodesiense STIB 900 trypomastigotes	2011	Journal of natural products, Apr-25, Volume: 74, Issue:4	Marinoquinolines A-F, pyrroloquinolines from Ohtaekwangia kribbensis (Bacteroidetes).
AID1062626	Selectivity index, ratio of IC50 for rat L6 cells to IC50 for Trypanosoma brucei rhodesiense STIB900	2014	Bioorganic & medicinal chemistry, Jan-01, Volume: 22, Issue:1	Antiprotozoal activity of dicationic 3,5-diphenylisoxazoles, their prodrugs and aza-analogues.
AID1410115	Antiplasmodial activity against Trypanosoma brucei rhodesiense STIB 900 trypomastigote after 72 hrs by Alamar blue assay	2018	Journal of natural products, 04-27, Volume: 81, Issue:4	Mbandakamine-Type Naphthylisoquinoline Dimers and Related Alkaloids from the Central African Liana Ancistrocladus ealaensis with Antiparasitic and Antileukemic Activities.
AID1126157	Antitrypanosomal activity against bloodstream forms of Trypanosoma brucei rhodesiense STIB900	2014	Journal of natural products, Apr-25, Volume: 77, Issue:4	Antiparasitic chaiyaphumines from entomopathogenic Xenorhabdus sp. PB61.4.
AID1163241	Metabolic stability in mouse plasma assessed as compound remaining after 1 hr	2014	Bioorganic & medicinal chemistry, Oct-01, Volume: 22, Issue:19	From human immunodeficiency virus non-nucleoside reverse transcriptase inhibitors to potent and selective antitrypanosomal compounds.
AID582593	Antitrypanosomal activity against Trypanosoma brucei rhodesiense ST1B900 trypomastigote infected in NMR1 mouse assessed as inhibition of parasitemia at 50 mg/kg, ip administered on day 3 post infection for 4 days	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Antiprotozoal activity of 1-phenethyl-4-aminopiperidine derivatives.
AID1068802	Cytotoxicity against rat L6 cells assessed as cell viability after 70 hrs by MTT assay	2014	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 24, Issue:3	Activity of diimidazoline amides against African trypanosomiasis.
AID1254914	Antitrypanosomal activity against bloodstream trypomastigote forms of Trypanosoma brucei rhodesiense STIB 900 assessed as inhibition of growth	2015	European journal of medicinal chemistry, Oct-20, Volume: 103	3-Nitrotriazole-based piperazides as potent antitrypanosomal agents.
AID765718	Cytotoxicity against rat L6 cells after 72 hrs by Alamar blue assay	2013	European journal of medicinal chemistry, Sep, Volume: 67	Synthesis and antiprotozoal activities of benzyl phenyl ether diamidine derivatives.
AID616288	Antiparasitic activity against Trypanosoma brucei rhodesiense STIB 900 trypomastigotes stage forms incubated for 72 hrs by Alamar blue staining based fluorometric assay	2011	Journal of natural products, Sep-23, Volume: 74, Issue:9	Antimalarial β-carbolines from the New Zealand ascidian Pseudodistoma opacum.
AID251291	In vivo antitrypanosomal activity at a dose of 4*1 mg/kg, i.p., in mice infected with Trypanosoma brucei brucei STIB 795 strain, measured as survival days (control 7 days)	2005	Journal of medicinal chemistry, Aug-25, Volume: 48, Issue:17	Design and synthesis of a series of melamine-based nitroheterocycles with activity against Trypanosomatid parasites.
AID1079946	Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID404598	Cytotoxicity against rat L6 cells after 72 hrs by microplate alamar blue assay	2008	Bioorganic & medicinal chemistry, Jun-15, Volume: 16, Issue:12	Novel azabicyclo[3.2.2]nonane derivatives and their activities against Plasmodium falciparum K1 and Trypanosoma brucei rhodesiense.
AID1779353	Antitrypanosomal activity against bloodstream form of Trypanosoma brucei rhodesiense STIB900 incubated for 70 hrs by resazurin dye-based fluorometric analysis	2021	European journal of medicinal chemistry, Oct-05, Volume: 221	Synthesis, in vitro antiprotozoal activity, molecular docking and molecular dynamics studies of some new monocationic guanidinobenzimidazoles.
AID372430	Antileishmanial activity against Leishmania donovani MHOMET-67/L82 amastigotes infected in mouse macrophage by reporter dye assay	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	2,N6-disubstituted adenosine analogs with antitrypanosomal and antimalarial activities.
AID1177050	Antiprotozoan activity against Trypanosoma brucei rhodesiense STIB 900 trypomastigotes	2015	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 25, Issue:3	Hydroxamic acid based histone deacetylase inhibitors with confirmed activity against the malaria parasite.
AID562486	Antitrypanosomal activity against melasoprol-resistant Trypanosoma brucei rhodesiense STIB900 by Alamar blue assay	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	New treatment option for second-stage African sleeping sickness: in vitro and in vivo efficacy of aza analogs of DB289.
AID400721	Cytotoxicity against human HT-29 cells	1998	Journal of natural products, May, Volume: 61, Issue:5	Total synthesis and biological activities of (+)- and (-)-boscialin and their 1'-epimers.
AID671047	Antitrypanosomal activity against Trypanosoma brucei rhodesiense STIB900 by Alamar blue growth inhibition assay	2012	Bioorganic & medicinal chemistry letters, Jul-15, Volume: 22, Issue:14	Discovery of nitroheterocycles active against African trypanosomes. In vitro screening and preliminary SAR studies.
AID692982	Cytotoxicity against in rat L6 cells assessed as reduction in cell viability after 70 hrs by alamar blue assay	2011	European journal of medicinal chemistry, May, Volume: 46, Issue:5	1-Aryl-4-nitro-1H-imidazoles, a new promising series for the treatment of human African trypanosomiasis.
AID264012	Inhibition of Trypanosoma brucei rhodesiense rhodesain at 200 uM	2006	Bioorganic & medicinal chemistry letters, May-15, Volume: 16, Issue:10	Aziridine-2,3-dicarboxylate inhibitors targeting the major cysteine protease of Trypanosoma brucei as lead trypanocidal agents.
AID482888	Inhibition of human liver cathepsin B at 100 uM	2009	Journal of medicinal chemistry, Sep-24, Volume: 52, Issue:18	On-bead screening of a combinatorial fumaric acid derived peptide library yields antiplasmodial cysteine protease inhibitors with unusual peptide sequences.
AID1500573	Antitrypanosomal activity against blood stream form of Trypanosoma brucei rhodesiense STIB900 trypomastigotes after 72 hrs by Alamar Blue assay	2017	European journal of medicinal chemistry, Sep-29, Volume: 138	The antitrypanosomal and antitubercular activity of some nitro(triazole/imidazole)-based aromatic amines.
AID311643	Antiparasitic activity against Trypanosoma brucei rhodesiense by Alamar blue assay	2007	Journal of natural products, Oct, Volume: 70, Issue:10	Antiprotozoal polyacetylenes from the Tanzanian medicinal plant Cussonia zimmermannii.
AID482887	Antitrypanosomal activity against Trypanosoma brucei brucei	2009	Journal of medicinal chemistry, Sep-24, Volume: 52, Issue:18	On-bead screening of a combinatorial fumaric acid derived peptide library yields antiplasmodial cysteine protease inhibitors with unusual peptide sequences.
AID341604	Antimicrobial activity against Giardia duodenalis WB	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Peroxide bond-dependent antiplasmodial specificity of artemisinin and OZ277 (RBx11160).
AID1313991	Antiparasitic activity against bloodstream forms of Trypanosoma brucei rhodesiense STIB 900 assessed as growth inhibition after 72 hrs by resazurin assay	2016	Bioorganic & medicinal chemistry, 09-15, Volume: 24, Issue:18	Synthesis and potent antiprotozoal activity of mono/di amidino 2-anilinobenzimidazoles versus Plasmodium falciparum and Trypanosoma brucei rhodesiense.
AID562495	Ratio of IC50 for Trypanosoma brucei gambiense ITMAP141267 to IC50 for wild-type Trypanosoma brucei rhodesiense STIB903	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	New treatment option for second-stage African sleeping sickness: in vitro and in vivo efficacy of aza analogs of DB289.
AID1062624	Trypanocidal activity against bloodstream form of Trypanosoma brucei rhodesiense STIB900 infected in NMRI mouse assessed as decrease in parasitemia at 5 mg/kg, ip qd administered for 4 days measured once per week until 60 days by microscopic analysis	2014	Bioorganic & medicinal chemistry, Jan-01, Volume: 22, Issue:1	Antiprotozoal activity of dicationic 3,5-diphenylisoxazoles, their prodrugs and aza-analogues.
AID432044	Selectivity index, ratio of IC50 for rat L6 cells to IC50 for Trypanosoma brucei rhodesiense STIB900	2009	European journal of medicinal chemistry, Sep, Volume: 44, Issue:9	Synthesis and antiprotozoal activities of dicationic bis(phenoxymethyl)benzenes, bis(phenoxymethyl)naphthalenes, and bis(benzyloxy)naphthalenes.
AID378568	Antitrypanosomal activity against Trypanosoma cruzi trypomastigotes	2005	Journal of natural products, Mar, Volume: 68, Issue:3	Ambigol C and 2,4-dichlorobenzoic acid, natural products produced by the terrestrial cyanobacterium Fischerella ambigua.
AID482885	Inhibition of Trypanosoma brucei rhodesiense recombinant rhodesain at 100 uM	2009	Journal of medicinal chemistry, Sep-24, Volume: 52, Issue:18	On-bead screening of a combinatorial fumaric acid derived peptide library yields antiplasmodial cysteine protease inhibitors with unusual peptide sequences.
AID439872	Antimicrobial activity against Trypanosoma brucei rhodesiense STIB 900 trypomastigote forms	2009	Journal of medicinal chemistry, Nov-12, Volume: 52, Issue:21	Searching for new cures for tuberculosis: design, synthesis, and biological evaluation of 2-methylbenzothiazoles.
AID774788	Antiprotozoal activity against Trypanosoma brucei rhodesiense assessed as parasite growth inhibition	2013	Journal of medicinal chemistry, Sep-26, Volume: 56, Issue:18	Natural product derived antiprotozoal agents: synthesis, biological evaluation, and structure-activity relationships of novel chromene and chromane derivatives.
AID562498	Ratio of IC50 for Trypanosoma brucei gambiense K03048 to IC50 for Trypanosoma brucei gambiense STIB930	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	New treatment option for second-stage African sleeping sickness: in vitro and in vivo efficacy of aza analogs of DB289.
AID1546292	Antiprotozoal activity against Trypanosoma brucei rhodesiense STIB900 amastigotes assessed as growth inhibition after 72 hrs by Alamar Blue dye-based fluorometric analysis	2020	Bioorganic & medicinal chemistry letters, 01-01, Volume: 30, Issue:1	A new chemotype with promise against Trypanosoma cruzi.
AID1079936	Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID1743672	Trypanocidal activity against Trypanosoma brucei rhodesiense STIB900 trypomastigotes incubated for 72 hrs by Alamar blue assay	2020	European journal of medicinal chemistry, Dec-01, Volume: 207	Palladium-catalysed synthesis of arylnaphthoquinones as antiprotozoal and antimycobacterial agents.
AID404375	Antitrypanosomal activity against Trypanosoma brucei rhodesiense STIB900	2008	Journal of medicinal chemistry, Jun-26, Volume: 51, Issue:12	Synthesis and in vitro antiprotozoal activities of water-soluble, inexpensive 3,7-bis(dialkylamino)phenoxazin-5-ium derivatives.
AID723217	Trypanocidal activity against Trypanosoma brucei rhodesiense Z310 after 72 hrs by Alamar blue assay	2013	Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3	A class of 5-nitro-2-furancarboxylamides with potent trypanocidal activity against Trypanosoma brucei in vitro.
AID322078	Selectivity index, ratio of EC50 for HL60 cells to EC50 for Trypanosoma brucei brucei clone 427-221a	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Bis-acridines as lead antiparasitic agents: structure-activity analysis of a discrete compound library in vitro.
AID644196	Antitrypanosomal activity against blood stream form of Trypanosoma brucei after 69 hrs by resazurin-based fluorescence assay	2012	Bioorganic & medicinal chemistry, Feb-15, Volume: 20, Issue:4	Quinol derivatives as potential trypanocidal agents.
AID384321	Antiprotozoal activity against Trypanosoma brucei rhodesiense STIB900	2008	European journal of medicinal chemistry, Apr, Volume: 43, Issue:4	Epimers of bicyclo[2.2.2]octan-2-ol derivatives with antiprotozoal activity.
AID710596	Antitrypanosomal activity against trypomastigote form of Trypanosoma brucei rhodesiense STIB 900 assessed as growth inhibition after 72 hrs by microplate fluorometry	2012	Journal of medicinal chemistry, Dec-13, Volume: 55, Issue:23	Conjugation of quinones with natural polyamines: toward an expanded antitrypanosomatid profile.
AID1271906	Antitrypanosomal activity against Trypanosoma brucei rhodesiense STIB 900 after 72 hrs by alamar blue assay	2016	European journal of medicinal chemistry, Jan-27, Volume: 108	Design, synthesis and antitrypanosomal activities of 2,6-disubstituted-4,5,7-trifluorobenzothiophenes.
AID1240903	Selectivity index, ratio of IC50 for rat L6 cells to IC50 for bloodstream forms of Trypanosoma brucei rhodesiense STIB 900	2015	Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16	2-Phenoxy-1,4-naphthoquinones: From a Multitarget Antitrypanosomal to a Potential Antitumor Profile.
AID692981	Antiparasitic activity against Trypanosoma brucei rhodesiense STIB900 bloodstream forms assessed as reduction in cell viability after 70 hrs by alamar blue assay	2011	European journal of medicinal chemistry, May, Volume: 46, Issue:5	1-Aryl-4-nitro-1H-imidazoles, a new promising series for the treatment of human African trypanosomiasis.
AID509507	Antiprotozoal activity against Trypanosoma brucei rhodesiense STIB900 at 4.8 ug/mL by microplate alamar blue assay	2010	European journal of medicinal chemistry, Sep, Volume: 45, Issue:9	Synthesis and preliminary bioactivity assays of 3,4-dichloro-5-(omega-hydroxyalkylamino)-2(5H)-furanones.
AID235934	In vivo antitrypanosomal activity at a dose of 4*8 mg/kg, i.p., in mice infected with Trypanosoma brucei rhodesiense STIB 900 strain, measured as survival days (control 7 days); ND is not determined	2005	Journal of medicinal chemistry, Aug-25, Volume: 48, Issue:17	Design and synthesis of a series of melamine-based nitroheterocycles with activity against Trypanosomatid parasites.
AID418759	Antitrypanosomal activity against Trypanosoma brucei rhodesiense STIB900 trypomastigotes infected in NMRI mouse assessed as mouse survival at 8 mg/kg, ip administered from day 3 to day 6 postinfection	2009	Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7	Structure-activity study of pentamidine analogues as antiprotozoal agents.
AID473011	Inhibition of Trypanosoma brucei rhodesiense recombinant rhodesain by standard fluorescence assay	2010	Journal of medicinal chemistry, Mar-11, Volume: 53, Issue:5	Michael acceptor based antiplasmodial and antitrypanosomal cysteine protease inhibitors with unusual amino acids.
AID400720	Antitrypanosomal activity against blood stream form of Trypanosoma brucei rhodesiense STIB 900	1998	Journal of natural products, May, Volume: 61, Issue:5	Total synthesis and biological activities of (+)- and (-)-boscialin and their 1'-epimers.
AID1359978	Antitrypanosomal activity against Trypanosoma brucei gambiense GUTat 3.1 after 72 hrs by Alamar Blue assay	2018	European journal of medicinal chemistry, Jun-25, Volume: 154	Synthesis of proline derived benzenesulfonamides: A potent anti-Trypanosoma brucei gambiense agent.
AID231796	Ratio of cytotoxicity against L6 cells to that of antitrypanosomal activity against Trypanosoma brucei rhodesiense	2004	Journal of medicinal chemistry, Apr-22, Volume: 47, Issue:9	Bisguanidine, bis(2-aminoimidazoline), and polyamine derivatives as potent and selective chemotherapeutic agents against Trypanosoma brucei rhodesiense. Synthesis and in vitro evaluation.
AID351792	Cytotoxicity against rat L6 cells after 72 hrs by alamar blue assay	2009	Bioorganic & medicinal chemistry, May-15, Volume: 17, Issue:10	Antiplasmodial and antitrypanosomal activity of bicyclic amides and esters of dialkylamino acids.
AID260370	Antiprotozoal activity against Trypanosoma brucei brucei GVR35	2006	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 16, Issue:4	Synthesis and antiprotozoal activity of some new synthetic substituted quinoxalines.
AID341607	Antimicrobial activity against Babesia divergens 4201	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Peroxide bond-dependent antiplasmodial specificity of artemisinin and OZ277 (RBx11160).
AID247964	Concentration causing cytotoxicity to 50% of L-6 rat skeletal myoblasts	2005	Journal of medicinal chemistry, Aug-25, Volume: 48, Issue:17	Design and synthesis of a series of melamine-based nitroheterocycles with activity against Trypanosomatid parasites.
AID1306903	Antitrypanosomal activity against Trypanosoma brucei rhodesiense STIB 900 bloodstream forms after 72 hrs by Alamar blue assay	2016	Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16	Antiprotozoal activity of bicycles featuring a dimethylamino group at their bridgehead.
AID432049	Cytotoxicity against rat L6 cells	2009	European journal of medicinal chemistry, Sep, Volume: 44, Issue:9	Synthesis and antiprotozoal activities of dicationic bis(phenoxymethyl)benzenes, bis(phenoxymethyl)naphthalenes, and bis(benzyloxy)naphthalenes.
AID351791	Antitrypanosomal activity against Trypanosoma brucei rhodesiense after 72 hrs by alamar blue assay	2009	Bioorganic & medicinal chemistry, May-15, Volume: 17, Issue:10	Antiplasmodial and antitrypanosomal activity of bicyclic amides and esters of dialkylamino acids.
AID445257	Toxicity in NMRI mouse infected with Trypanosoma brucei rhodesiense STIB900 assessed as survival at 8 mg/kg, ip after administered for 4 consecutive days from day 3 postinfection measured after 7 to 30 days	2010	Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1	Synthesis and antiprotozoal activity of cationic 1,4-diphenyl-1H-1,2,3-triazoles.
AID1728297	Selectivity index, ratio of IC50 for rat L6 cells to IC50 for Trypanosoma brucei rhodesiense STIB900	2021	European journal of medicinal chemistry, Jan-15, Volume: 210	Preparation of new 1,3-dibenzyl tetrahydropyridinylidene ammonium salts and their antimicrobial and anticellular activities.
AID634012	Antitrypanosomal activity against Trypanosoma brucei rhodesiense STIB900 bloodstream forms after 72 hrs by serial dilution Alamar blue assay	2012	European journal of medicinal chemistry, Jan, Volume: 47, Issue:1	New N-methylpiperazinyl derivatives of bicyclic antiprotozoal compounds.
AID418755	Antitrypanosomal activity against Trypanosoma brucei rhodesiense STIB900 trypomastigotes infected in NMRI mouse assessed as survival and aparasitemic condition at 2 mg/kg, ip administered from day 3 to day 6 postinfection measured after 60 days postinfect	2009	Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7	Structure-activity study of pentamidine analogues as antiprotozoal agents.
AID666698	Antitrypanosomal activity against Trypanosoma brucei rhodesiense STIB900 infected in rat L6 cells after 72 hrs by alamar blue assay	2012	Journal of medicinal chemistry, Mar-22, Volume: 55, Issue:6	Synthesis and structure-activity analysis of new phosphonium salts with potent activity against African trypanosomes.
AID1298168	Cytotoxicity against rat L6 cells measured after 70 hrs by alamar blue staining based fluorescence analysis	2016	Bioorganic & medicinal chemistry, 06-01, Volume: 24, Issue:11	Synthesis of novel amide and urea derivatives of thiazol-2-ethylamines and their activity against Trypanosoma brucei rhodesiense.
AID1405620	Antiprotozoal activity against Trypanosoma brucei rhodesiense STIB900 trypomastigote after 72 hrs by Alamar Blue assay	2018	European journal of medicinal chemistry, Aug-05, Volume: 156	Biological evaluation and structure-activity relationships of imidazole-based compounds as antiprotozoal agents.
AID1177591	Antiparasitic activity against Trypanosoma brucei rhodesiense STIB900	2014	Journal of natural products, Aug-22, Volume: 77, Issue:8	Xenortide Biosynthesis by Entomopathogenic Xenorhabdus nematophila.
AID260369	Antiprotozoal activity against Leishmania donovani MHOM/ET/L82/LV9	2006	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 16, Issue:4	Synthesis and antiprotozoal activity of some new synthetic substituted quinoxalines.
AID1079937	Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID765716	Antitrypanosomal activity against Trypanosoma brucei rhodesiense STIB900 infected in NMRI mouse assessed as mean survival days at 2 mg/kg, ip administered for 4 days	2013	European journal of medicinal chemistry, Sep, Volume: 67	Synthesis and antiprotozoal activities of benzyl phenyl ether diamidine derivatives.
AID562484	Antitrypanosomal activity against wild-type Trypanosoma brucei rhodesiense STIB900 by Alamar blue assay	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	New treatment option for second-stage African sleeping sickness: in vitro and in vivo efficacy of aza analogs of DB289.
AID418748	Antiprotozoal activity against Trypanosoma brucei rhodesiense STIB900 trypomastigotes after 70 hrs by alamar blue assay	2009	Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7	Structure-activity study of pentamidine analogues as antiprotozoal agents.
AID335551	Antitrypanosomal activity against Trypanosoma brucei rhodesiense after 72 hrs by alamar blue assay	2002	Journal of natural products, Aug, Volume: 65, Issue:8	Ancistrocongolines A-D, new naphthylisoquinoline alkaloids from ancistrocladus congolensis.
AID475977	Inhibition of Trypanosoma brucei brucei recombinant cathepsin B assessed after 5 mins by spectrofluorimetry	2010	Bioorganic & medicinal chemistry, Apr-01, Volume: 18, Issue:7	Assessing the trypanocidal potential of natural and semi-synthetic diketopiperazines from two deep water marine-derived fungi.
AID106021	Tested for cytotoxicity towards human MRC-5 cells	2002	Bioorganic & medicinal chemistry letters, Dec-16, Volume: 12, Issue:24	Antitrypanosomal activities and cytotoxicity of 5-nitro-2-furancarbohydrazides.
AID562489	Antitrypanosomal activity against Trypanosoma brucei gambiense STIB930 by Alamar blue assay	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	New treatment option for second-stage African sleeping sickness: in vitro and in vivo efficacy of aza analogs of DB289.
AID473010	Inhibition of Plasmodium falciparum recombinant falcipain-3 by standard fluorescence assay	2010	Journal of medicinal chemistry, Mar-11, Volume: 53, Issue:5	Michael acceptor based antiplasmodial and antitrypanosomal cysteine protease inhibitors with unusual amino acids.
AID336751	Antitrypanosomal activity against Trypanosoma brucei brucei Lab110 EATRO after 48 hrs	2003	Journal of natural products, Mar, Volume: 66, Issue:3	Trypanocidal diarylheptanoids from Aframomum letestuianum.
AID475975	Antitrypanosomal activity against Trypanosoma brucei brucei 427-221a after 40 hrs by bioluminescence assay	2010	Bioorganic & medicinal chemistry, Apr-01, Volume: 18, Issue:7	Assessing the trypanocidal potential of natural and semi-synthetic diketopiperazines from two deep water marine-derived fungi.
AID1348371	Cytotoxicity against human MRC5 SV2 cells assessed as decrease in cell viability after 72 hrs by resazurin dye-based fluorometric method	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Novel triazine dimers with potent antitrypanosomal activity.
AID341601	Antitrypanosomal activity against Trypanosoma brucei rhodesiense STIB900	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Peroxide bond-dependent antiplasmodial specificity of artemisinin and OZ277 (RBx11160).
AID720847	Antitrypanosomal activity against Trypanosoma brucei rhodesiense STIB900 after 70 hrs by resazurin reduction assay	2013	Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3	Aminoalkyl derivatives of guanidine diaromatic minor groove binders with antiprotozoal activity.
AID1541166	Antiprotozoal activity against Trypanosoma brucei rhodesiense STIB900 trypomastigotes assessed as growth inhibition after 72 hrs by Alamar Blue dye-based fluorometric analysis
AID764882	Cytotoxicity against rat L6 cells after 72 hrs by microplate fluorometry	2013	Bioorganic & medicinal chemistry, Sep-01, Volume: 21, Issue:17	Antiprotozoal activity of bicyclic diamines with a N-methylpiperazinyl group at the bridgehead atom.
AID264016	Selectivity index, IC50 for J774.1/IC50 for Trypanosoma brucei brucei	2006	Bioorganic & medicinal chemistry letters, May-15, Volume: 16, Issue:10	Aziridine-2,3-dicarboxylate inhibitors targeting the major cysteine protease of Trypanosoma brucei as lead trypanocidal agents.
AID765710	Antitrypanosomal activity against Trypanosoma brucei rhodesiense STIB900 infected in NMRI mouse assessed as cured animal at 2 mg/kg, ip administered for 4 days	2013	European journal of medicinal chemistry, Sep, Volume: 67	Synthesis and antiprotozoal activities of benzyl phenyl ether diamidine derivatives.
AID552695	Cytotoxicity against rat L6 cells after 70 hrs by alamar blue assay	2011	Bioorganic & medicinal chemistry, Jan-01, Volume: 19, Issue:1	Synthesis and antitrypanosomal evaluation of derivatives of N-benzyl-1,2-dihydroquinolin-6-ols: Effect of core substitutions and salt formation.
AID316592	Antiplasmodial activity against Plasmodium falciparum K1 in [3H]hypoxanthine incorporation assay	2008	Journal of medicinal chemistry, Feb-28, Volume: 51, Issue:4	New bis(2-aminoimidazoline) and bisguanidine DNA minor groove binders with potent in vivo antitrypanosomal and antiplasmodial activity.
AID1163238	Metabolic stability in human liver microsomes assessed as compound remaining after 15 mins by UPLC analysis	2014	Bioorganic & medicinal chemistry, Oct-01, Volume: 22, Issue:19	From human immunodeficiency virus non-nucleoside reverse transcriptase inhibitors to potent and selective antitrypanosomal compounds.
AID1462698	Antiparasitic activity against Trypanosoma brucei rhodesiense STIB 900 trypomastigote bloodstream form assessed as growth inhibition at 0.8 ug/ml after 72 hrs by resazurin dye-based fluorometric analysis relative to control	2017	Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17	Lead selection of antiparasitic compounds from a focused library of benzenesulfonyl derivatives of heterocycles.
AID441747	Cytotoxicity against rat L6 cells after 70 hrs by alamar blue assay	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Antitrypanosomal activity of 1,2-dihydroquinolin-6-ols and their ester derivatives.
AID562488	Antitrypanosomal activity against Trypanosoma brucei gambiense ITMAP141267 by Alamar blue assay	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	New treatment option for second-stage African sleeping sickness: in vitro and in vivo efficacy of aza analogs of DB289.
AID728609	Antitrypanosomal activity against bloodstream forms of wild type Trypanosoma brucei rhodesiense STIB900 after 70 hrs by Alamar Blue assay	2013	Journal of medicinal chemistry, Apr-11, Volume: 56, Issue:7	Optimization of chloronitrobenzamides (CNBs) as therapeutic leads for human African trypanosomiasis (HAT).
AID453254	Antitrypanosomal activity against Trypanosoma brucei rhodesiense	2009	Bioorganic & medicinal chemistry, Oct-15, Volume: 17, Issue:20	Structure-activity relationship of antiparasitic and cytotoxic indoloquinoline alkaloids, and their tricyclic and bicyclic analogues.
AID303243	Cytotoxicity against rat L6 cells	2007	Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23	Synthesis and in vitro antiprotozoal activity of bisbenzofuran cations.
AID243451	In vitro inhibitory concentration against P2 aminopurine transporter of Trypanosoma brucei brucei 427 adenosine (0.5 uM) uptake in presence of 1 mM inosine	2005	Journal of medicinal chemistry, Aug-25, Volume: 48, Issue:17	Design and synthesis of a series of melamine-based nitroheterocycles with activity against Trypanosomatid parasites.
AID300097	Antitrypanosomal activity against Trypanosoma brucei rhodesiense after 72 hrs by microplate assay	2007	Bioorganic & medicinal chemistry, Aug-15, Volume: 15, Issue:16	Bicyclo[2.2.2]octyl esters of dialkylamino acids as antiprotozoals.
AID725218	Antiprotozoal activity against Trypanosoma brucei rhodesiense STIB 900 after 72 hrs by Alamar blue assay	2013	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 23, Issue:2	Discovery and preliminary structure-activity relationship analysis of 1,14-sperminediphenylacetamides as potent and selective antimalarial lead compounds.
AID562493	Ratio of IC50 for melasoprol-resistant Trypanosoma brucei rhodesiense STIB900 to IC50 for wild-type Trypanosoma brucei rhodesiense STIB901	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	New treatment option for second-stage African sleeping sickness: in vitro and in vivo efficacy of aza analogs of DB289.
AID621153	Antiprotozoal activity against Trypanosoma brucei rhodesiense STIB900 at pH 7.4 by microplate assay	2011	Bioorganic & medicinal chemistry letters, Oct-01, Volume: 21, Issue:19	Synthesis and in vitro antiprotozoal activities of 5-phenyliminobenzo[a]phenoxazine derivatives.
AID756883	Antiprotozoal activity against Trypanosoma brucei rhodesiense STIB900 infected in NMRI mouse assessed as host mean survival days at 5 mg/kg, ip qd for 4 days	2013	Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13	Synthesis and antiprotozoal activity of dicationic m-terphenyl and 1,3-dipyridylbenzene derivatives.
AID215678	Minimum concentration producing complete lysis of all trypanosomes within 30 min at 37 degrees C in vitro	1982	Journal of medicinal chemistry, Jun, Volume: 25, Issue:6	Potential antitrypanosomal agents. 1,N2-Disubstituted 2-amino-5-hydroxy-4-methylnaphtho[1,2-d]thiazolium salts and related compounds.
AID1432876	Cytotoxicity against rat L6 cells assessed as growth inhibition after 72 hrs by alamar blue assay	2017	Bioorganic & medicinal chemistry, 04-01, Volume: 25, Issue:7	Synthesis and activity of nucleoside-based antiprotozoan compounds.
AID1163240	Metabolic stability in human plasma assessed as compound remaining after 1 hr	2014	Bioorganic & medicinal chemistry, Oct-01, Volume: 22, Issue:19	From human immunodeficiency virus non-nucleoside reverse transcriptase inhibitors to potent and selective antitrypanosomal compounds.
AID677571	Antitrypanosomal activity against bloodstream form of Trypanosoma brucei brucei Lister 427 clone 221a overexpressing tet-inducible NTR in presence of tetracycline after 3 days	2012	Journal of medicinal chemistry, Jun-14, Volume: 55, Issue:11	Novel 3-nitro-1H-1,2,4-triazole-based amides and sulfonamides as potential antitrypanosomal agents.
AID372438	Antitrypanosomal activity against wild type Trypanosoma cruzi BS221 infected in mouse macrophage by reporter dye assay	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	2,N6-disubstituted adenosine analogs with antitrypanosomal and antimalarial activities.
AID727321	Antiparasitic activity against Trypanosoma brucei rhodesiense STIB900 bloodstream forms incubated for 70 hrs by Alamar blue assay	2013	Journal of medicinal chemistry, Feb-28, Volume: 56, Issue:4	Synthesis and in vitro antimalarial testing of neocryptolepines: SAR study for improved activity by introduction and modifications of side chains at C2 and C11 on indolo[2,3-b]quinolines.
AID373520	Antiparasitic activity against Trypanosoma brucei rhodesiense STIB900	2009	European journal of medicinal chemistry, May, Volume: 44, Issue:5	Synthesis and antiparasitic and antifungal evaluation of 2'-arylsubstituted-1H,1'H-[2,5']bisbenzimidazolyl-5-carboxamidines.
AID252610	In vivo antitrypanosomal activity at a dose of 4*1 mg/kg, i.p., in mice infected with Trypanosoma brucei rhodesiense STIB 900 strain, measured as cured/infected; 0/4	2005	Journal of medicinal chemistry, Aug-25, Volume: 48, Issue:17	Design and synthesis of a series of melamine-based nitroheterocycles with activity against Trypanosomatid parasites.
AID1163231	Antitrypanocidal activity against suramin-sensitive Trypanosoma brucei rhodesiense STIB-900 assessed as reduction in parasite growth after 72 hrs	2014	Bioorganic & medicinal chemistry, Oct-01, Volume: 22, Issue:19	From human immunodeficiency virus non-nucleoside reverse transcriptase inhibitors to potent and selective antitrypanosomal compounds.
AID1163237	Stability of the compound in PBS buffer assessed as recovery at pH 7.4 measured after 24 hrs by UPLC analysis	2014	Bioorganic & medicinal chemistry, Oct-01, Volume: 22, Issue:19	From human immunodeficiency virus non-nucleoside reverse transcriptase inhibitors to potent and selective antitrypanosomal compounds.
AID562490	Antitrypanosomal activity against Trypanosoma brucei brucei BS221 by Alamar blue assay	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	New treatment option for second-stage African sleeping sickness: in vitro and in vivo efficacy of aza analogs of DB289.
AID1480085	Antitrypanosomal activity against bloodstream form of Trypanosoma brucei rhodesiense STIB 900 assessed as parasite growth inhibition after 6 hrs by Alamar blue assay	2018	Journal of medicinal chemistry, 04-26, Volume: 61, Issue:8	2 H-1,2,3-Triazole-Based Dipeptidyl Nitriles: Potent, Selective, and Trypanocidal Rhodesain Inhibitors by Structure-Based Design.
AID456259	Antitrypanosomal activity against Trypanosoma brucei rhodesiense infected in rat L6 cells	2010	Bioorganic & medicinal chemistry, Jan-01, Volume: 18, Issue:1	Synthesis, stereoelectronic characterization and antiparasitic activity of new 1-benzenesulfonyl-2-methyl-1,2,3,4-tetrahydroquinolines.
AID1586758	Antiprotozoal activity against trypomastigote stage of Trypanosoma brucei rhodesiense STIB900 after 72 hrs by Alamar Blue assay	2018	Journal of natural products, 12-28, Volume: 81, Issue:12	Antiprotozoal Isoprenoids from Salvia hydrangea.
AID1617101	Antiprotozoal activity against Trypanosoma brucei rhodesiense STIB900 trypomastigotes incubated for 72 hrs by Alamar blue staining-based fluorometric analysis	2019	Journal of natural products, 11-22, Volume: 82, Issue:11	Ealamines A-H, a Series of Naphthylisoquinolines with the Rare 7,8'-Coupling Site, from the Congolese Liana
AID1727700	Antitrypanosomal activity against bloodstream Trypanosoma brucei rhodesiense STIB900 assessed as parasite growth inhibition measured after 70 hrs by Alamar blue assay	2021	European journal of medicinal chemistry, Jan-01, Volume: 209	The discovery of novel antitrypanosomal 4-phenyl-6-(pyridin-3-yl)pyrimidines.
AID1193543	Cytotoxicity against rat L6 cells after 72 hrs by alamar blue assay	2015	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 25, Issue:7	Synthesis of 3-azabicyclo[3.2.2]nonanes and their antiprotozoal activities.
AID1653740	Antitrypanosomal activity against bloodstream Trypanosoma brucei rhodesiense STIB900 assessed as parasite growth inhibition measured after 70 hrs by Alamar blue assay	2020	Bioorganic & medicinal chemistry, 01-01, Volume: 28, Issue:1	Synthesis, in-vitro antiprotozoal activity and molecular docking study of isothiocyanate derivatives.
AID562485	Antitrypanosomal activity against pentamidine-resistant Trypanosoma brucei rhodesiense STIB900 by Alamar blue assay	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	New treatment option for second-stage African sleeping sickness: in vitro and in vivo efficacy of aza analogs of DB289.
AID664487	Antitrypanosomal activity against trypomastigotes of Trypanosoma brucei rhodesiense STIB 900 infected in rat L6 cells after 72 hrs by alamar blue assay	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7	Synthesis, biological evaluation, and structure-activity relationships of N-benzoyl-2-hydroxybenzamides as agents active against P. falciparum (K1 strain), Trypanosomes, and Leishmania.
AID1165097	Ratio of IC50 for bloodstream forms of Trypanosoma brucei brucei Lister 427 clone 221a overexpressing type I nitroreductase in absence of tetracycline to IC50 for bloodstream forms of Trypanosoma brucei brucei Lister 427 clone 221a overexpressing type I n	2014	European journal of medicinal chemistry, Nov-24, Volume: 87	Novel nitro(triazole/imidazole)-based heteroarylamides/sulfonamides as potential antitrypanosomal agents.
AID372440	Resistance factor, ratio of IC50 for tbat1 knock out Trypanosoma cruzi BS221 to IC50 for wild type Trypanosoma cruzi BS221	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	2,N6-disubstituted adenosine analogs with antitrypanosomal and antimalarial activities.
AID562494	Ratio of IC50 for Trypanosoma brucei gambiense K03048 to IC50 for wild-type Trypanosoma brucei rhodesiense STIB902	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	New treatment option for second-stage African sleeping sickness: in vitro and in vivo efficacy of aza analogs of DB289.
AID764881	Selectivity index, ratio of IC50 for rat L6 cells to IC50 for bloodstream form of Trypanosoma brucei rhodesiense STIB 900	2013	Bioorganic & medicinal chemistry, Sep-01, Volume: 21, Issue:17	Antiprotozoal activity of bicyclic diamines with a N-methylpiperazinyl group at the bridgehead atom.
AID1079940	Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID124568	The compound was tested for in vivo activity against a rodent model of Trypanosoma brucei at the specified dose: 5 mg/kg, ip no. of days dosing = 1; All servived	1999	Journal of medicinal chemistry, Oct-21, Volume: 42, Issue:21	Design, synthesis, and evaluation of inhibitors of trypanosomal and leishmanial dihydrofolate reductase.
AID626317	Antiparasitic activity against bloodstream form of Trypanosoma brucei rhodesiense STIB 900 infected in rat L6 cells after 72 hrs by Alamar blue assay	2011	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 21, Issue:21	Biological evaluation of glycosyl-isoindigo derivatives against the pathogenic agents of tropical diseases (malaria, Chagas disease, leishmaniasis and human African trypanosomiasis).
AID1079949	Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID453258	Toxicity against rat L6 cells	2009	Bioorganic & medicinal chemistry, Oct-15, Volume: 17, Issue:20	Structure-activity relationship of antiparasitic and cytotoxic indoloquinoline alkaloids, and their tricyclic and bicyclic analogues.
AID274294	Selectivity index, IC50 for L6 cells/ IC50 for Trypanosoma brucei rhodesience	2006	Bioorganic & medicinal chemistry letters, Oct-15, Volume: 16, Issue:20	Antiprotozoal activities of new bis-chlorophenyl derivatives of bicyclic octanes and aza-nonanes.
AID213651	50% antitrypanosomal activity against Trypanosoma cruzi	2002	Journal of medicinal chemistry, Jul-04, Volume: 45, Issue:14	Lepadins D-F: antiplasmodial and antitrypanosomal decahydroquinoline derivatives from the tropical marine tunicate Didemnum sp.
AID552697	Antitrypanosomal activity against bloodstream form of Trypanosoma brucei rhodesiense STIB900 after 70 hrs by alamar blue assay	2011	Bioorganic & medicinal chemistry, Jan-01, Volume: 19, Issue:1	Synthesis and antitrypanosomal evaluation of derivatives of N-benzyl-1,2-dihydroquinolin-6-ols: Effect of core substitutions and salt formation.
AID779145	Antimicrobial activity against blood stream form of Trypanosoma brucei rhodesiense STIB 900 after 72 hrs by Alamar blue assay	2013	Bioorganic & medicinal chemistry, Nov-01, Volume: 21, Issue:21	Novel 3-nitro-1H-1,2,4-triazole-based piperazines and 2-amino-1,3-benzothiazoles as antichagasic agents.
AID1462699	Antiparasitic activity against Trypanosoma brucei rhodesiense STIB 900 trypomastigote bloodstream form assessed as growth inhibition at 4.8 ug/ml after 72 hrs by resazurin dye-based fluorometric analysis relative to control	2017	Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17	Lead selection of antiparasitic compounds from a focused library of benzenesulfonyl derivatives of heterocycles.
AID418760	Antitrypanosomal activity against Trypanosoma brucei rhodesiense STIB900 trypomastigotes infected in NMRI mouse assessed as mouse survival at 2 mg/kg, ip administered from day 3 to day 6 postinfection	2009	Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7	Structure-activity study of pentamidine analogues as antiprotozoal agents.
AID401527	Antitrypanosomal activity against Trypanosoma brucei rhodesiense	2004	Journal of natural products, May, Volume: 67, Issue:5	Ancistrotanzanine C and related 5,1'- and 7,3'-coupled naphthylisoquinoline alkaloids from Ancistrocladus tanzaniensis.
AID626322	Selectivity index, ratio of IC50 for rat L6 cells to IC50 for bloodstream form of Trypanosoma brucei rhodesiense STIB 900	2011	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 21, Issue:21	Biological evaluation of glycosyl-isoindigo derivatives against the pathogenic agents of tropical diseases (malaria, Chagas disease, leishmaniasis and human African trypanosomiasis).
AID728605	Antitrypanosomal activity against Trypanosoma brucei gambiense DAL 898R after 70 hrs by Alamar Blue assay	2013	Journal of medicinal chemistry, Apr-11, Volume: 56, Issue:7	Optimization of chloronitrobenzamides (CNBs) as therapeutic leads for human African trypanosomiasis (HAT).
AID1504891	Antitrypanosomal activity against Trypanosoma brucei rhodesiense STIB 900 bloodstream forms after 72 hrs by alamar blue staining based fluorescence assay	2018	Journal of natural products, 01-26, Volume: 81, Issue:1	Antiprotozoal Sesquiterpene Lactones and Other Constituents from Tarchonanthus camphoratus and Schkuhria pinnata.
AID1298166	Antitrypanosomal activity against Trypanosoma brucei rhodesiense STIB900 measured after 70 hrs by alamar blue staining based fluorescence analysis	2016	Bioorganic & medicinal chemistry, 06-01, Volume: 24, Issue:11	Synthesis of novel amide and urea derivatives of thiazol-2-ethylamines and their activity against Trypanosoma brucei rhodesiense.
AID389457	Antitrypanosomal activity against Trypanosoma brucei rhodesiense STIB 900 infected acute mouse model assessed as cured mouse at 2 mg/kg, ip daily for 4 days	2008	Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21	Synthesis and antiprotozoal activity of cationic 2-phenylbenzofurans.
AID1846640	Antiprotozoal activity against patient-derived Trypanosoma brucei rhodesiense STIB assessed as parasite growth inhibition incubated for 70 hrs by resazurin dye based fluorometry	2021	Journal of medicinal chemistry, 05-13, Volume: 64, Issue:9	Synthesis and Biological Evaluation of Natural-Product-Inspired, Aminoalkyl-Substituted 1-Benzopyrans as Novel Antiplasmodial Agents.
AID336753	Antitrypanosomal activity against Trypanosoma brucei rhodesiense KETRI 243 As 10-3 isolate after 48 hrs	2003	Journal of natural products, Mar, Volume: 66, Issue:3	Trypanocidal diarylheptanoids from Aframomum letestuianum.
AID1165096	Trypanocidal activity against bloodstream forms of Trypanosoma brucei brucei Lister 427 clone 221a overexpressing type I nitroreductase assessed as inhibition of proliferation after 3 days by resazurin assay in presence of tetracycline	2014	European journal of medicinal chemistry, Nov-24, Volume: 87	Novel nitro(triazole/imidazole)-based heteroarylamides/sulfonamides as potential antitrypanosomal agents.
AID1679082	Antitrypanosomal activity against bloodstream form of Trypanosoma brucei rhodesiense STIB900 incubated for 70 hrs by Alamar blue dye-based fluorometric analysis	2020	RSC medicinal chemistry, Dec-17, Volume: 11, Issue:12	Investigation of thiazolyl-benzothiophenamides as potential agents for African sleeping sickness.
AID1163230	Antitrypanocidal activity against suramin-sensitive Trypanosoma brucei brucei Squib427 assessed as reduction in parasite growth after 72 hrs	2014	Bioorganic & medicinal chemistry, Oct-01, Volume: 22, Issue:19	From human immunodeficiency virus non-nucleoside reverse transcriptase inhibitors to potent and selective antitrypanosomal compounds.
AID1480087	Antitrypanosomal activity against bloodstream form of Trypanosoma brucei rhodesiense STIB 900 assessed as parasite growth inhibition after 24 hrs by Alamar blue assay	2018	Journal of medicinal chemistry, 04-26, Volume: 61, Issue:8	2 H-1,2,3-Triazole-Based Dipeptidyl Nitriles: Potent, Selective, and Trypanocidal Rhodesain Inhibitors by Structure-Based Design.
AID1176975	Antiplasmodial activity against Trypanosoma brucei rhodesiense assessed as growth inhibition	2015	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 25, Issue:3	Exploring in vitro and in vivo Hsp90 inhibitors activity against human protozoan parasites.
AID445252	Selectivity index, ratio of IC50 for rat L6 cells to IC50 for Trypanosoma brucei rhodesiense STIB900	2010	Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1	Synthesis and antiprotozoal activity of cationic 1,4-diphenyl-1H-1,2,3-triazoles.
AID1355403	Antitrypanosomal activity against Trypanosoma brucei rhodesiense STIB900 bloodstream forms after 70 hrs by Alamar blue assay	2018	Journal of natural products, 06-22, Volume: 81, Issue:6	Phytochemical Study of Salvia leriifolia Roots: Rearranged Abietane Diterpenoids with Antiprotozoal Activity.
AID384322	Cytotoxicity against rat L6 cells	2008	European journal of medicinal chemistry, Apr, Volume: 43, Issue:4	Epimers of bicyclo[2.2.2]octan-2-ol derivatives with antiprotozoal activity.
AID473012	Antiplasmodial activity against Plasmodium falciparum W2 by flow cytometry	2010	Journal of medicinal chemistry, Mar-11, Volume: 53, Issue:5	Michael acceptor based antiplasmodial and antitrypanosomal cysteine protease inhibitors with unusual amino acids.
AID1079945	Animal toxicity known. [column 'TOXIC' in source]
AID1193501	Antiprotozoal activity against bloodstream forms of Trypanosoma brucei rhodesiense STIB 900 after 70 hrs by Alamar blue assay	2015	Bioorganic & medicinal chemistry, Apr-01, Volume: 23, Issue:7	Anti-trypanosomal cadinanes synthesized by transannular cyclization of the natural sesquiterpene lactone nobilin.
AID482886	Inhibition of Trypanosoma brucei rhodesiense recombinant rhodesain	2009	Journal of medicinal chemistry, Sep-24, Volume: 52, Issue:18	On-bead screening of a combinatorial fumaric acid derived peptide library yields antiplasmodial cysteine protease inhibitors with unusual peptide sequences.
AID764884	Antiprotozoal activity against bloodstream form of Trypanosoma brucei rhodesiense STIB 900 after 72 hrs by microplate fluorometry	2013	Bioorganic & medicinal chemistry, Sep-01, Volume: 21, Issue:17	Antiprotozoal activity of bicyclic diamines with a N-methylpiperazinyl group at the bridgehead atom.
AID634014	Selectivity index, ratio of IC50 for rat L6 cells to IC50 for Trypanosoma brucei rhodesiense STIB900	2012	European journal of medicinal chemistry, Jan, Volume: 47, Issue:1	New N-methylpiperazinyl derivatives of bicyclic antiprotozoal compounds.
AID578277	Antitrypanosomal activity against TbAT1 and HAPT1-deficient Trypanosoma brucei brucei B48 after 48 hrs by alamar blue assay	2011	Bioorganic & medicinal chemistry, Mar-01, Volume: 19, Issue:5	Synthesis and biological evaluation of 1,4-benzodiazepin-2-ones with antitrypanosomal activity.
AID322079	Selectivity index, ratio of MIC for HL60 cells to MIC for Trypanosoma brucei brucei clone 427-221a	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Bis-acridines as lead antiparasitic agents: structure-activity analysis of a discrete compound library in vitro.
AID558400	Antitrypanosomal activity against Trypanosoma brucei rhodesiense STIB900 bloodstream forms	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	Trypanothione reductase high-throughput screening campaign identifies novel classes of inhibitors with antiparasitic activity.
AID401652	Antitrypanosomal activity against Trypanosoma brucei rhodesiense	2005	Journal of natural products, May, Volume: 68, Issue:5	ent-Dioncophylleine A and related dehydrogenated naphthylisoquinoline alkaloids, the first Asian dioncophyllaceae-type alkaloids, from the "new"plant species Ancistrocladus benomensis.
AID1653746	Selectivity index, ratio of IC50 for rat L6 cells assessed as reduction in cell viability measured after 72 hrs by Alamar blue based inverted microscopy analysis to IC50 for bloodstream Trypanosoma brucei rhodesiense STIB900 assessed as parasite growth in	2020	Bioorganic & medicinal chemistry, 01-01, Volume: 28, Issue:1	Synthesis, in-vitro antiprotozoal activity and molecular docking study of isothiocyanate derivatives.
AID736793	Antitrypanosomal activity against Trypanosoma brucei TC211 after 24 hrs by alamar blue assay	2013	Bioorganic & medicinal chemistry, Feb-01, Volume: 21, Issue:3	Conjugation to 4-aminoquinoline improves the anti-trypanosomal activity of Deferiprone-type iron chelators.
AID1348367	Antitrypanosomal activity against Trypanosoma brucei rhodesiense STIB-900 after 72 hrs by resazurin dye-based fluorometric method	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Novel triazine dimers with potent antitrypanosomal activity.
AID432054	Antitrypanosomal activity against Trypanosoma brucei rhodesiense STIB900 infected NMRI mouse assessed as infection cure rate at 4 mg/kg, ip dosed for 4 days	2009	European journal of medicinal chemistry, Sep, Volume: 44, Issue:9	Synthesis and antiprotozoal activities of dicationic bis(phenoxymethyl)benzenes, bis(phenoxymethyl)naphthalenes, and bis(benzyloxy)naphthalenes.
AID389464	Antitrypanosomal activity against Trypanosoma brucei rhodesiense STIB 900 infected acute mouse model assessed as survival time at 1 mg/kg, ip administered daily for 4 days	2008	Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21	Synthesis and antiprotozoal activity of cationic 2-phenylbenzofurans.
AID416485	Antitrypanosomal activity against Trypanosoma brucei rhodesiense STIB900 by microplate assay	2009	European journal of medicinal chemistry, Feb, Volume: 44, Issue:2	Antiplasmodial and antitrypanosomal activities of aminobicyclo[2.2.2]octyl omega-aminoalkanoates.
AID315105	Antitrypanosomal activity against Trypanosoma brucei rhodesiense STIB900 trypomastigotes by microplate assay	2008	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 18, Issue:7	Synthesis of a small library of 2-phenoxy-1,4-naphthoquinone and 2-phenoxy-1,4-anthraquinone derivatives bearing anti-trypanosomal and anti-leishmanial activity.
AID1614010	Selectivity index, ratio of CC50 for rat L6 cels to IC50 for Trypanosoma brucei rhodesiense STIB900 trypomastigotes	2019	Journal of medicinal chemistry, 02-14, Volume: 62, Issue:3	Design, Synthesis, and Biological Evaluation of New 1-(Aryl-1 H-pyrrolyl)(phenyl)methyl-1 H-imidazole Derivatives as Antiprotozoal Agents.
AID248973	In vitro inhibitory concentration against intracellular amastigotes of Trypanosoma cruzi in rat skeletal myoblasts incubated for 37 degree C for 4 days	2005	Journal of medicinal chemistry, Aug-25, Volume: 48, Issue:17	Design and synthesis of a series of melamine-based nitroheterocycles with activity against Trypanosomatid parasites.
AID736304	Antiparasitic activity against Trypanosoma brucei assessed as growth inhibition	2013	Journal of natural products, Apr-26, Volume: 76, Issue:4	Examination of the mode of action of the almiramide family of natural products against the kinetoplastid parasite Trypanosoma brucei.
AID710591	Selectivity index, ratio of IC50 for rat L6 cells to IC50 for trypomastigote form of Trypanosoma brucei rhodesiense strain STIB 900	2012	Journal of medicinal chemistry, Dec-13, Volume: 55, Issue:23	Conjugation of quinones with natural polyamines: toward an expanded antitrypanosomatid profile.
AID1079932	Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID1165095	Trypanocidal activity against bloodstream forms of Trypanosoma brucei brucei Lister 427 clone 221a overexpressing type I nitroreductase assessed as inhibition of proliferation after 3 days by resazurin assay in absence of tetracycline	2014	European journal of medicinal chemistry, Nov-24, Volume: 87	Novel nitro(triazole/imidazole)-based heteroarylamides/sulfonamides as potential antitrypanosomal agents.
AID389451	Selectivity index, ratio of IC50 for rat L6 cells to IC50 for Trypanosoma brucei rhodesiense STIB 900	2008	Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21	Synthesis and antiprotozoal activity of cationic 2-phenylbenzofurans.
AID464872	Antiparasitic activity against Trypanosoma brucei rhodesiense STIB900 bloodstream form	2010	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 20, Issue:6	Discovery of novel and potent benzhydryl-tropane trypanocides highly selective for Trypanosoma cruzi.
AID303262	Antiparasitic activity against Trypanosoma brucei rhodesiense STIB900 in procyclic stage	2007	Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23	Synthesis and evaluation of antiparasitic activities of new 4-[5-(4-phenoxyphenyl)-2H-pyrazol-3-yl]morpholine derivatives.
AID637699	Trypanocidal activity against Trypanosoma brucei rhodesiense STIB 900 bloodstream forms after 72 hrs by resazurin assay	2012	European journal of medicinal chemistry, Feb, Volume: 48	Synthesis and anti-protozoal activity of novel dihydropyrrolo[3,4-d][1,2,3]triazoles.
AID253519	In vitro inhibitory concentration against blood stream Trypanosoma brucei brucei AT1 knockout mutant with a non functional P2 transporter incubated for 72 h at 37 degree C	2005	Journal of medicinal chemistry, Aug-25, Volume: 48, Issue:17	Design and synthesis of a series of melamine-based nitroheterocycles with activity against Trypanosomatid parasites.
AID445268	Antitrypanosomal activity against Trypanosoma brucei rhodesiense STIB900 infected in NMRI mouse assessed as mean parasitemia relaps day at 1 mg/kg, ip	2010	Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1	Synthesis and antiprotozoal activity of cationic 1,4-diphenyl-1H-1,2,3-triazoles.
AID1163235	Solubility of the compound in 10 mM PBS buffer solution at pH7.4 at 3.125 to 200 uM after 2 hrs	2014	Bioorganic & medicinal chemistry, Oct-01, Volume: 22, Issue:19	From human immunodeficiency virus non-nucleoside reverse transcriptase inhibitors to potent and selective antitrypanosomal compounds.
AID106020	In Vitro cytotoxicity on MRC-5 cells	2000	Journal of medicinal chemistry, Jul-13, Volume: 43, Issue:14	Antimalarial, antitrypanosomal, and antileishmanial activities and cytotoxicity of bis(9-amino-6-chloro-2-methoxyacridines): influence of the linker.
AID1079935	Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID1079939	Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID677575	Selectivity ratio of IC50 for Trypanosoma brucei brucei Lister 427 clone 221a overexpressing tet-inducible NTR in presence of tetracycline to IC50 for Trypanosoma brucei brucei overexpressing tet-inducible NTR in absence of tetracyclin	2012	Journal of medicinal chemistry, Jun-14, Volume: 55, Issue:11	Novel 3-nitro-1H-1,2,4-triazole-based amides and sulfonamides as potential antitrypanosomal agents.
AID756894	Selectivity index, ratio of IC50 for rat L6 cells to IC50 for Trypanosoma brucei rhodesiense STIB900	2013	Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13	Synthesis and antiprotozoal activity of dicationic m-terphenyl and 1,3-dipyridylbenzene derivatives.
AID677572	Antitrypanosomal activity against bloodstream form of Trypanosoma brucei brucei Lister 427 clone 221a overexpressing tet-inducible NTR in absence of tetracycline after 3 days	2012	Journal of medicinal chemistry, Jun-14, Volume: 55, Issue:11	Novel 3-nitro-1H-1,2,4-triazole-based amides and sulfonamides as potential antitrypanosomal agents.
AID419752	Cytotoxicity against rat L6 cells after 70 hrs by alamar blue assay	2009	Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15	Synthesis and antiprotozoal activity of pyridyl analogues of pentamidine.
AID300101	Cytotoxicity against rat L6 cells after 72 hrs by microplate assay	2007	Bioorganic & medicinal chemistry, Aug-15, Volume: 15, Issue:16	Bicyclo[2.2.2]octyl esters of dialkylamino acids as antiprotozoals.
AID1079948	Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID525502	Antiparasitic activity against Trypanosoma brucei BSF overexpressing NTR gene after 3 days by Alamar blue assay	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Exploiting the drug-activating properties of a novel trypanosomal nitroreductase.
AID1165094	Trypanocidal activity against wild type bloodstream forms of Trypanosoma brucei brucei Lister 427 clone 221a assessed as inhibition of proliferation after 3 days by resazurin assay	2014	European journal of medicinal chemistry, Nov-24, Volume: 87	Novel nitro(triazole/imidazole)-based heteroarylamides/sulfonamides as potential antitrypanosomal agents.
AID1359979	Toxicity in ip dosed mouse measured over 72 hrs	2018	European journal of medicinal chemistry, Jun-25, Volume: 154	Synthesis of proline derived benzenesulfonamides: A potent anti-Trypanosoma brucei gambiense agent.
AID482884	Inhibition of Trypanosoma brucei rhodesiense rhodesain after 12 hrs by fluorescence spectroscopy-based on-bead assay	2009	Journal of medicinal chemistry, Sep-24, Volume: 52, Issue:18	On-bead screening of a combinatorial fumaric acid derived peptide library yields antiplasmodial cysteine protease inhibitors with unusual peptide sequences.
AID303247	Selectivity index, ratio for IC50 of rat L6 cells to IC50 of Trypanosoma brucei rhodesiense STIB900	2007	Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23	Synthesis and in vitro antiprotozoal activity of bisbenzofuran cations.
AID1079944	Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID475983	Selectivity index, ratio of IC50 for rat L6 cells to IC50 for Trypanosoma brucei brucei	2010	Bioorganic & medicinal chemistry, Apr-01, Volume: 18, Issue:7	Assessing the trypanocidal potential of natural and semi-synthetic diketopiperazines from two deep water marine-derived fungi.
AID1143878	Selectivity index, ratio of CC50 for rat L6 cells to IC50 for Trypanosoma brucei rhodesiense	2014	European journal of medicinal chemistry, Jun-23, Volume: 81	Antiprotozoal activity and DNA binding of N-substituted N-phenylbenzamide and 1,3-diphenylurea bisguanidines.
AID356389	Antitrypanosomal activity against Trypanosoma brucei rhodesiense	2003	Journal of natural products, Sep, Volume: 66, Issue:9	Ancistrotanzanine A, the first 5,3'-coupled naphthylisoquinoline alkaloid, and two further, 5,8'-linked related compounds from the newly described species Ancistrocladus tanzaniensis.
AID1348066	Antitrypanosomal activity against Trypanosoma brucei rhodesiense STIB900 bloodstream forms after 70 hrs by Alamar blue staining-based fluorometric analysis	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Synthesis of new 1-benzyl tetrahydropyridinylidene ammonium salts and their antimicrobial and anticellular activities.
AID215356	In Vitro inhibition concentration against Trypomastigote form of Trypanosoma brucei	2000	Journal of medicinal chemistry, Jul-13, Volume: 43, Issue:14	Antimalarial, antitrypanosomal, and antileishmanial activities and cytotoxicity of bis(9-amino-6-chloro-2-methoxyacridines): influence of the linker.
AID1503756	Antitrypanosomal activity against Trypanosoma brucei rhodesiense bloodstream forms after 72 hrs by alamar blue staining based fluorescence assay	2017	Journal of natural products, 10-27, Volume: 80, Issue:10	Jozilebomines A and B, Naphthylisoquinoline Dimers from the Congolese Liana Ancistrocladus ileboensis, with Antiausterity Activities against the PANC-1 Human Pancreatic Cancer Cell Line.
AID1614009	Cytotoxicity against rat L6 cels assessed as reduction in cell viability after 72 hrs by Alamar Blue dye-based fluorometric analysis	2019	Journal of medicinal chemistry, 02-14, Volume: 62, Issue:3	Design, Synthesis, and Biological Evaluation of New 1-(Aryl-1 H-pyrrolyl)(phenyl)methyl-1 H-imidazole Derivatives as Antiprotozoal Agents.
AID1541616	Antitrypanosomal activity against Trypanosoma brucei rhodesiense STI B900 measured after 72 hrs by alamar blue dye based fluorimetry analysis	2019	Journal of natural products, 12-27, Volume: 82, Issue:12	Structure, Biosynthesis, and Bioactivity of Photoditritide from
AID1240908	Cytotoxicity against rat L6 cells after 72 hrs by alamar blue assay	2015	Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16	2-Phenoxy-1,4-naphthoquinones: From a Multitarget Antitrypanosomal to a Potential Antitumor Profile.
AID389459	Antitrypanosomal activity against Trypanosoma brucei rhodesiense STIB 900 infected acute mouse model assessed as cured mouse at 1 mg/kg, ip daily for 4 days	2008	Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21	Synthesis and antiprotozoal activity of cationic 2-phenylbenzofurans.
AID1240902	Antitrypanosomal activity against bloodstream forms of Trypanosoma brucei rhodesiense STIB 900 after 72 hrs by alamar blue assay	2015	Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16	2-Phenoxy-1,4-naphthoquinones: From a Multitarget Antitrypanosomal to a Potential Antitumor Profile.
AID389462	Antitrypanosomal activity against Trypanosoma brucei rhodesiense STIB 900 infected acute mouse model assessed as survival time at 8 mg/kg, ip administered daily for 4 days	2008	Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21	Synthesis and antiprotozoal activity of cationic 2-phenylbenzofurans.
AID341600	Antiplasmodial activity against Plasmodium falciparum NF54	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Peroxide bond-dependent antiplasmodial specificity of artemisinin and OZ277 (RBx11160).
AID264013	Trypanocidal activity against Trypanosoma brucei brucei after 48 hrs	2006	Bioorganic & medicinal chemistry letters, May-15, Volume: 16, Issue:10	Aziridine-2,3-dicarboxylate inhibitors targeting the major cysteine protease of Trypanosoma brucei as lead trypanocidal agents.
AID1348366	Antitrypanosomal activity against suramin-sensitive Trypanosoma brucei brucei Squib 427 after 72 hrs by resazurin dye-based fluorometric method	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Novel triazine dimers with potent antitrypanosomal activity.
AID1079934	Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID1062629	Antitrypanosomal activity against Trypanosoma brucei rhodesiense STIB900 assessed as growth inhibition after 70 hrs by Alamar blue assay	2014	Bioorganic & medicinal chemistry, Jan-01, Volume: 22, Issue:1	Antiprotozoal activity of dicationic 3,5-diphenylisoxazoles, their prodrugs and aza-analogues.
AID389456	Antitrypanosomal activity against Trypanosoma brucei rhodesiense STIB 900 infected acute mouse model assessed as cured mouse at 8 mg/kg, ip daily for 4 days	2008	Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21	Synthesis and antiprotozoal activity of cationic 2-phenylbenzofurans.
AID1079942	Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID646379	Antitrypanosomal activity against Trypanosoma brucei brucei GVR35 infected in NMRI mouse assessed as increase in survival time at 20 mg/kg, ip qd for 5 days measured after 180 days	2012	Journal of medicinal chemistry, Jan-12, Volume: 55, Issue:1	Discovery of a novel class of orally active trypanocidal N-myristoyltransferase inhibitors.
AID562496	Ratio of IC50 for Trypanosoma brucei gambiense STIB930 to IC50 for wild-type Trypanosoma brucei rhodesiense STIB904	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	New treatment option for second-stage African sleeping sickness: in vitro and in vivo efficacy of aza analogs of DB289.
AID419680	Antitrypanosomal activity against Trypanosoma brucei rhodesiense bloodstream trypomastigotes	2009	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 19, Issue:11	Privileged structure-guided synthesis of quinazoline derivatives as inhibitors of trypanothione reductase.
AID536810	Antitrypanosomal activity against Trypanosoma brucei rhodesiense STIB900	2010	European journal of medicinal chemistry, Nov, Volume: 45, Issue:11	QSAR guided synthesis of simplified antiplasmodial analogs of naphthylisoquinoline alkaloids.
AID341605	Antimicrobial activity against Giardia duodenalis G1	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Peroxide bond-dependent antiplasmodial specificity of artemisinin and OZ277 (RBx11160).
AID1432875	Antitrypanosomal activity against bloodstream forms of Trypanosoma brucei rhodesiense STIB900 trypomastigotes after 72 hrs by alamar blue assay	2017	Bioorganic & medicinal chemistry, 04-01, Volume: 25, Issue:7	Synthesis and activity of nucleoside-based antiprotozoan compounds.
AID1062617	Trypanocidal activity against bloodstream form of Trypanosoma brucei rhodesiense STIB900 infected in NMRI mouse assessed as mean survival days at 5 mg/kg, ip qd administered for 4 days	2014	Bioorganic & medicinal chemistry, Jan-01, Volume: 22, Issue:1	Antiprotozoal activity of dicationic 3,5-diphenylisoxazoles, their prodrugs and aza-analogues.
AID562492	Ratio of IC50 for pentamidine-resistant Trypanosoma brucei rhodesiense STIB900 to IC50 for wild-type Trypanosoma brucei rhodesiense STIB900	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	New treatment option for second-stage African sleeping sickness: in vitro and in vivo efficacy of aza analogs of DB289.
AID419753	Antitrypanosomal activity against bloodstream Trypanosoma brucei rhodesiense STIB900 after 70 hrs by alamar blue assay	2009	Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15	Synthesis and antiprotozoal activity of pyridyl analogues of pentamidine.
AID728606	Antitrypanosomal activity against Trypanosoma brucei gambiense STIB930 after 70 hrs by Alamar Blue assay	2013	Journal of medicinal chemistry, Apr-11, Volume: 56, Issue:7	Optimization of chloronitrobenzamides (CNBs) as therapeutic leads for human African trypanosomiasis (HAT).
AID1578096	Antitrypanosomal activity against Leishmania donovani after 48 hrs by [3H]-hypoxanthine incorporation assay	2019	Bioorganic & medicinal chemistry letters, 10-15, Volume: 29, Issue:20	Antiprotozoal alkaloid principles of the plant family Amaryllidaceae.
AID251297	In vivo antitrypanosomal activity at a dose of 4*1 mg/kg, i.p., in mice infected with Trypanosoma brucei rhodesiense STIB 900 strain, measured as survival days (control 7 days); ND is not determined	2005	Journal of medicinal chemistry, Aug-25, Volume: 48, Issue:17	Design and synthesis of a series of melamine-based nitroheterocycles with activity against Trypanosomatid parasites.
AID418761	Antitrypanosomal activity against Trypanosoma brucei rhodesiense STIB900 trypomastigotes infected in NMRI mouse assessed as mouse survival at 1 mg/kg, ip administered from day 3 to day 6 postinfection	2009	Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7	Structure-activity study of pentamidine analogues as antiprotozoal agents.
AID235940	In vivo antitrypanosomal activity at a dose of 4*8 mg/kg, i.p., in mice infected with Trypanosoma brucei brucei STIB 795 strain; Not determined	2005	Journal of medicinal chemistry, Aug-25, Volume: 48, Issue:17	Design and synthesis of a series of melamine-based nitroheterocycles with activity against Trypanosomatid parasites.
AID1163236	Octanol-phosphate buffer partition coefficient, log D of the compound at pH 7.4 after 2 hrs of shaking after 2 hrs	2014	Bioorganic & medicinal chemistry, Oct-01, Volume: 22, Issue:19	From human immunodeficiency virus non-nucleoside reverse transcriptase inhibitors to potent and selective antitrypanosomal compounds.
AID445258	Toxicity in NMRI mouse infected with Trypanosoma brucei rhodesiense STIB900 assessed as survival at 2 mg/kg, ip after administered for 4 consecutive days from day 3 postinfection measured after 7 to 30 days	2010	Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1	Synthesis and antiprotozoal activity of cationic 1,4-diphenyl-1H-1,2,3-triazoles.
AID756895	Antiprotozoal activity against Trypanosoma brucei rhodesiense STIB900 after 72 hrs by Alamar Blue assay	2013	Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13	Synthesis and antiprotozoal activity of dicationic m-terphenyl and 1,3-dipyridylbenzene derivatives.
AID710592	Cytotoxicity against rat L6 cells assessed as growth inhibition after 72 hrs by inverted microscopy	2012	Journal of medicinal chemistry, Dec-13, Volume: 55, Issue:23	Conjugation of quinones with natural polyamines: toward an expanded antitrypanosomatid profile.
AID621158	Selectivity index, ratio of IC50 for rat L6 cells to IC50 for Trypanosoma brucei rhodesiense STIB900	2011	Bioorganic & medicinal chemistry letters, Oct-01, Volume: 21, Issue:19	Synthesis and in vitro antiprotozoal activities of 5-phenyliminobenzo[a]phenoxazine derivatives.
AID404597	Antitrypanosomal activity against Trypanosoma brucei rhodesiense STIB 900 after 72 hrs by microplate alamar blue assay	2008	Bioorganic & medicinal chemistry, Jun-15, Volume: 16, Issue:12	Novel azabicyclo[3.2.2]nonane derivatives and their activities against Plasmodium falciparum K1 and Trypanosoma brucei rhodesiense.
AID260371	Antiprotozoal activity against Trichomonas vaginalis CMP	2006	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 16, Issue:4	Synthesis and antiprotozoal activity of some new synthetic substituted quinoxalines.
AID728604	Antitrypanosomal activity against Trypanosoma brucei gambiense KO48 after 70 hrs by Alamar Blue assay	2013	Journal of medicinal chemistry, Apr-11, Volume: 56, Issue:7	Optimization of chloronitrobenzamides (CNBs) as therapeutic leads for human African trypanosomiasis (HAT).
AID1480082	Antitrypanosomal activity against bloodstream form of Trypanosoma brucei rhodesiense STIB 900 assessed as parasite growth inhibition after 72 hrs by Alamar blue assay	2018	Journal of medicinal chemistry, 04-26, Volume: 61, Issue:8	2 H-1,2,3-Triazole-Based Dipeptidyl Nitriles: Potent, Selective, and Trypanocidal Rhodesain Inhibitors by Structure-Based Design.
AID274745	Antiprotozoal activity against Trypanosoma brucei rhodesiense STIB900	2007	Journal of natural products, Jan, Volume: 70, Issue:1	Limonoid orthoacetates and antiprotozoal compounds from the roots of Pseudocedrela kotschyi.
AID482889	Inhibition of human liver cathepsin B	2009	Journal of medicinal chemistry, Sep-24, Volume: 52, Issue:18	On-bead screening of a combinatorial fumaric acid derived peptide library yields antiplasmodial cysteine protease inhibitors with unusual peptide sequences.
AID1578093	Antitrypanosomal activity against Trypanosoma cruzi	2019	Bioorganic & medicinal chemistry letters, 10-15, Volume: 29, Issue:20	Antiprotozoal alkaloid principles of the plant family Amaryllidaceae.
AID362548	Antiprotozoal activity against Trypanosoma brucei rhodesiense STIB900	2008	Journal of natural products, Sep, Volume: 71, Issue:9	Antiprotozoal activities of heterocyclic-substituted xanthones from the marine-derived fungus Chaetomium sp.
AID235933	In vivo antitrypanosomal activity at a dose of 4*8 mg/kg, i.p., in mice infected with Trypanosoma brucei brucei STIB 795 strain, measured as survival days (control 7 days)	2005	Journal of medicinal chemistry, Aug-25, Volume: 48, Issue:17	Design and synthesis of a series of melamine-based nitroheterocycles with activity against Trypanosomatid parasites.
AID632296	Antitrypanosomal activity against blood stream form of Trypanosoma brucei rhodesiense STIB 900 infected in rat L6 cells after 72 hrs by alamar blue assay	2011	Journal of medicinal chemistry, Dec-08, Volume: 54, Issue:23	Novel 3-nitro-1H-1,2,4-triazole-based aliphatic and aromatic amines as anti-chagasic agents.
AID728616	Antitrypanosomal activity against Trypanosoma brucei brucei 221 after 48 hrs by Cell Titre Glo assay	2013	Journal of medicinal chemistry, Apr-11, Volume: 56, Issue:7	Optimization of chloronitrobenzamides (CNBs) as therapeutic leads for human African trypanosomiasis (HAT).
AID1181596	Antimicrobial activity against bloodstream form of Trypanosoma brucei rhodesiense STIB 900 after 70 hrs by alamar blue assay	2014	Journal of medicinal chemistry, Aug-14, Volume: 57, Issue:15	Pyridyl benzamides as a novel class of potent inhibitors for the kinetoplastid Trypanosoma brucei.
AID578276	Antitrypanosomal activity against TbAT1-deficient Trypanosoma brucei brucei after 48 hrs by alamar blue assay	2011	Bioorganic & medicinal chemistry, Mar-01, Volume: 19, Issue:5	Synthesis and biological evaluation of 1,4-benzodiazepin-2-ones with antitrypanosomal activity.
AID377196	Antitrypanosomal activity against Trypanosoma rhodesiense	2000	Journal of natural products, Aug, Volume: 63, Issue:8	Pelorol from the tropical marine sponge Dactylospongia elegans.
AID372431	Trypanocidal activity against Trypanosoma brucei rhodesiense STIB 900 infected in mouse macrophage by reporter dye assay	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	2,N6-disubstituted adenosine analogs with antitrypanosomal and antimalarial activities.
AID1306904	Cytotoxicity against rat L6 cells assessed as reduction in cell viability after 72 hrs by Alamar blue assay	2016	Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16	Antiprotozoal activity of bicycles featuring a dimethylamino group at their bridgehead.
AID767873	Antitrypanosomal activity against bloodstream form of Trypanosoma brucei rhodesiense STIB 900 by Alamar Blue assay	2013	Journal of natural products, Sep-27, Volume: 76, Issue:9	Antitrypanosomal triterpenoid with an ε-lactone E-ring from Salvia urmiensis.
AID1728298	Cytotoxicity against rat L6 cells after 70 hrs by Alamar blue assay	2021	European journal of medicinal chemistry, Jan-15, Volume: 210	Preparation of new 1,3-dibenzyl tetrahydropyridinylidene ammonium salts and their antimicrobial and anticellular activities.
AID351794	Selectivity index, ratio of IC50 for rat L6 cells to IC50 for Trypanosoma brucei rhodesiense	2009	Bioorganic & medicinal chemistry, May-15, Volume: 17, Issue:10	Antiplasmodial and antitrypanosomal activity of bicyclic amides and esters of dialkylamino acids.
AID418747	Cytotoxicity against rat L6 cells after 70 hrs by alamar blue assay	2009	Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7	Structure-activity study of pentamidine analogues as antiprotozoal agents.
AID765724	Selectivity index, ratio of IC50 for rat L6 cells to IC50 for Trypanosoma brucei rhodesiense STIB900	2013	European journal of medicinal chemistry, Sep, Volume: 67	Synthesis and antiprotozoal activities of benzyl phenyl ether diamidine derivatives.
AID1156603	Cytotoxicity against rat L6 cells after 3 days by Alamar blue assay	2014	European journal of medicinal chemistry, Aug-18, Volume: 83	Synthesis and antiparasitic activity of new bis-arylimidamides: DB766 analogs modified in the terminal groups.
AID419764	Antitrypanosomal activity against bloodstream Trypanosoma brucei rhodesiense STIB900 infected in NMRI mouse assessed as survival rate at 1 mg/kg, ip administered 4 consecutive days from day 3 to 6 postinfection	2009	Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15	Synthesis and antiprotozoal activity of pyridyl analogues of pentamidine.
AID483199	Antitrypanosomal activity against Trypanosoma brucei brucei 427 bloodstream form after 72 hrs by LILIT method	2010	Bioorganic & medicinal chemistry letters, Jun-15, Volume: 20, Issue:12	Antitrypanosomal alkaloids from Polyalthia suaveolens (Annonaceae): their effects on three selected glycolytic enzymes of Trypanosoma brucei.
AID759435	Resistant factor, ratio of IC50 for bloodstream form of Trypanosoma brucei brucei expressing TbMRPA protein to IC50 for bloodstream form of wild type Trypanosoma brucei 247	2013	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 23, Issue:15	N-Benzyloxycarbonyl-S-(2,4-dinitrophenyl)glutathione dibutyl diester is inhibitory to melarsoprol resistant cell lines overexpressing the T. bruceiMRPA transporter.
AID419763	Antitrypanosomal activity against bloodstream Trypanosoma brucei rhodesiense STIB900 infected in NMRI mouse assessed as survival rate at 2 mg/kg, ip administered 4 consecutive days from day 3 to 6 postinfection	2009	Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15	Synthesis and antiprotozoal activity of pyridyl analogues of pentamidine.
AID248971	Inhibitory concentration in vitro against intracellular amastigotes of Leishmania donovani in rat skeletal myoblasts incubated for 96 hr at 27 degree C	2005	Journal of medicinal chemistry, Aug-25, Volume: 48, Issue:17	Design and synthesis of a series of melamine-based nitroheterocycles with activity against Trypanosomatid parasites.
AID1455940	Antiprotozoal activity against bloodstream form of Trypanosoma brucei rhodesiense STIB900 after 72 hrs by Alamar Blue assay
AID309300	Antitrypanosomal activity against Trypanosoma brucei rhodesiense after 72 hrs by Alamar blue assay	2007	Bioorganic & medicinal chemistry, Nov-01, Volume: 15, Issue:21	Marine natural products from the Turkish sponge Agelas oroides that inhibit the enoyl reductases from Plasmodium falciparum, Mycobacterium tuberculosis and Escherichia coli.
AID552696	Antitrypanosomal activity against bloodstream form of Trypanosoma brucei s427 after 72 hrs by MTT assay	2011	Bioorganic & medicinal chemistry, Jan-01, Volume: 19, Issue:1	Synthesis and antitrypanosomal evaluation of derivatives of N-benzyl-1,2-dihydroquinolin-6-ols: Effect of core substitutions and salt formation.
AID739090	Antitrypanosomal activity against bloodstream form Trypanosoma brucei brucei Lister 427 after 48 hrs by hemocytometer	2013	Journal of medicinal chemistry, May-23, Volume: 56, Issue:10	Kinase scaffold repurposing for neglected disease drug discovery: discovery of an efficacious, lapatinib-derived lead compound for trypanosomiasis.
AID762348	Antitrypanosomal activity against Trypanosoma brucei rhodesiense STIB 900 bloodstream form after 70 hrs by Alamar blue assay	2013	European journal of medicinal chemistry, Aug, Volume: 66	3-(Oxazolo[4,5-b]pyridin-2-yl)anilides as a novel class of potent inhibitors for the kinetoplastid Trypanosoma brucei, the causative agent for human African trypanosomiasis.
AID1728296	Trypanocidal activity against Trypanosoma brucei rhodesiense STIB900 incubated for 70 hrs by Alamar blue assay	2021	European journal of medicinal chemistry, Jan-15, Volume: 210	Preparation of new 1,3-dibenzyl tetrahydropyridinylidene ammonium salts and their antimicrobial and anticellular activities.
AID389463	Antitrypanosomal activity against Trypanosoma brucei rhodesiense STIB 900 infected acute mouse model assessed as survival time at 2 mg/kg, ip administered daily for 4 days	2008	Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21	Synthesis and antiprotozoal activity of cationic 2-phenylbenzofurans.
AID445250	Cytotoxicity against rat L6 cells after 70 hrs by alamar blue assay	2010	Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1	Synthesis and antiprotozoal activity of cationic 1,4-diphenyl-1H-1,2,3-triazoles.
AID1300851	Antitrypanosomal activity against bloodstream form of Trypanosoma brucei rhodesiense STIB 900 trypomastigotes assessed as inhibition of parasite growth after 72 hrs by Alamar blue assay	2016	European journal of medicinal chemistry, Jul-19, Volume: 117	Antitrypanosomal activity of 5-nitro-2-aminothiazole-based compounds.
AID1169287	Antitrypanosomal activity against Trypanosoma brucei rhodesiense STIB900 trypomastigote forms	2014	Journal of natural products, Oct-24, Volume: 77, Issue:10	Antitrypanosomal quinoline alkaloids from the roots of Waltheria indica.
AID378201	Antitrypanosomal activity against Trypanosoma brucei rhodesiense STIB900 by Alamar blue assay	2000	Journal of natural products, Nov, Volume: 63, Issue:11	Ancistroealaines A and B, two new bioactive naphthylisoquinolines, and related naphthoic acids from Ancistrocladus ealaensis.
AID400722	Selectivity index, ratio of IC50 for human HT29 cells to IC50 for Trypanosoma brucei rhodesiense STIB 900	1998	Journal of natural products, May, Volume: 61, Issue:5	Total synthesis and biological activities of (+)- and (-)-boscialin and their 1'-epimers.
AID527276	Trypanocidal activity against bloodstream form of Trypanosoma brucei rhodesiense STIB 900 after 72 hrs	2010	Bioorganic & medicinal chemistry, Nov-01, Volume: 18, Issue:21	2-Hexadecynoic acid inhibits plasmodial FAS-II enzymes and arrests erythrocytic and liver stage Plasmodium infections.
AID661007	Antitrypanosomal activity against Trypanosoma brucei brucei TC221 infected in mouse J774.1 cells after 48 hrs by alamar blue assay	2012	Journal of medicinal chemistry, Mar-22, Volume: 55, Issue:6	Synthesis and structure-activity relationships of new quinolone-type molecules against Trypanosoma brucei.
AID372429	Trypanocidal activity against Trypanosoma cruzi Tulahuen C4 trypomastigotes infected in mouse macrophage by reporter dye assay	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	2,N6-disubstituted adenosine analogs with antitrypanosomal and antimalarial activities.
AID1578094	Antitrypanosomal activity against Trypanosoma brucei rhodesiense after 48 hrs by [3H]-hypoxanthine incorporation assay	2019	Bioorganic & medicinal chemistry letters, 10-15, Volume: 29, Issue:20	Antiprotozoal alkaloid principles of the plant family Amaryllidaceae.
AID1439212	Antitrypanosomal activity against Trypanosoma brucei rhodesiense STIB900 after 72 hrs by Alamar blue assay	2017	European journal of medicinal chemistry, Mar-10, Volume: 128	Synthesis and antitrypanosomal activities of novel pyridylchalcones.
AID274300	Cytotoxicity against L6 cells	2006	Bioorganic & medicinal chemistry letters, Oct-15, Volume: 16, Issue:20	Antiprotozoal activities of new bis-chlorophenyl derivatives of bicyclic octanes and aza-nonanes.
AID418749	Selectivity index, ratio of IC50 for rat L6 cells to IC50 for Trypanosoma brucei rhodesiense STIB900 trypomastigotes	2009	Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7	Structure-activity study of pentamidine analogues as antiprotozoal agents.
AID1245578	Antiparasitic activity against trypomastigote stage of Trypanosoma brucei rhodesiense STIB 900 assessed as parasite growth inhibition after 72 hrs by Alamar blue assay	2015	Bioorganic & medicinal chemistry, Oct-01, Volume: 23, Issue:19	Discovery of potent nitrotriazole-based antitrypanosomal agents: In vitro and in vivo evaluation.
AID1079941	Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID1193546	Antitrypanosomal activity against Trypanosoma brucei rhodesiense STIB900 bloodstream forms after 72 hrs by alamar blue assay	2015	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 25, Issue:7	Synthesis of 3-azabicyclo[3.2.2]nonanes and their antiprotozoal activities.
AID1079938	Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID1079947	Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID475976	Inhibition of Trypanosoma brucei brucei recombinant rhodesain after 5 mins by spectrofluorimetry	2010	Bioorganic & medicinal chemistry, Apr-01, Volume: 18, Issue:7	Assessing the trypanocidal potential of natural and semi-synthetic diketopiperazines from two deep water marine-derived fungi.
AID634013	Cytotoxicity against rat L6 cells	2012	European journal of medicinal chemistry, Jan, Volume: 47, Issue:1	New N-methylpiperazinyl derivatives of bicyclic antiprotozoal compounds.
AID1336738	Cytotoxicity against rat L6 cells assessed as growth inhibition after 70 hrs by alamar blue assay	2017	Bioorganic & medicinal chemistry, 02-01, Volume: 25, Issue:3	New derivatives of 7-chloroquinolin-4-amine with antiprotozoal activity.
AID1199917	Antiprotozoal activity against bloodstream form of Trypanosoma brucei rhodesiense STIB900 trypomastigote by alamar-blue assay	2015	Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4	Antiprotozoal activity and DNA binding of dicationic acridones.
AID441746	Antitrypanosomal activity against bloodstream Trypanosoma brucei rhodesiense STIB 900 after 70 hrs by alamar blue assay	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Antitrypanosomal activity of 1,2-dihydroquinolin-6-ols and their ester derivatives.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	80 (18.52)	18.7374
1990's	65 (15.05)	18.2507
2000's	130 (30.09)	29.6817
2010's	143 (33.10)	24.3611
2020's	14 (3.24)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	21 (4.58%)	5.53%
Reviews	22 (4.79%)	6.00%
Case Studies	26 (5.66%)	4.05%
Observational	0 (0.00%)	0.25%
Other	390 (84.97%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (1)

Trial Overview

Trial			Phase	Enrollment	Study Type	Start Date	Status
Clinical Trial Comparing the Therapeutic Combinations Melarsoprol-Nifurtimox, Melarsoprol-Eflornithine and Eflornithine-Nifurtimox in the Treatment of Gambiense Human African Trypanosomiasis in the Meningo-Encephalitic Phase [NCT00330148]			Phase 3	435 participants	Interventional	2001-03-31	Terminated
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
adenine [no description available]	2.92	4	0	6-aminopurines; purine nucleobase	Daphnia magna metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
quinacrine Quinacrine: An acridine derivative formerly widely used as an antimalarial but superseded by chloroquine in recent years. It has also been used as an anthelmintic and in the treatment of giardiasis and malignant effusions. It is used in cell biological experiments as an inhibitor of phospholipase A2.. quinacrine : A member of the class of acridines that is acridine substituted by a chloro group at position 6, a methoxy group at position 2 and a [5-(diethylamino)pentan-2-yl]nitrilo group at position 9.	2.44	2	0	acridines; aromatic ether; organochlorine compound; tertiary amino compound	antimalarial; EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor
dimethyl sulfoxide Dimethyl Sulfoxide: A highly polar organic liquid, that is used widely as a chemical solvent. Because of its ability to penetrate biological membranes, it is used as a vehicle for topical application of pharmaceuticals. It is also used to protect tissue during CRYOPRESERVATION. Dimethyl sulfoxide shows a range of pharmacological activity including analgesia and anti-inflammation.. dimethyl sulfoxide : A 2-carbon sulfoxide in which the sulfur atom has two methyl substituents.	1.99	1	0	sulfoxide; volatile organic compound	alkylating agent; antidote; Escherichia coli metabolite; geroprotector; MRI contrast agent; non-narcotic analgesic; polar aprotic solvent; radical scavenger
glyceraldehyde Glyceraldehyde: An aldotriose containing the propionaldehyde structure with hydroxy groups at the 2- and 3-positions. It is involved in the formation of ADVANCED GLYCOSYLATION END PRODUCTS.. glyceraldehyde : An aldotriose comprising propanal having hydroxy groups at the 2- and 3-positions. It plays role in the formation of advanced glycation end-products (AGEs), a deleterious accompaniment to ageing.. aldose : Aldehydic parent sugars (polyhydroxy aldehydes H[CH(OH)]nC(=O)H, n >= 2) and their intramolecular hemiacetals.	1.98	1	0	aldotriose	fundamental metabolite
glycerol Moon: The natural satellite of the planet Earth. It includes the lunar cycles or phases, the lunar month, lunar landscapes, geography, and soil.	2.41	2	0	alditol; triol	algal metabolite; detergent; Escherichia coli metabolite; geroprotector; human metabolite; mouse metabolite; osmolyte; Saccharomyces cerevisiae metabolite; solvent
melatonin [no description available]	2	1	0	acetamides; tryptamines	anticonvulsant; central nervous system depressant; geroprotector; hormone; human metabolite; immunological adjuvant; mouse metabolite; radical scavenger
niacin Niacin: A water-soluble vitamin of the B complex occurring in various animal and plant tissues. It is required by the body for the formation of coenzymes NAD and NADP. It has PELLAGRA-curative, vasodilating, and antilipemic properties.. vitamin B3 : Any member of a group of vitamers that belong to the chemical structural class called pyridines that exhibit biological activity against vitamin B3 deficiency. Vitamin B3 deficiency causes a condition known as pellagra whose symptoms include depression, dermatitis and diarrhea. The vitamers include nicotinic acid and nicotinamide (and their ionized and salt forms).. nicotinic acid : A pyridinemonocarboxylic acid that is pyridine in which the hydrogen at position 3 is replaced by a carboxy group.	3.31	1	0	pyridine alkaloid; pyridinemonocarboxylic acid; vitamin B3	antidote; antilipemic drug; EC 3.5.1.19 (nicotinamidase) inhibitor; Escherichia coli metabolite; human urinary metabolite; metabolite; mouse metabolite; plant metabolite; vasodilator agent
nitrites Nitrites: Salts of nitrous acid or compounds containing the group NO2-. The inorganic nitrites of the type MNO2 (where M=metal) are all insoluble, except the alkali nitrites. The organic nitrites may be isomeric, but not identical with the corresponding nitro compounds. (Grant & Hackh's Chemical Dictionary, 5th ed)	2.04	1	0	monovalent inorganic anion; nitrogen oxoanion; reactive nitrogen species	human metabolite
palmitic acid Palmitic Acid: A common saturated fatty acid found in fats and waxes including olive oil, palm oil, and body lipids.. hexadecanoic acid : A straight-chain, sixteen-carbon, saturated long-chain fatty acid.	2.47	2	0	long-chain fatty acid; straight-chain saturated fatty acid	algal metabolite; Daphnia magna metabolite; EC 1.1.1.189 (prostaglandin-E2 9-reductase) inhibitor; plant metabolite
phosphorylcholine Phosphorylcholine: Calcium and magnesium salts used therapeutically in hepatobiliary dysfunction.. phosphocholine : The phosphate of choline; and the parent compound of the phosphocholine family.	2.15	1	0	phosphocholines	allergen; epitope; hapten; human metabolite; mouse metabolite
propylene glycol Propylene Glycol: A clear, colorless, viscous organic solvent and diluent used in pharmaceutical preparations.. propane-1,2-diol : The simplest member of the class of propane-1,2-diols, consisting of propane in which a hydrogen at position 1 and a hydrogen at position 2 are substituted by hydroxy groups. A colourless, viscous, hygroscopic, low-melting (-59degreeC) and high-boiling (188degreeC) liquid with low toxicity, it is used as a solvent, emulsifying agent, and antifreeze.	1.99	1	0	glycol; propane-1,2-diols	allergen; human xenobiotic metabolite; mouse metabolite; protic solvent
spermidine [no description available]	2.01	1	0	polyazaalkane; triamine	autophagy inducer; fundamental metabolite; geroprotector
taurine [no description available]	2.03	1	0	amino sulfonic acid; zwitterion	antioxidant; Escherichia coli metabolite; glycine receptor agonist; human metabolite; mouse metabolite; nutrient; radical scavenger; Saccharomyces cerevisiae metabolite
thiamine thiamine(1+) : A primary alcohol that is 1,3-thiazol-3-ium substituted by (4-amino-2-methylpyrimidin-5-yl)methyl, methyl and 2-hydroxyethyl groups at positions 3, 4 and 5, respectively.	7.43	2	0	primary alcohol; vitamin B1	Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
17-octadecynoic acid octadec-17-ynoic acid : An acetylenic fatty acid that is octadecanoi acid (stearic acid) which has been doubly dehydrogenated at positions 17 and 18 to give the corresponding alkynoic acid.	2.07	1	0	acetylenic fatty acid; long-chain fatty acid; monounsaturated fatty acid; terminal acetylenic compound	EC 1.14.14.94 (leukotriene-B4 20-monooxygenase) inhibitor; EC 1.14.15.3 (alkane 1-monooxygenase) inhibitor; P450 inhibitor
albendazole [no description available]	2.03	1	0	aryl sulfide; benzimidazoles; benzimidazolylcarbamate fungicide; carbamate ester	anthelminthic drug; microtubule-destabilising agent; tubulin modulator
atenolol Atenolol: A cardioselective beta-1 adrenergic blocker possessing properties and potency similar to PROPRANOLOL, but without a negative inotropic effect.. atenolol : An ethanolamine compound having a (4-carbamoylmethylphenoxy)methyl group at the 1-position and an N-isopropyl substituent.	2.52	2	0	ethanolamines; monocarboxylic acid amide; propanolamine	anti-arrhythmia drug; antihypertensive agent; beta-adrenergic antagonist; environmental contaminant; sympatholytic agent; xenobiotic
benzyl isothiocyanate benzyl isothiocyanate: inhibits carcinogen-induced neoplasia; structure in Negwer, 5th ed, #715; also promotes urinary bladder carcinoma	2.25	1	0	benzenes; isothiocyanate	antibacterial drug
diminazene Diminazene: An effective trypanocidal agent.. diminazene : A triazene derivative that is triazene in which each of the terminal nitrogens is substituted by a 4-carbamimidoylphenyl group.	10.67	25	0	carboxamidine; triazene derivative	antiparasitic agent; trypanocidal drug
bithionol Bithionol: Halogenated anti-infective agent that is used against trematode and cestode infestations.. bithionol : An aryl sulfide that is diphenyl sulfide in which each phenyl group is substituted at position 2 by hydroxy and at positions 3 and 5 by chlorine. A fungicide and anthelmintic, it was used in various topical drug products for the treatment of liver flukes, but withdrawn after being shown to be a potent photosensitizer with the potential to cause serious skin disorders.	3.06	1	0	aryl sulfide; bridged diphenyl antifungal drug; bridged diphenyl fungicide; dichlorobenzene; organochlorine pesticide; polyphenol	antifungal agrochemical; antiplatyhelmintic drug
verapamil Verapamil: A calcium channel blocker that is a class IV anti-arrhythmia agent.. verapamil : A racemate comprising equimolar amounts of dexverapamil and (S)-verapamil. An L-type calcium channel blocker of the phenylalkylamine class, it is used (particularly as the hydrochloride salt) in the treatment of hypertension, angina pectoris and cardiac arrhythmia, and as a preventive medication for migraine.. 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile : A tertiary amino compound that is 3,4-dimethoxyphenylethylamine in which the hydrogens attached to the nitrogen are replaced by a methyl group and a 4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl group.	3.16	5	0	aromatic ether; nitrile; polyether; tertiary amino compound
chloroquine Chloroquine: The prototypical antimalarial agent with a mechanism that is not well understood. It has also been used to treat rheumatoid arthritis, systemic lupus erythematosus, and in the systemic therapy of amebic liver abscesses.. chloroquine : An aminoquinoline that is quinoline which is substituted at position 4 by a [5-(diethylamino)pentan-2-yl]amino group at at position 7 by chlorine. It is used for the treatment of malaria, hepatic amoebiasis, lupus erythematosus, light-sensitive skin eruptions, and rheumatoid arthritis.	7.13	105	0	aminoquinoline; organochlorine compound; secondary amino compound; tertiary amino compound	anticoronaviral agent; antimalarial; antirheumatic drug; autophagy inhibitor; dermatologic drug
chlorpromazine Chlorpromazine: The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking DOPAMINE RECEPTORS. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the treatment of intractable hiccup.. chlorpromazine : A substituted phenothiazine in which the ring nitrogen at position 10 is attached to C-3 of an N,N-dimethylpropanamine moiety.	1.99	1	0	organochlorine compound; phenothiazines; tertiary amine	anticoronaviral agent; antiemetic; dopaminergic antagonist; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; phenothiazine antipsychotic drug
ciprofloxacin Ciprofloxacin: A broad-spectrum antimicrobial carboxyfluoroquinoline.. ciprofloxacin : A quinolone that is quinolin-4(1H)-one bearing cyclopropyl, carboxylic acid, fluoro and piperazin-1-yl substituents at positions 1, 3, 6 and 7, respectively.	2.54	2	0	aminoquinoline; cyclopropanes; fluoroquinolone antibiotic; N-arylpiperazine; quinolinemonocarboxylic acid; quinolone antibiotic; quinolone; zwitterion	antibacterial drug; antiinfective agent; antimicrobial agent; DNA synthesis inhibitor; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; environmental contaminant; topoisomerase IV inhibitor; xenobiotic
clomipramine Clomipramine: A tricyclic antidepressant similar to IMIPRAMINE that selectively inhibits the uptake of serotonin in the brain. It is readily absorbed from the gastrointestinal tract and demethylated in the liver to form its primary active metabolite, desmethylclomipramine.. clomipramine : A dibenzoazepine that is 10,11-dihydro-5H-dibenzo[b,f]azepine which is substituted by chlorine at position 3 and in which the hydrogen attached to the nitrogen is replaced by a 3-(dimethylamino)propyl group. One of the more sedating tricyclic antidepressants, it is used as the hydrochloride salt for the treatment of depression as well as obsessive-compulsive disorder and phobias.	2.05	1	0	dibenzoazepine	anticoronaviral agent; antidepressant; EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor; serotonergic antagonist; serotonergic drug; serotonin uptake inhibitor
cyproheptadine Cyproheptadine: A serotonin antagonist and a histamine H1 blocker used as antipruritic, appetite stimulant, antiallergic, and for the post-gastrectomy dumping syndrome, etc.. cyproheptadine : The product resulting from the formal oxidative coupling of position 5 of 5H-dibenzo[a,d]cycloheptene with position 4 of 1-methylpiperidine resulting in the formation of a double bond between the two fragments. It is a sedating antihistamine with antimuscarinic and calcium-channel blocking actions. It is used (particularly as the hydrochloride sesquihydrate) for the relief of allergic conditions including rhinitis, conjunctivitis due to inhalant allergens and foods, urticaria and angioedema, and in pruritic skin disorders. Unlike other antihistamines, it is also a seratonin receptor antagonist, making it useful in conditions such as vascular headache and anorexia.	1.99	1	0	piperidines; tertiary amine	anti-allergic agent; antipruritic drug; gastrointestinal drug; H1-receptor antagonist; serotonergic antagonist
dapi DAPI: RN given refers to parent cpd.	2.4	2	0	indoles	fluorochrome
deferiprone Deferiprone: A pyridone derivative and iron chelator that is used in the treatment of IRON OVERLOAD in patients with THALASSEMIA.. deferiprone : A member of the class of 4-pyridones that is pyridin-4(1H)-one substituted at positions 1 and 2 by methyl groups and at position 3 by a hydroxy group. A lipid-soluble iron-chelator used for treatment of thalassaemia.	2.08	1	0	4-pyridones	iron chelator; protective agent
deferoxamine Deferoxamine: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.. desferrioxamine B : An acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N(1)-(5-aminopentyl)-N(1)-hydroxy-N(4)-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator.	2.08	1	0	acyclic desferrioxamine	bacterial metabolite; ferroptosis inhibitor; iron chelator; siderophore
desipramine Desipramine: A tricyclic dibenzazepine compound that potentiates neurotransmission. Desipramine selectively blocks reuptake of norepinephrine from the neural synapse, and also appears to impair serotonin transport. This compound also possesses minor anticholinergic activity, through its affinity to muscarinic receptors.. desipramine : A dibenzoazepine consisting of 10,11-dihydro-5H-dibenzo[b,f]azepine substituted on nitrogen with a 3-(methylamino)propyl group.	1.99	1	0	dibenzoazepine; secondary amino compound	adrenergic uptake inhibitor; alpha-adrenergic antagonist; antidepressant; cholinergic antagonist; drug allergen; EC 3.1.4.12 (sphingomyelin phosphodiesterase) inhibitor; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; H1-receptor antagonist; serotonin uptake inhibitor
eflornithine Eflornithine: An inhibitor of ORNITHINE DECARBOXYLASE, the rate limiting enzyme of the polyamine biosynthetic pathway.. eflornithine : A fluoroamino acid that is ornithine substituted by a difluoromethyl group at position 2.	11.9	51	3	alpha-amino acid; fluoroamino acid	trypanocidal drug
diclofenac Diclofenac: A non-steroidal anti-inflammatory agent (NSAID) with antipyretic and analgesic actions. It is primarily available as the sodium salt.. diclofenac : A monocarboxylic acid consisting of phenylacetic acid having a (2,6-dichlorophenyl)amino group at the 2-position.	2.52	2	0	amino acid; aromatic amine; dichlorobenzene; monocarboxylic acid; secondary amino compound	antipyretic; drug allergen; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; environmental contaminant; non-narcotic analgesic; non-steroidal anti-inflammatory drug; xenobiotic
diethylcarbamazine Diethylcarbamazine: An anthelmintic used primarily as the citrate in the treatment of filariasis, particularly infestations with Wucheria bancrofti or Loa loa.	3.47	2	0	N-carbamoylpiperazine; N-methylpiperazine
dimercaprol Dimercaprol: An anti-gas warfare agent that is effective against Lewisite (dichloro(2-chlorovinyl)arsine) and formerly known as British Anti-Lewisite or BAL. It acts as a chelating agent and is used in the treatment of arsenic, gold, and other heavy metal poisoning.. dimercaprol : A dithiol that is propane-1,2-dithiol in which one of the methyl hydrogens is replaced by a hydroxy group. a chelating agent originally developed during World War II as an experimental antidote against the arsenic-based poison gas Lewisite, it has been used clinically since 1949 for the treatment of poisoning by arsenic, mercury and gold. It can also be used for treatment of poisoning by antimony, bismuth and possibly thallium, and (with sodium calcium edetate) in cases of acute leaad poisoning. Administration is by (painful) intramuscular injection of a suspension of dimercaprol in peanut oil, typically every 4 hours for 2-10 days depending on the toxicity. In the past, dimercaprol was also used for the treatment of Wilson's disease, a severely debilitating genetic disorder in which the body tends to retain copper, with resultant liver and brain injury.	7.87	4	0	dithiol; primary alcohol	chelator
fluconazole Fluconazole: Triazole antifungal agent that is used to treat oropharyngeal CANDIDIASIS and cryptococcal MENINGITIS in AIDS.. fluconazole : A member of the class of triazoles that is propan-2-ol substituted at position 1 and 3 by 1H-1,2,4-triazol-1-yl groups and at position 2 by a 2,4-difluorophenyl group. It is an antifungal drug used for the treatment of mucosal candidiasis and for systemic infections including systemic candidiasis, coccidioidomycosis, and cryptococcosis.	3.19	5	0	conazole antifungal drug; difluorobenzene; tertiary alcohol; triazole antifungal drug	environmental contaminant; P450 inhibitor; xenobiotic
furafylline [no description available]	2.21	1	0	oxopurine
miltefosine miltefosine: hexadecyl phosphocholine derivative of cisplatin; did not substantially activate HIV long terminal repeat; less toxic than cisplatin. miltefosine : A phospholipid that is the hexadecyl monoester of phosphocholine.	6.83	76	0	phosphocholines; phospholipid	anti-inflammatory agent; anticoronaviral agent; antifungal agent; antineoplastic agent; antiprotozoal drug; apoptosis inducer; immunomodulator; protein kinase inhibitor
ethidium Ethidium: A trypanocidal agent and possible antiviral agent that is widely used in experimental cell biology and biochemistry. Ethidium has several experimentally useful properties including binding to nucleic acids, noncompetitive inhibition of nicotinic acetylcholine receptors, and fluorescence among others. It is most commonly used as the bromide.. ethidium : The fluorescent compound widely used in experimental cell biology and biochemistry to reveal double-stranded DNA and RNA.	2.65	3	0	phenanthridines	fluorochrome; intercalator
indomethacin Indomethacin: A non-steroidal anti-inflammatory agent (NSAID) that inhibits CYCLOOXYGENASE, which is necessary for the formation of PROSTAGLANDINS and other AUTACOIDS. It also inhibits the motility of POLYMORPHONUCLEAR LEUKOCYTES.. indometacin : A member of the class of indole-3-acetic acids that is indole-3-acetic acid in which the indole ring is substituted at positions 1, 2 and 5 by p-chlorobenzoyl, methyl, and methoxy groups, respectively. A non-steroidal anti-inflammatory drug, it is used in the treatment of musculoskeletal and joint disorders including osteoarthritis, rheumatoid arthritis, gout, bursitis and tendinitis.	2.49	2	0	aromatic ether; indole-3-acetic acids; monochlorobenzenes; N-acylindole	analgesic; drug metabolite; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; environmental contaminant; gout suppressant; non-steroidal anti-inflammatory drug; xenobiotic metabolite; xenobiotic
iodoquinol Iodoquinol: One of the halogenated 8-quinolinols widely used as an intestinal antiseptic, especially as an antiamebic agent. It is also used topically in other infections and may cause CNS and eye damage. It is known by very many similar trade names world-wide.. iodoquinol : A monohydroxyquinoline that is quinolin-8-ol in which the hydrogens at positions 5 and 7 are replaced by iodine. It is considered the drug of choice for treating asymptomatic or moderate forms of amoebiasis.	1.97	1	0	monohydroxyquinoline; organoiodine compound	antiamoebic agent; antibacterial agent; antiprotozoal drug; antiseptic drug
isoniazid Hydra: A genus of freshwater polyps in the family Hydridae, order Hydroida, class HYDROZOA. They are of special interest because of their complex organization and because their adult organization corresponds roughly to the gastrula of higher animals.. hydrazide : Compounds derived from oxoacids RkE(=O)l(OH)m (l =/= 0) by replacing -OH by -NRNR2 (R groups are commonly H). (IUPAC).	3.37	6	0	carbohydrazide	antitubercular agent; drug allergen
mebendazole Mebendazole: A benzimidazole that acts by interfering with CARBOHYDRATE METABOLISM and inhibiting polymerization of MICROTUBULES.. mebendazole : A carbamate ester that is methyl 1H-benzimidazol-2-ylcarbamate substituted by a benzoyl group at position 5.	8.46	2	0	aromatic ketone; benzimidazoles; carbamate ester	antinematodal drug; microtubule-destabilising agent; tubulin modulator
mefloquine hydrochloride [2,8-bis(trifluoromethyl)quinolin-4-yl]-(2-piperidyl)methanol : An organofluorine compound that consists of quinoline bearing trifluoromethyl substituents at positions 2 and 8 as well as a (2-piperidinyl)hydroxymethyl substituent at position 4.	3.12	5	0	organofluorine compound; piperidines; quinolines; secondary alcohol
metronidazole Metronidazole: A nitroimidazole used to treat AMEBIASIS; VAGINITIS; TRICHOMONAS INFECTIONS; GIARDIASIS; ANAEROBIC BACTERIA; and TREPONEMAL INFECTIONS.. metronidazole : A member of the class of imidazoles substituted at C-1, -2 and -5 with 2-hydroxyethyl, nitro and methyl groups respectively. It has activity against anaerobic bacteria and protozoa, and has a radiosensitising effect on hypoxic tumour cells. It may be given by mouth in tablets, or as the benzoate in an oral suspension. The hydrochloride salt can be used in intravenous infusions. Metronidazole is a prodrug and is selective for anaerobic bacteria due to their ability to intracellularly reduce the nitro group of metronidazole to give nitroso-containing intermediates. These can covalently bind to DNA, disrupting its helical structure, inducing DNA strand breaks and inhibiting bacterial nucleic acid synthesis, ultimately resulting in bacterial cell death.	4.82	10	0	C-nitro compound; imidazoles; primary alcohol	antiamoebic agent; antibacterial drug; antimicrobial agent; antiparasitic agent; antitrichomonal drug; environmental contaminant; prodrug; radiosensitizing agent; xenobiotic
miconazole Miconazole: An imidazole antifungal agent that is used topically and by intravenous infusion.. 1-[2-(2,4-dichlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl]imidazole : A member of the class of imidazoles that is 1-(2,4-dichlorophenyl)-2-(imidazol-1-yl)ethanol in which the hydroxyl hydrogen is replaced by a 2,4-dichlorobenzyl group.. miconazole : A racemate composed of equimolar amounts of (R)- and (S)-miconazole. Used (as its nitrate salt) to treat skin infections such as athlete's foot, jock itch, ringworm and other fungal skin infections. It inhibits the synthesis of ergosterol, a critical component of fungal cell membranes.	2.42	2	0	dichlorobenzene; ether; imidazoles
nevirapine Nevirapine: A potent, non-nucleoside reverse transcriptase inhibitor used in combination with nucleoside analogues for treatment of HIV INFECTIONS and AIDS.. nevirapine : A dipyridodiazepine that is 5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepine which is substituted by methyl, oxo, and cyclopropyl groups at positions 4, 6, and 11, respectively. A non-nucleoside reverse transcriptase inhibitor with activity against HIV-1, it is used in combination with other antiretrovirals for the treatment of HIV infection.	2.1	1	0	cyclopropanes; dipyridodiazepine	antiviral drug; HIV-1 reverse transcriptase inhibitor
niclosamide Niclosamide: An antihelmintic that is active against most tapeworms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p48). niclosamide : A secondary carboxamide resulting from the formal condensation of the carboxy group of 5-chlorosalicylic acid with the amino group of 2-chloro-4-nitroaniline. It is an oral anthelmintic drug approved for use against tapeworm infections.	3.06	1	0	benzamides; C-nitro compound; monochlorobenzenes; salicylanilides; secondary carboxamide	anthelminthic drug; anticoronaviral agent; antiparasitic agent; apoptosis inducer; molluscicide; piscicide; STAT3 inhibitor
oxamniquine Oxamniquine: An anthelmintic with schistosomicidal activity against Schistosoma mansoni, but not against other Schistosoma spp. Oxamniquine causes worms to shift from the mesenteric veins to the liver where the male worms are retained; the female worms return to the mesentery, but can no longer release eggs. (From Martindale, The Extra Pharmacopoeia, 31st ed, p121). oxamniquine : A racemate comprising equimolar amounts of (R)- and (S)-oxamniquine. An anthelmintic, it is administered orally for the treatment of schistomiasis caused by Schistosoma mansoni (but not by other Schistosoma species); intramuscular administration is no longer used as it causes severe pain at the injection site.. {2-[(isopropylamino)methyl]-7-nitro-1,2,3,4-tetrahydroquinolin-6-yl}methanol : A member of the class of quinolines that is 1,2,3,4-tetrahydroquinoline which is substituted at positions 2, 6, and 7 by (isopropylamino)methyl, hydroxymethyl, and nitro groups, respectively.	3.06	1	0	aromatic primary alcohol; C-nitro compound; quinolines; secondary amino compound
pentamidine Pentamidine: Antiprotozoal agent effective in trypanosomiasis, leishmaniasis, and some fungal infections; used in treatment of PNEUMOCYSTIS pneumonia in HIV-infected patients. It may cause diabetes mellitus, central nervous system damage, and other toxic effects.. pentamidine : A diether consisting of pentane-1,5-diol in which both hydroxyl hydrogens have been replaced by 4-amidinophenyl groups. A trypanocidal drug that is used for treatment of cutaneous leishmaniasis and Chagas disease.	11.32	93	3	aromatic ether; carboxamidine; diether	anti-inflammatory agent; antifungal agent; calmodulin antagonist; chemokine receptor 5 antagonist; EC 2.3.1.48 (histone acetyltransferase) inhibitor; NMDA receptor antagonist; S100 calcium-binding protein B inhibitor; trypanocidal drug; xenobiotic
pentobarbital Pentobarbital: A short-acting barbiturate that is effective as a sedative and hypnotic (but not as an anti-anxiety) agent and is usually given orally. It is prescribed more frequently for sleep induction than for sedation but, like similar agents, may lose its effectiveness by the second week of continued administration. (From AMA Drug Evaluations Annual, 1994, p236). pentobarbital : A member of the class of barbiturates, the structure of which is that of barbituric acid substituted at C-5 by ethyl and sec-pentyl groups.	1.96	1	0	barbiturates	GABAA receptor agonist
4-phenylbutyric acid 4-phenylbutyric acid: RN refers to the parent cpd. 4-phenylbutyric acid : A monocarboxylic acid the structure of which is that of butyric acid substituted with a phenyl group at C-4. It is a histone deacetylase inhibitor that displays anticancer activity. It inhibits cell proliferation, invasion and migration and induces apoptosis in glioma cells. It also inhibits protein isoprenylation, depletes plasma glutamine, increases production of foetal haemoglobin through transcriptional activation of the gamma-globin gene and affects hPPARgamma activation.	3.1	1	0	monocarboxylic acid	antineoplastic agent; apoptosis inducer; EC 3.5.1.98 (histone deacetylase) inhibitor; prodrug
oxophenylarsine oxophenylarsine: inhibits protein-tyrosine-phosphatase. phenylarsine oxide : An arsine oxide derived from phenylarsine.	2.92	4	0	arsine oxides	antineoplastic agent; apoptosis inducer; EC 3.1.3.48 (protein-tyrosine-phosphatase) inhibitor
praziquantel azinox: Russian drug	2.03	1	0	isoquinolines
primaquine Primaquine: An aminoquinoline that is given by mouth to produce a radical cure and prevent relapse of vivax and ovale malarias following treatment with a blood schizontocide. It has also been used to prevent transmission of falciparum malaria by those returning to areas where there is a potential for re-introduction of malaria. Adverse effects include anemias and GI disturbances. (From Martindale, The Extra Pharmacopeia, 30th ed, p404). primaquine : An N-substituted diamine that is pentane-1,4-diamine substituted by a 6-methoxyquinolin-8-yl group at the N(4) position. It is a drug used in the treatment of malaria and Pneumocystis pneumonia.	3.06	1	0	aminoquinoline; aromatic ether; N-substituted diamine	antimalarial
propranolol Propranolol: A widely used non-cardioselective beta-adrenergic antagonist. Propranolol has been used for MYOCARDIAL INFARCTION; ARRHYTHMIA; ANGINA PECTORIS; HYPERTENSION; HYPERTHYROIDISM; MIGRAINE; PHEOCHROMOCYTOMA; and ANXIETY but adverse effects instigate replacement by newer drugs.. propranolol : A propanolamine that is propan-2-ol substituted by a propan-2-ylamino group at position 1 and a naphthalen-1-yloxy group at position 3.	2.52	2	0	naphthalenes; propanolamine; secondary amine	anti-arrhythmia drug; antihypertensive agent; anxiolytic drug; beta-adrenergic antagonist; environmental contaminant; human blood serum metabolite; vasodilator agent; xenobiotic
protopine [no description available]	3.31	1	0	dibenzazecine alkaloid	plant metabolite
pyrimethamine Maloprim: contains above 2 cpds	3.79	3	0	aminopyrimidine; monochlorobenzenes	antimalarial; antiprotozoal drug; EC 1.5.1.3 (dihydrofolate reductase) inhibitor
ranitidine [no description available]	2.11	1	0	aralkylamine
vorinostat Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.. vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).	2.11	1	0	dicarboxylic acid diamide; hydroxamic acid	antineoplastic agent; apoptosis inducer; EC 3.5.1.98 (histone deacetylase) inhibitor
suramin Suramin: A polyanionic compound with an unknown mechanism of action. It is used parenterally in the treatment of African trypanosomiasis and it has been used clinically with diethylcarbamazine to kill the adult Onchocerca. (From AMA Drug Evaluations Annual, 1992, p1643) It has also been shown to have potent antineoplastic properties.. suramin : A member of the class of phenylureas that is urea in which each of the amino groups has been substituted by a 3-({2-methyl-5-[(4,6,8-trisulfo-1-naphthyl)carbamoyl]phenyl}carbamoyl)phenyl group. An activator of both the rabbit skeletal muscle RyR1 and sheep cardiac RyR2 isoform ryanodine receptor channels, it has been used for the treatment of human African trypanosomiasis for over 100 years.	10.11	63	2	naphthalenesulfonic acid; phenylureas; secondary carboxamide	angiogenesis inhibitor; antinematodal drug; antineoplastic agent; apoptosis inhibitor; EC 2.7.11.13 (protein kinase C) inhibitor; GABA antagonist; GABA-gated chloride channel antagonist; purinergic receptor P2 antagonist; ryanodine receptor agonist; trypanocidal drug
temozolomide [no description available]	7.15	1	0	imidazotetrazine; monocarboxylic acid amide; triazene derivative	alkylating agent; antineoplastic agent; prodrug
thiabendazole Tresaderm: dermatologic soln containing dexamethasone, thiabendazole & neomycin sulfate	3.47	2	0	1,3-thiazoles; benzimidazole fungicide; benzimidazoles	antifungal agrochemical; antinematodal drug
triclosan [no description available]	2.45	2	0	aromatic ether; dichlorobenzene; monochlorobenzenes; phenols	antibacterial agent; antimalarial; drug allergen; EC 1.3.1.9 [enoyl-[acyl-carrier-protein] reductase (NADH)] inhibitor; EC 1.5.1.3 (dihydrofolate reductase) inhibitor; fungicide; persistent organic pollutant; xenobiotic
trimethoprim Trimethoprim: A pyrimidine inhibitor of dihydrofolate reductase, it is an antibacterial related to PYRIMETHAMINE. It is potentiated by SULFONAMIDES and the TRIMETHOPRIM, SULFAMETHOXAZOLE DRUG COMBINATION is the form most often used. It is sometimes used alone as an antimalarial. TRIMETHOPRIM RESISTANCE has been reported.. trimethoprim : An aminopyrimidine antibiotic whose structure consists of pyrimidine 2,4-diamine and 1,2,3-trimethoxybenzene moieties linked by a methylene bridge.	2.46	2	0	aminopyrimidine; methoxybenzenes	antibacterial drug; diuretic; drug allergen; EC 1.5.1.3 (dihydrofolate reductase) inhibitor; environmental contaminant; xenobiotic
delavirdine Delavirdine: A potent, non-nucleoside reverse transcriptase inhibitor with activity specific for HIV-1.. delavirdine : The amide resulting from the formal condensation of 5-[(methylsulfonyl)amino]-1H-indole-2-carboxylic acid and 4-amino group of 1-[3-(isopropylamino)pyridin-2-yl]piperazine, delavirdine is a non-nucleoside reverse transcriptase inhibitor with activity specific for HIV-1. Viral resistance emerges rapidly when delavirdine is used alone, so it is therefore used (as the methanesulfonic acid salt) with other antiretrovirals for combination therapy of HIV infection.	2.1	1	0	aminopyridine; indolecarboxamide; N-acylpiperazine; sulfonamide	antiviral drug; HIV-1 reverse transcriptase inhibitor
mitomycin Mitomycin: An antineoplastic antibiotic produced by Streptomyces caespitosus. It is one of the bi- or tri-functional ALKYLATING AGENTS causing cross-linking of DNA and inhibition of DNA synthesis.. mitomycin : A family of aziridine-containing natural products isolated from Streptomyces caespitosus or Streptomyces lavendulae.	2.06	1	0	mitomycin	alkylating agent; antineoplastic agent
prednisolone Prednisolone: A glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states.. prednisolone : A glucocorticoid that is prednisone in which the oxo group at position 11 has been reduced to the corresponding beta-hydroxy group. It is a drug metabolite of prednisone.	11.24	6	1	11beta-hydroxy steroid; 17alpha-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(1),Delta(4)-steroid; C21-steroid; glucocorticoid; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone	adrenergic agent; anti-inflammatory drug; antineoplastic agent; drug metabolite; environmental contaminant; immunosuppressive agent; xenobiotic
trichlorfon Trichlorfon: An organochlorophosphate cholinesterase inhibitor that is used as an insecticide for the control of flies and roaches. It is also used in anthelmintic compositions for animals. (From Merck, 11th ed). trichlorfon : A phosphonic ester that is dimethyl phosphonate in which the hydrogen atom attched to the phosphorous is substituted by a 2,2,2-trichloro-1-hydroxyethyl group.	3.06	1	0	organic phosphonate; organochlorine compound; phosphonic ester	agrochemical; anthelminthic drug; EC 3.1.1.7 (acetylcholinesterase) inhibitor; EC 3.1.1.8 (cholinesterase) inhibitor; insecticide
penicillin g Penicillin G: A penicillin derivative commonly used in the form of its sodium or potassium salts in the treatment of a variety of infections. It is effective against most gram-positive bacteria and against gram-negative cocci. It has also been used as an experimental convulsant because of its actions on GAMMA-AMINOBUTYRIC ACID mediated synaptic transmission.. benzylpenicillin : A penicillin in which the substituent at position 6 of the penam ring is a phenylacetamido group.	2.54	2	0	penicillin allergen; penicillin	antibacterial drug; drug allergen; epitope
4-nitroquinoline-1-oxide 4-nitroquinoline N-oxide : A quinoline N-oxide carrying a nitro substituent at position 4.	2.06	1	0	C-nitro compound; quinoline N-oxide	carcinogenic agent
chloramphenicol Amphenicol: Chloramphenicol and its derivatives.	2.21	1	0	C-nitro compound; carboxamide; diol; organochlorine compound	antibacterial drug; antimicrobial agent; Escherichia coli metabolite; geroprotector; Mycoplasma genitalium metabolite; protein synthesis inhibitor
kanamycin a Kanamycin: Antibiotic complex produced by Streptomyces kanamyceticus from Japanese soil. Comprises 3 components: kanamycin A, the major component, and kanamycins B and C, the minor components.. kanamycin : Kanamycin is a naturally occurring antibiotic complex from Streptomyces kanamyceticus that consists of several components: kanamycin A, the major component (also usually designated as kanamycin), and kanamycins B, C, D and X the minor components.	2.54	2	0	kanamycins	bacterial metabolite
tyrosine Tyrosine: A non-essential amino acid. In animals it is synthesized from PHENYLALANINE. It is also the precursor of EPINEPHRINE; THYROID HORMONES; and melanin.. tyrosine : An alpha-amino acid that is phenylalanine bearing a hydroxy substituent at position 4 on the phenyl ring.	2.04	1	0	amino acid zwitterion; erythrose 4-phosphate/phosphoenolpyruvate family amino acid; L-alpha-amino acid; proteinogenic amino acid; tyrosine	EC 1.3.1.43 (arogenate dehydrogenase) inhibitor; fundamental metabolite; micronutrient; nutraceutical
niridazole Niridazole: An antischistosomal agent that has become obsolete.	3.06	1	0	1,3-thiazoles; C-nitro compound
gliotoxin Gliotoxin: A fungal toxin produced by various species of Trichoderma, Gladiocladium fimbriatum, Aspergillus fumigatus, and Penicillium. It is used as an immunosuppressive agent.. gliotoxin : A pyrazinoindole with a disulfide bridge spanning a dioxo-substituted pyrazine ring; mycotoxin produced by several species of fungi.	2.05	1	0	dipeptide; organic disulfide; organic heterotetracyclic compound; pyrazinoindole	antifungal agent; EC 2.5.1.58 (protein farnesyltransferase) inhibitor; immunosuppressive agent; mycotoxin; proteasome inhibitor
ampicillin Ampicillin: Semi-synthetic derivative of penicillin that functions as an orally active broad-spectrum antibiotic.. ampicillin : A penicillin in which the substituent at position 6 of the penam ring is a 2-amino-2-phenylacetamido group.	2.66	2	0	beta-lactam antibiotic; penicillin allergen; penicillin	antibacterial drug
propane Propane: A three carbon alkane with the formula H3CCH2CH3.	1.98	1	0	alkane; gas molecular entity	food propellant
methylprednisolone Methylprednisolone: A PREDNISOLONE derivative with similar anti-inflammatory action.. 6alpha-methylprednisolone : The 6alpha-stereoisomer of 6-methylprednisolone.	2.03	1	0	6-methylprednisolone; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone	adrenergic agent; anti-inflammatory drug; antiemetic; environmental contaminant; neuroprotective agent; xenobiotic
xanthenes Xanthenes: Compounds with three aromatic rings in linear arrangement with an OXYGEN in the center ring.	2.44	2	0	xanthene
benzidine benzidine: RN given refers to parent cpd. benzidine : A member of the class of biphenyls that is 1,1'-biphenyl in which the hydrogen at the para-position of each phenyl group has been replaced by an amino group.	2.02	1	0	biphenyls; substituted aniline	carcinogenic agent
arsthinol arsthinol: nanosuspensions of arsthinol could be used for treatment of acute promyelocytic leukaemia	2.47	2	0	acetamides; anilide
suramin sodium suramin sodium : An organic sodium salt that is the hexasodium salt of suramin. It is an FDA approved drug for African sleeping sickness and river blindness.	2.74	3	0	organic sodium salt	angiogenesis inhibitor; antinematodal drug; antineoplastic agent; apoptosis inhibitor; EC 2.7.11.13 (protein kinase C) inhibitor; GABA antagonist; GABA-gated chloride channel antagonist; purinergic receptor P2 antagonist; ryanodine receptor agonist; trypanocidal drug
pentamidine isethionate pentamidine isethionate : An organosulfonate salt obtained by reaction of pentamidine with two equivalents of 2-hydroxyethylsulfonic acid.	2.75	3	0	organosulfonate salt	trypanocidal drug
galantamine Galantamine: A benzazepine derived from norbelladine. It is found in GALANTHUS and other AMARYLLIDACEAE. It is a cholinesterase inhibitor that has been used to reverse the muscular effects of GALLAMINE TRIETHIODIDE and TUBOCURARINE and has been studied as a treatment for ALZHEIMER DISEASE and other central nervous system disorders.. galanthamine : A benzazepine alkaloid isolated from certain species of daffodils.	3.31	1	0	benzazepine alkaloid fundamental parent; benzazepine alkaloid; organic heterotetracyclic compound; tertiary amino compound	antidote to curare poisoning; cholinergic drug; EC 3.1.1.7 (acetylcholinesterase) inhibitor; EC 3.1.1.8 (cholinesterase) inhibitor; plant metabolite
podophyllotoxin Podophyllum: A genus of poisonous American herbs, family BERBERIDACEAE. The roots yield PODOPHYLLOTOXIN and other pharmacologically important agents. The plant was formerly used as a cholagogue and cathartic. It is different from the European mandrake, MANDRAGORA.	7	90	0	furonaphthodioxole; lignan; organic heterotetracyclic compound	antimitotic; antineoplastic agent; keratolytic drug; microtubule-destabilising agent; plant metabolite; tubulin modulator
copper gluconate Gluconates: Derivatives of gluconic acid (the structural formula HOCH2(CHOH)4COOH), including its salts and esters.	1.96	1	0	organic molecular entity
azomycin azomycin: RN given refers to parent cpd with specified locant; structure	5.64	10	0	C-nitro compound; imidazoles	antitubercular agent
gentian violet Gentian Violet: A dye that is a mixture of violet rosanilinis with antibacterial, antifungal, and anthelmintic properties.. crystal violet : An organic chloride salt that is the monochloride salt of crystal violet cation. It has been used in creams for the topical treatment of bacterial and fungal infections, being effective against some Gram-positive bacteria (notably Staphylococcus species) and some pathogenic fungi (including Candida species) but use declined following reports of animal carcinogenicity. It has also been used for dying wood, silk, and paper, as well as a histological stain.	3.06	1	0	organic chloride salt	anthelminthic drug; antibacterial agent; antifungal agent; antiseptic drug; histological dye
resazurin resazurin: used as indicator in detection of hyposulfite (sulfoxylate); in food research (reductase test); structure	2.44	2	0	phenoxazine
5-nitro-2-furoic acid 5-nitro-2-furoic acid: structure given in first source	2.01	1	0
vinblastine [no description available]	2.47	2	0
2'-deoxyadenosine 2'-deoxyformycin A: RN not in Chemline 9/85; RN and structure given in first source	2.03	1	0	purine 2'-deoxyribonucleoside; purines 2'-deoxy-D-ribonucleoside	Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
ethidium bromide [no description available]	2.25	1	0	organic bromide salt	geroprotector; intercalator; trypanocidal drug
arsenic trioxide Arsenic Trioxide: An inorganic compound with the chemical formula As2O3 that is used for the treatment of ACUTE PROMYELOCYTIC LEUKEMIA in patients who have relapsed from, or are resistant to, conventional drug therapy.	4.5	7	0
2-toluanilide 2-toluanilide: structure given in first source	2.1	1	0	benzamides; benzanilide fungicide
camptothecin NSC 100880: carboxylate (opened lactone) form of camptothecin; RN refers to (S)-isomer; structure given in first source	2.07	1	0	delta-lactone; pyranoindolizinoquinoline; quinoline alkaloid; tertiary alcohol	antineoplastic agent; EC 5.99.1.2 (DNA topoisomerase) inhibitor; genotoxin; plant metabolite
melarsonic acid melarsonic acid: RN given refers to parent cpd	3.97	5	0
ornidazole Ornidazole: A nitroimidazole antiprotozoal agent used in ameba and trichomonas infections. It is partially plasma-bound and also has radiation-sensitizing action.. ornidazole : A C-nitro compound that is 5-nitroimidazole in which the hydrogens at positions 1 and 2 are replaced by 3-chloro-2-hydroxypropyl and methyl groups, respectively. It is used in the treatment of susceptible protozoal infections and for the treatment of anaerobic bacterial infections.	3.31	1	0	C-nitro compound; imidazoles; organochlorine compound; secondary alcohol	antiamoebic agent; antibacterial drug; antiinfective agent; antiprotozoal drug; antitrichomonal drug; epitope
cl 64855 [no description available]	5.79	6	0
octylguanidine octylguanidine: RN given refers to parent cpd	2.02	1	0
melarsen oxide melarsen oxide: inhibits glutathione reductase	8.79	11	0
benzonidazole benzonidazole: used in treatment of Chagas' disease. benznidazole : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of (2-nitroimidazol-1-yl)acetic acid with the aromatic amino group of benzylamine. Used for treatment of Chagas disease.	7.48	89	0	C-nitro compound; imidazoles; monocarboxylic acid amide	antiprotozoal drug
paclitaxel Taxus: Genus of coniferous yew trees or shrubs, several species of which have medicinal uses. Notable is the Pacific yew, Taxus brevifolia, which is used to make the anti-neoplastic drug taxol (PACLITAXEL).	2.15	1	0	taxane diterpenoid; tetracyclic diterpenoid	antineoplastic agent; human metabolite; metabolite; microtubule-stabilising agent
mefloquine (-)-(11S,2'R)-erythro-mefloquine : An optically active form of [2,8-bis(trifluoromethyl)quinolin-4-yl]-(2-piperidyl)methanol having (-)-(11S,2'R)-erythro-configuration. An antimalarial agent, used in racemic form, which acts as a blood schizonticide; its mechanism of action is unknown.	2.11	1	0	[2,8-bis(trifluoromethyl)quinolin-4-yl]-(2-piperidyl)methanol	antimalarial
staurosporine [no description available]	2.15	1	0	indolocarbazole alkaloid; organic heterooctacyclic compound	apoptosis inducer; bacterial metabolite; EC 2.7.11.13 (protein kinase C) inhibitor; geroprotector
1,2-di(5-amidino-2-benzofuranyl)ethane 1,2-di(5-amidino-2-benzofuranyl)ethane: preferential inhibitor of bovine factor Xa; structure given in first source	2.03	1	0
adenosine quinquefolan B: isolated from roots of Panax quinquefolium L.; RN not in Chemline 10/87; RN from Toxlit	8.26	6	0	adenosines; purines D-ribonucleoside	analgesic; anti-arrhythmia drug; fundamental metabolite; human metabolite; vasodilator agent
efavirenz efavirenz: HIV-1 reverse transcriptase inhibitor. efavirenz : 1,4-Dihydro-2H-3,1-benzoxazin-2-one substituted at the 4 position by cyclopropylethynyl and trifluoromethyl groups (S configuration) and at the 6 position by chlorine. A non-nucleoside reverse transcriptase inhibitor with activity against HIV, it is used with other antiretrovirals for combination therapy of HIV infection.	2.1	1	0	acetylenic compound; benzoxazine; cyclopropanes; organochlorine compound; organofluorine compound	antiviral drug; HIV-1 reverse transcriptase inhibitor
propamidine propamidine: structure given in first source. propamidine : A polyether that is the bis(4-guanidinophenyl) ether of propane-1,3-diol. Used (as its isethionate salt) for the treatment of minor eye or eyelid infections, such as conjunctivitis and blepharitis.	2.01	1	0	aromatic ether; guanidines; polyether	antimicrobial agent; antiseptic drug
arctigenin arctigenin: precursor to catechols; in many plants	2.58	2	0	lignan
epigallocatechin gallate epigallocatechin gallate: a steroid 5alpha-reductase inhibitor and antimutagen in green tea (Camellia sinensis). (-)-epigallocatechin 3-gallate : A gallate ester obtained by the formal condensation of gallic acid with the (3R)-hydroxy group of (-)-epigallocatechin.	2.05	1	0	flavans; gallate ester; polyphenol	antineoplastic agent; antioxidant; apoptosis inducer; geroprotector; Hsp90 inhibitor; neuroprotective agent; plant metabolite
salicylhydroxamic acid [no description available]	1.96	1	0	hydroxamic acid; phenols	antibacterial drug; EC 1.11.2.2 (myeloperoxidase) inhibitor; EC 3.5.1.5 (urease) inhibitor; trypanocidal drug
triazoles Triazoles: Heterocyclic compounds containing a five-membered ring with two carbon atoms and three nitrogen atoms with the molecular formula C2H3N3.. triazoles : An azole in which the five-membered heterocyclic aromatic skeleton contains three N atoms and two C atoms.	2.15	1	0	1,2,3-triazole
talinolol [no description available]	2.52	2	0	ureas
fexinidazole fexinidazole: structure given in first source	9.41	6	0
artemisinin (+)-artemisinin : A sesquiterpene lactone obtained from sweet wormwood, Artemisia annua, which is used as an antimalarial for the treatment of multi-drug resistant strains of falciparum malaria.	3.28	5	0	organic peroxide; sesquiterpene lactone	antimalarial; plant metabolite
artemether Artemether: An artemisinin derivative that is used in the treatment of MALARIA.. artemether : An artemisinin derivative that is artemisinin in which the lactone has been converted to the corresponding lactol methyl ether. It is used in combination with lumefantrine as an antimalarial for the treatment of multi-drug resistant strains of falciparum malaria.	2.53	2	0	artemisinin derivative; cyclic acetal; organic peroxide; semisynthetic derivative; sesquiterpenoid	antimalarial
illimaquinone illimaquinone: structure given in first source; isolated from the Red Sea sponge Smenospongia; inhibits the RNase H. activity of HIV-1 reverse transcriptase	2	1	0	monohydroxy-1,4-benzoquinones; prenylquinone	metabolite
lycorine lycorine: from bulbs of LYCORIS & other plants; RN given refers to (1 alpha,2 beta)-isomer; structure in Merck Index, 9th ed, #5444. lycorine : An indolizidine alkaloid that is 3,12-didehydrogalanthan substituted by hydroxy groups at positions and 2 and a methylenedioxy group across positions 9 and 10. Isolated from Crinum asiaticum, it has been shown to exhibit antimalarial activity.	3.31	1	0	indolizidine alkaloid	anticoronaviral agent; antimalarial; plant metabolite; protein synthesis inhibitor
gentamicin c1 [no description available]	2.17	1	0
pretazettine pretazettine: potent inhibitor of viral reverse transcriptase; narcissus alkaloid; prolongs life of leukemic mice; RN given refers to (6a beta,8 beta)-isomer; structure	3.31	1	0	alkaloid
atovaquone Atovaquone: A hydroxynaphthoquinone that has antimicrobial activity and is being used in antimalarial protocols.. atovaquone : A naphthoquinone compound having a 4-(4-chlorophenyl)cyclohexyl group at the 2-position and a hydroxy substituent at the 3-position.	2.45	2	0	hydroxy-1,2-naphthoquinone
reuterin [no description available]	6.98	1	0	alpha-CH2-containing aldehyde; propanals
melarsen melarsen: product of the decomposition in aqueous solution of melarsamine HCl; RN given refers to di-Na salt; structure	2.4	2	0
cryptolepine cryptolepine: fused indole-quinoline; structure in first source; from CRYPTOLEPIS sanguinolenta. cryptolepine : An organic heterotetracyclic compound that is 5H-indolo[3,2-b]quinoline in which the hydrogen at position N-5 is replaced by a methyl group.	2.05	1	0	indole alkaloid; organic heterotetracyclic compound; organonitrogen heterocyclic compound	anti-inflammatory agent; antimalarial; antineoplastic agent; cysteine protease inhibitor; plant metabolite
tetrahydroharmane [no description available]	2.05	1	0
taraxerol taraxerol: structure. taraxerol : A pentacyclic triterpenoid that is oleanan-3-ol lacking the methyl group at position 14, with an alpha-methyl substituent at position 13 and a double bond between positions 14 and 15.	2.06	1	0	pentacyclic triterpenoid; secondary alcohol	metabolite
lupenone lupenone: structure in first source	2.06	1	0	triterpenoid	metabolite
isometamidium chloride isometamidium chloride: Samorin & Veridium are tradenames	3.37	7	0	organic molecular entity
taraxerone taraxerone: structure	2.06	1	0	scalarane sesterterpenoid	metabolite
glucuronic acid Glucuronic Acid: A sugar acid formed by the oxidation of the C-6 carbon of GLUCOSE. In addition to being a key intermediate metabolite of the uronic acid pathway, glucuronic acid also plays a role in the detoxification of certain drugs and toxins by conjugating with them to form GLUCURONIDES.. D-glucuronic acid : The D-enantiomer of glucuronic acid.. D-glucopyranuronic acid : A D-glucuronic acid in cyclic pyranose form.	2	1	0	D-glucuronic acid	algal metabolite
methyl 5-nitro-2-furoate [no description available]	2.44	2	0	carboxylic ester
n',n'-dibenzylbenzohydrazide [no description available]	2.07	1	0
2-methyl-1,2,3,4-tetrahydroquinoline 2-methyl-1,2,3,4-tetrahydroquinoline: found in brains of Parkinson patients	2.05	1	0
hippadine hippadine: isolated from Crinum bulbs	3.31	1	0
parthenolide [no description available]	2.17	1	0	germacranolide
trypanothione trypanothione disulfide : An organic disulfide resulting from the formal oxidative coupling of the thiol groups of N(1),N(8)-bis(glutathionyl)-spermidine from the insect-parasitic trypanosomatid Crithidia fasciculata.	2.01	1	0	organic disulfide
basic blue 3 Basic Blue 3: structure in first source	2.04	1	0
mk 436 MK 436: structure	3.49	2	0
quinapyramine quinapyramine: RN given refers to hydride; structure	2.37	2	0
peroxynitrous acid Peroxynitrous Acid: A potent oxidant synthesized by the cell during its normal metabolism. Peroxynitrite is formed from the reaction of two free radicals, NITRIC OXIDE and the superoxide anion (SUPEROXIDES).	2.04	1	0	nitrogen oxoacid
melarsomine dihydrochloride [no description available]	4.19	5	0
e 64 E 64: cysteine protease inhibitor of microbial origin, which inhibits cathepsin B (EC 3.4.22.1) and cathepsin L (EC 3.4.22.-)	2.46	2	0	dicarboxylic acid monoamide; epoxy monocarboxylic acid; guanidines; L-leucine derivative; zwitterion	antimalarial; antiparasitic agent; protease inhibitor
furamidine furamidine: RN given refers to parent cpd; WR 199385 refers to di-HCl; pafuramidine is a prodrug of this	3.56	8	0
ro 15-0216 [no description available]	2.39	2	0
2-(4-amidinophenyl)-1-benzofuran-5-carboxamidine 2-(4-amidinophenyl)-1-benzofuran-5-carboxamidine: structure given in first source	2.04	1	0
levofloxacin Levofloxacin: The L-isomer of Ofloxacin.. levofloxacin : An optically active form of ofloxacin having (S)-configuration; an inhibitor of bacterial topoisomerase IV and DNA gyrase.	2.15	1	0	9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid; fluoroquinolone antibiotic; quinolone antibiotic	antibacterial drug; DNA synthesis inhibitor; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; topoisomerase IV inhibitor
cryptolepine monohydrochloride [no description available]	2.44	2	0
cyc 202 seliciclib : 2,6-Diaminopurine carrying benzylamino, (2R)-1-hydroxybutan-2-yl and isopropyl substituents at C-6, C-2-N and N-9 respectively. It is an experimental drug candidate in the family of pharmacological cyclin-dependent kinase (CDK) inhibitors.	2.13	1	0	2,6-diaminopurines	antiviral drug; EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
7,8-dihydro-5,6-dehydrokawain 7,8-dihydro-5,6-dehydrokawain: from Alpinia speciosa rhizoma; structure given in first source	2.07	1	0	2-pyranones; aromatic ether
4,5-dibromo-2-pyrrolic acid 4,5-dibromo-2-pyrrolic acid: isol from marine sponge Agelas flabelliformis; structure given in first source	2.03	1	0
4-methoxy-1-vinylcarboline [no description available]	2.05	1	0
ancistrocladidine ancistrocladidine: RN given for unspecified stereoisomer; structure in first source	2.02	1	0
etravirine [no description available]	2.1	1	0	aminopyrimidine; aromatic ether; dinitrile; organobromine compound	antiviral agent; HIV-1 reverse transcriptase inhibitor
bisdethiobis(methylthio)gliotoxin bisdethiobis(methylthio)gliotoxin: structure given in first source; a platelet activating factor antagonist	2.05	1	0
lapatinib [no description available]	2.08	1	0	furans; organochlorine compound; organofluorine compound; quinazolines	antineoplastic agent; tyrosine kinase inhibitor
dapivirine Dapivirine: effectively prevented human immunodeficiency virus (HIV) infection in cocultures of monocyte-derived dendritic cells and T cells, representing primary targets in sexual transmission	2.1	1	0
1-(benzenesulfonyl)indole [no description available]	2.15	1	0	sulfonamide
2-guanidine-4-methylquinazoline 2-guanidine-4-methylquinazoline: structure given in first source	2.05	1	0
isocryptolepine isocryptolepine: synthetic antimalarial alkaloid; structure in first source	2.05	1	0
neocryptolepine neocryptolepine: isolated from the roots of the African plant Cryptolepis sanguinolenta; structure in first source	2.47	2	0
korupensamine-b korupensamine A: from Ancistrocladus and triphyophyllum; structure in first source	2.46	2	0	isoquinolines; naphthalenes
crinine crinine: structure in first source	3.31	1	0	alkaloid
4-(3-(2-nitro-1-imidazolyl)-propylamino)-7-chloroquinoline hydrochloride 4-(3-(2-nitro-1-imidazolyl)-propylamino)-7-chloroquinoline hydrochloride: structure in first source	2.5	2	0
puromycin [no description available]	2.55	2	0	puromycins	antiinfective agent; antimicrobial agent; antineoplastic agent; EC 3.4.11.14 (cytosol alanyl aminopeptidase) inhibitor; EC 3.4.14.2 (dipeptidyl-peptidase II) inhibitor; nucleoside antibiotic; protein synthesis inhibitor
quinidine Quinidine: An optical isomer of quinine, extracted from the bark of the CHINCHONA tree and similar plant species. This alkaloid dampens the excitability of cardiac and skeletal muscles by blocking sodium and potassium currents across cellular membranes. It prolongs cellular ACTION POTENTIALS, and decreases automaticity. Quinidine also blocks muscarinic and alpha-adrenergic neurotransmission.. quinidine : A cinchona alkaloid consisting of cinchonine with the hydrogen at the 6-position of the quinoline ring substituted by methoxy.	2.21	1	0	cinchona alkaloid	alpha-adrenergic antagonist; anti-arrhythmia drug; antimalarial; drug allergen; EC 1.14.13.181 (13-deoxydaunorubicin hydroxylase) inhibitor; EC 3.6.3.44 (xenobiotic-transporting ATPase) inhibitor; muscarinic antagonist; P450 inhibitor; potassium channel blocker; sodium channel blocker
hemanthamine [no description available]	3.31	1	0	alkaloid
hippeastrine hippeastrine: isolated from Amaryllidaceae; structure given in first source; RN given refers to (5alpha)-isomer. hippeastrine : An indole alkaloid isolated from the Amaryllidaceae family and has been shown to exhibit cytotoxic activity.	3.31	1	0	delta-lactone; indole alkaloid; organic heteropentacyclic compound; secondary alcohol	antineoplastic agent; metabolite
acriflavine Acriflavine: 3,6-Diamino-10-methylacridinium chloride mixt. with 3,6-acridinediamine. Fluorescent dye used as a local antiseptic and also as a biological stain. It intercalates into nucleic acids thereby inhibiting bacterial and viral replication.	1.97	1	0
pancracine pancracine: structure in first source	3.31	1	0	isoquinoline alkaloid fundamental parent; isoquinoline alkaloid
pseudolycorine pseudolycorine: alkaloid isolated from Narcissus tazetta var. chinensis Roem, N. papyraceus or Lycoris radiata Herb; structure in first source	3.31	1	0	phenanthridines
sanguinine sanguinine: from Amaryllidaceae; structure in first source	3.31	1	0	benzazepine
dioncophylline a dioncophylline A: derived from the tropical vine Triphyophyllum peltatum; structure given in first source. dioncophylline A : An isoquinoline alkaloid that is the biaryl resulting from substitution of the hydrogen at the 7-position of (1R,3R)-1,3-dimethyl-1,2,3,4-tetrahydroisoquinolin-8-ol by a 4,5-dimethoxy-2-methylnaphthalen-1-yl group. It is a naphthylisoquinoline alkaloid isolated from the roots and stem barks of Triphyophyllum peltatum and exhibits antifungal, antimalarial, antineoplastic and molluscicidal activites.	2.15	1	0	biaryl; isoquinoline alkaloid; isoquinolines; methoxynaphthalene; methylnaphthalenes; naphthalenes	antifungal agent; antimalarial; metabolite; molluscicide
dioncophylline c dioncophylline C: structure given in first source. dioncophylline C : An isoquinoline alkaloid that is the biaryl resulting from substitution of the hydrogen at the 5-position of (1R,3R)-1,3-dimethyl-1,2,3,4-tetrahydroisoquinolin-8-ol by a 5-hydroxy-4-methoxy-2-methylnaphthalen-1-yl group. It is a naphthylisoquinoline alkaloid isolated from the roots and stem barks of Triphyophyllum peltatum and exhibits antimalarial activity.	2.15	1	0	aromatic ether; biaryl; isoquinoline alkaloid; isoquinolines; methoxynaphthalene; methylnaphthalenes; naphthols	antimalarial; antiplasmodial drug; metabolite
betadex beta-Cyclodextrins: Cyclic GLUCANS consisting of seven (7) glucopyranose units linked by 1,4-glycosidic bonds.	2.46	2	0	cyclodextrin
tretinoin Tretinoin: An important regulator of GENE EXPRESSION during growth and development, and in NEOPLASMS. Tretinoin, also known as retinoic acid and derived from maternal VITAMIN A, is essential for normal GROWTH; and EMBRYONIC DEVELOPMENT. An excess of tretinoin can be teratogenic. It is used in the treatment of PSORIASIS; ACNE VULGARIS; and several other SKIN DISEASES. It has also been approved for use in promyelocytic leukemia (LEUKEMIA, PROMYELOCYTIC, ACUTE).. retinoic acid : A retinoid consisting of 3,7-dimethylnona-2,4,6,8-tetraenoic acid substituted at position 9 by a 2,6,6-trimethylcyclohex-1-en-1-yl group (geometry of the four exocyclic double bonds is not specified).. all-trans-retinoic acid : A retinoic acid in which all four exocyclic double bonds have E- (trans-) geometry.	3.5	2	0	retinoic acid; vitamin A	anti-inflammatory agent; antineoplastic agent; antioxidant; AP-1 antagonist; human metabolite; keratolytic drug; retinoic acid receptor agonist; retinoid X receptor agonist; signalling molecule
pa 824 pretomanid: nitroimidazopyran derived from 5-nitroimidazoles; a prodrug that requires activation by a bacterial F420-depedent glucose-6-phosphate dehydrogenase (Fgd) and nitroreductase to activate components that then inhibit bacterial mycolic acid and protein synthesis; structure in first source	2.15	1	0
ketoconazole (2R,4S)-ketoconazole : A cis-1-acetyl-4-(4-{[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazine which dioxolane moiety has (2R,4S)-configuration.	2.21	1	0	cis-1-acetyl-4-(4-{[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazine
melphalan Melphalan: An alkylating nitrogen mustard that is used as an antineoplastic in the form of the levo isomer - MELPHALAN, the racemic mixture - MERPHALAN, and the dextro isomer - MEDPHALAN; toxic to bone marrow, but little vesicant action; potential carcinogen.. melphalan : A phenylalanine derivative comprising L-phenylalanine having [bis(2-chloroethyl)amino group at the 4-position on the phenyl ring.	2.15	1	0	L-phenylalanine derivative; nitrogen mustard; non-proteinogenic L-alpha-amino acid; organochlorine compound	alkylating agent; antineoplastic agent; carcinogenic agent; drug allergen; immunosuppressive agent
posaconazole [no description available]	2.59	2	0	aromatic ether; conazole antifungal drug; N-arylpiperazine; organofluorine compound; oxolanes; triazole antifungal drug; triazoles	trypanocidal drug
pmx 464 PMX 464: induces Nrf2; structure in first source	2.07	1	0
3,3',4,5'-tetrahydroxystilbene 3,3',4,5'-tetrahydroxystilbene: demethyl derivative of isorhapontigenin; structure in first source; a Syk kinase inhibitor; found in heartwood of FABACEAE; inhibitor of photosynthesis in spinach chloroplasts; may be inhibitor of plant growth; RN given refers to (E)-isomer. piceatannol : A stilbenol that is trans-stilbene in which one of the phenyl groups is substituted by hydroxy groups at positions 3 and 4, while the other phenyl group is substituted by hydroxy groups at positions 3 and 5.	2.01	1	0	catechols; polyphenol; resorcinols; stilbenol	antineoplastic agent; apoptosis inducer; geroprotector; hypoglycemic agent; plant metabolite; protein kinase inhibitor; tyrosine kinase inhibitor
uc-781 [no description available]	2.1	1	0
quinine [no description available]	2.02	1	0	cinchona alkaloid	antimalarial; muscle relaxant; non-narcotic analgesic
7-deacetylgedunin 7-deacetylgedunin : A limonoid that is the 7-deacetyl derivative of gedunin. It has been isolated from Azadirachta indica.	2.03	1	0	cyclic terpene ketone; delta-lactone; enone; epoxide; furans; limonoid; pentacyclic triterpenoid	anti-inflammatory agent; antimalarial; metabolite; plant metabolite
ungeremine [no description available]	3.31	1	0	organic molecular entity	metabolite
naphthoquinones Naphthoquinones: Naphthalene rings which contain two ketone moieties in any position. They can be substituted in any position except at the ketone groups.	1.95	1	0
5,6-dehydrokawain 5,6-dehydrokawain: from Alpinia speciosa rhizoma; RN given for cpd without isomeric designation; structure given in first source	2.07	1	0	2-pyranones; aromatic ether
scopoletin [no description available]	2.06	1	0	hydroxycoumarin	plant growth regulator; plant metabolite
amphotericin b Amphotericin B: Macrolide antifungal antibiotic produced by Streptomyces nodosus obtained from soil of the Orinoco river region of Venezuela.. amphotericin B : A macrolide antibiotic used to treat potentially life-threatening fungal infections.	3.45	7	0	antibiotic antifungal drug; macrolide antibiotic; polyene antibiotic	antiamoebic agent; antiprotozoal drug; bacterial metabolite
pyrantel pamoate Pyrantel Pamoate: Broad spectrum antinematodal anthelmintic used also in veterinary medicine.	3.06	1	0	organic molecular entity
harman harman: a beta-carboline; RN given refers to parent cpd; structure. harman : An indole alkaloid fundamental parent with a structure of 9H-beta-carboline carrying a methyl substituent at C-1. It has been isolated from the bark of Sickingia rubra, Symplocus racemosa, Passiflora incarnata, Peganum harmala, Banisteriopsis caapi and Tribulus terrestris, as well as from tobacco smoke. It is a specific, reversible inhibitor of monoamine oxidase A.	2.05	1	0	harmala alkaloid; indole alkaloid fundamental parent; indole alkaloid	anti-HIV agent; EC 1.4.3.4 (monoamine oxidase) inhibitor; plant metabolite
eupatoriopicrine [no description available]	2.17	1	0	germacranolide
diminazene aceturate diminazene diaceturate : An N-acetylglycinate salt resulting from the reaction of diminazene with 2 mol eq. of N-acetylglycine.	3.61	9	0	N-acetylglycinate salt	antiparasitic agent; trypanocidal drug
5,7-dihydroxy-4',6-dimethoxyflavone 5,7-dihydroxy-4',6-dimethoxyflavone: from Cirsium japonicum D. C.. pectolinarigenin : A dimethoxyflavone that is the 6,4'-dimethyl ether derivative of scutellarein.	2.17	1	0	dihydroxyflavone; dimethoxyflavone	plant metabolite
tazettine tazettine: from Amaryllidaceae	3.31	1	0	indole alkaloid fundamental parent; indole alkaloid
mitoguazone Mitoguazone: Antineoplastic agent effective against myelogenous leukemia in experimental animals. Also acts as an inhibitor of animal S-adenosylmethionine decarboxylase.. mitoguazone : A hydrazone obtained by formal condensation of the two carbonyl groups of methylglyoxal with the primary amino groups of two molecules of aminoguanidine.	2.37	2	0	guanidines; hydrazone	antineoplastic agent; apoptosis inducer; EC 4.1.1.50 (adenosylmethionine decarboxylase) inhibitor
stilbamidine stilbamidine: RN given refers to parent cpd	2.01	1	0
antimony Antimony: A metallic element that has the atomic symbol Sb, atomic number 51, and atomic weight 121.75. It is used as a metal alloy and as medicinal and poisonous salts. It is toxic and an irritant to the skin and the mucous membranes.	3.46	2	0	metalloid atom; pnictogen
lichexanthone lichexanthone: a dihydropyranexanthone derived from the natural xanthone; structure in first source. lichexanthone : A member of the class of xanthones that is 9H-xanthen-9-one substituted by a hydroxy group at position 1, a methyl group at position 8 and methoxy groups at positions 3 and 6. It has been isolated from the bark of Cupania cinerea.	2.06	1	0	aromatic ether; phenols; xanthones	plant metabolite
arsenic Arsenic: A shiny gray element with atomic symbol As, atomic number 33, and atomic weight 75. It occurs throughout the universe, mostly in the form of metallic arsenides. Most forms are toxic. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), arsenic and certain arsenic compounds have been listed as known carcinogens. (From Merck Index, 11th ed)	10.41	74	3	metalloid atom; pnictogen	micronutrient
dextromethorphan Dextromethorphan: Methyl analog of DEXTRORPHAN that shows high affinity binding to several regions of the brain, including the medullary cough center. This compound is an NMDA receptor antagonist (RECEPTORS, N-METHYL-D-ASPARTATE) and acts as a non-competitive channel blocker. It is one of the widely used ANTITUSSIVES, and is also used to study the involvement of glutamate receptors in neurotoxicity.. dextromethorphan : A 6-methoxy-11-methyl-1,3,4,9,10,10a-hexahydro-2H-10,4a-(epiminoethano)phenanthrene in which the sterocenters at positions 4a, 10 and 10a have S-configuration. It is a prodrug of dextrorphan and used as an antitussive drug for suppressing cough.	2.52	2	0	6-methoxy-11-methyl-1,3,4,9,10,10a-hexahydro-2H-10,4a-(epiminoethano)phenanthrene	antitussive; environmental contaminant; neurotoxin; NMDA receptor antagonist; oneirogen; prodrug; xenobiotic
pafuramidine pafuramidine: a prodrug of furamidine	4.74	3	0
proguanil Proguanil: A biguanide compound which metabolizes in the body to form cycloguanil, an anti-malaria agent.. proguanil : A biguanide compound which has isopropyl and p-chlorophenyl substituents on the terminal N atoms. A prophylactic antimalarial drug, it works by inhibiting the enzyme dihydrofolate reductase, which is involved in the reproduction of the malaria parasites Plasmodium falciparum and P. vivax within the red blood cells.	1.95	1	0	biguanides; monochlorobenzenes	antimalarial; antiprotozoal drug; EC 1.5.1.3 (dihydrofolate reductase) inhibitor
oroidin oroidin: from marine sponges of the genus Agelas; structure in first source	2.03	1	0	pyrroles; secondary carboxamide	metabolite
selenium Selenium: An element with the atomic symbol Se, atomic number 34, and atomic weight 78.97. It is an essential micronutrient for mammals and other animals but is toxic in large amounts. Selenium protects intracellular structures against oxidative damage. It is an essential component of GLUTATHIONE PEROXIDASE.	1.98	1	0	chalcogen; nonmetal atom	micronutrient
ascofuranone ascofuranone: structure. ascofuranone : A dihydroxybenzaldehyde that is 2,4-dihydroxybenzaldehyde which is substituted by a (2E,6E)-7-[(2S)-5,5-dimethyl-4-oxotetrahydrofuran-2-yl]-3-methylocta-2,6-dien-1-yl group at position 3, chlorine at position 5, and a methyl group at position 6. A meroterpenoid produced by the soil fungus, Acremonium sclerotigenum. It is a promising drug candidate against the tropical disease, African trypanosomiasis.	2.05	1	0	dihydroxybenzaldehyde; meroterpenoid; monochlorobenzenes; olefinic compound; resorcinols; sesquiterpenoid; tetrahydrofuranone	angiogenesis inhibitor; antilipemic drug; antineoplastic agent; antiprotozoal drug; fungal metabolite
nifuroxime 5-nitro-2-furaldehyde oxime: structure in first source	2.02	1	0
nifurtimox Nifurtimox: A nitrofuran thiazine that has been used against TRYPANOSOMIASIS.	15.12	37	1	nitrofuran antibiotic
db 820 [no description available]	2.05	1	0
mocetinostat mocetinostat: undergoing phase II clinical trials for treatment of cancer. mocetinostat : A benzamide obtained by formal condensation of the carboxy group of 4-({[4-(pyridin-3-yl)pyrimidin-2-yl]amino}methyl)benzoic acid with one of the amino groups of benzene-1,2-diamine. It is an orally active and isotype-selective HDAC inhibitor which exhibits antitumour activity (IC50 = 0.15, 0.29, 1.66 and 0.59 muM for HDAC1, HDAC2, HDAC3 and HDAC11).	2.04	1	0	aminopyrimidine; benzamides; pyridines; secondary amino compound; secondary carboxamide; substituted aniline	antineoplastic agent; apoptosis inducer; autophagy inducer; cardioprotective agent; EC 3.5.1.98 (histone deacetylase) inhibitor; hepatotoxic agent
ancistroealaine a ancistroealaine A: isolated from Ancistrocladus ealaensis; structure in first source. ancistrotanzanine B : An isoquinoline alkaloid that is (3S)-6,8-dimethoxy-1,3-dimethyl-3,4-dihydroisoquinoline substituted by a 4,5-dimethoxy-7-methylnaphthalen-1-yl group at position 5. It is isolated from the leaves of Ancistrocladus tanzaniensis and exhibits antiplasmodial, antileishmanial and antitrypanocidal activities.	2.7	3	0	aromatic ether; biaryl; isoquinoline alkaloid; isoquinolines; methoxynaphthalene; methylnaphthalenes	antileishmanial agent; antiplasmodial drug; metabolite; trypanocidal drug
pelorol pelorol: from the marine sponge Dactylospongia elegans & Petrosaspongia metachromia; structure in first source	2	1	0
artenimol artenimol: derivative of antimalarial drug artemisinin (quinghaosu)	2.11	1	0
spirotryprostatin a spirotryprostatin A: structure in first source	2.05	1	0
betulone [no description available]	2.06	1	0	triterpenoid	metabolite
lepadin f lepadin F: cis-decahydroquinoline alkaloid from the Australian ascidian Aplidium tabascum; structure in first source	2.01	1	0
arterolane arterolane: a trioxolane with antimalarial activity; structure in first source. arterolane : An oxaspiro compound that is dispiro[cyclohexane-1,3'-[1,2,4]trioxolane-5',2''-tricyclo[3.3.1.1(3,7)]decane] substituted by a 2-[(2-amino-2-methylpropyl)amino]-2-oxoethyl group at position 4s. Its maleic acid salt is used as an antimalarial drug in combination with piperaquine.	2.03	1	0
montanine montanine: has anxiolytic, antidepressant, and anticonvulsant activities	3.31	1	0
nystatin a1 Nystatin: Macrolide antifungal antibiotic complex produced by Streptomyces noursei, S. aureus, and other Streptomyces species. The biologically active components of the complex are nystatin A1, A2, and A3.. nystatin : A heterogeneous mixture of polyene compounds produced by cultures of Streptomyces noursei. It mainly consists of three biologically active components designated nystatin A1, nystatin A2, and nystatin A3. It is used to treat oral and dermal fungal infections.. nystatin A1 : A polyene macrolide antibiotic; part of the nystatin complex produced by several Streptomyces species. It is an antifungal antibiotic used for the treatment of topical fungal infections caused by a broad spectrum of fungal pathogens comprising yeast-like and filamentous species.	2.11	1	0	nystatins
dihydrolycorine [no description available]	3.31	1	0
rifamycins [no description available]	1.96	1	0
deoxyartemisinin [no description available]	2.03	1	0
mdl 73811 MDL 73811: structure given in first source; RN given refers to (Z)-isomer	1.98	1	0
uk 453,061 UK 453,061: a reverse transcriptase inhibitor/anti-HIV agent; structure in first source	2.1	1	0	aromatic ether
hoe 33342 bisbenzimide ethoxide trihydrochloride: benzimidazole fluorescent dye	1.97	1	0
tryparsamide tryparsamide: was MH 1963-92; use TRYPANOCIDAL AGENTS to search TRYPARSAMIDE 1966-92	2.35	2	0
6-methoxyspirotryprostatin b 6-methoxyspirotryprostatin B: cytotoxic compound from the marine-derived fungus Aspergillus sydowi; structure in first source. 6-methoxyspirotryprostatin B : An indole alkaloid isolated from a marine-derived fungal strain Aspergillus sydowii PFW1-13 and has been shown to exhibit cytotoxic activity.	2.05	1	0	aromatic ether; azaspiro compound; indole alkaloid; indolones	antineoplastic agent; Aspergillus metabolite
scyx 7158 [no description available]	2.08	1	0	(trifluoromethyl)benzenes
ddd 85646 DDD 85646: a trypanocidal agent for treating African sleeping sickness; structure in first source	2.07	1	0
marinoquinoline a marinoquinoline A: pyrroloquinoline from Ohtaekwangia kribbensis (Bacteroidetes); showed weak antibacterial and antifungal activities and moderate cytotoxicity against four growing mammalian cell lines; structure in first source. marinoquinoline A : A pyrroloquinoline that is 3H-pyrrolo[2,3-c]quinoline substituted by a methyl group at position 4. It is a natural product found in Ohtaekwangia kribbensis and Rapidithrix thailandica.	2.06	1	0	pyrroloquinoline	bacterial metabolite
heme Heme: The color-furnishing portion of hemoglobin. It is found free in tissues and as the prosthetic group in many hemeproteins.. ferroheme : Any iron(II)--porphyrin coordination complex.. ferroheme b : Heme b in which the iron has oxidation state +2.. heme : A heme is any tetrapyrrolic chelate of iron.	1.95	1	0
tetracycline Tetracycline: A naphthacene antibiotic that inhibits AMINO ACYL TRNA binding during protein synthesis.. tetracycline : A broad-spectrum polyketide antibiotic produced by the Streptomyces genus of actinobacteria.	2.17	1	0
warfarin Warfarin: An anticoagulant that acts by inhibiting the synthesis of vitamin K-dependent coagulation factors. Warfarin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, pulmonary embolism, and atrial fibrillation with embolization. It is also used as an adjunct in the prophylaxis of systemic embolism after myocardial infarction. Warfarin is also used as a rodenticide.. warfarin : A racemate comprising equal amounts of (R)- and (S)-warfarin. Extensively used as both an anticoagulant drug and as a pesticide against rats and mice.. 4-hydroxy-3-(3-oxo-1-phenylbutyl)-1-benzopyran-2-one : A member of the class of coumarins that is 4-hydroxycoumarin which is substituted at position 3 by a 1-phenyl-3-oxo-1-butyl group.	2.11	1	0	benzenes; hydroxycoumarin; methyl ketone
hypoxanthine [no description available]	2.68	3	0	nucleobase analogue; oxopurine; purine nucleobase	fundamental metabolite
inosine [no description available]	2.69	3	0	inosines; purines D-ribonucleoside	Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
folic acid folcysteine: used to promote fertility in chickens. vitamin B9 : Any B-vitamin that exhibits biological activity against vitamin B9 deficiency. Vitamin B9 refers to the many forms of folic acid and its derivatives, including tetrahydrofolic acid (the active form), methyltetrahydrofolate (the primary form found in blood), methenyltetrahydrofolate, folinic acid amongst others. They are present in abundance in green leafy vegetables, citrus fruits, and animal products. Lack of vitamin B9 leads to anemia, a condition in which the body cannot produce sufficient number of red blood cells. Symptoms of vitamin B9 deficiency include fatigue, muscle weakness, and pale skin.	2.6	1	0	folic acids; N-acyl-amino acid	human metabolite; mouse metabolite; nutrient
rifampin Rifampin: A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160)	2.75	3	0	cyclic ketal; hydrazone; N-iminopiperazine; N-methylpiperazine; rifamycins; semisynthetic derivative; zwitterion	angiogenesis inhibitor; antiamoebic agent; antineoplastic agent; antitubercular agent; DNA synthesis inhibitor; EC 2.7.7.6 (RNA polymerase) inhibitor; Escherichia coli metabolite; geroprotector; leprostatic drug; neuroprotective agent; pregnane X receptor agonist; protein synthesis inhibitor
dacarbazine (E)-dacarbazine : A dacarbazine in which the N=N double bond adopts a trans-configuration.	2.15	1	0	dacarbazine
aprepitant Aprepitant: A morpholine neurokinin-1 (NK1) receptor antagonist that is used in the management of nausea and vomiting caused by DRUG THERAPY, and for the prevention of POSTOPERATIVE NAUSEA AND VOMITING.. aprepitant : A morpholine-based antiemetic, which is or the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. Aprepitant is a selective high-affinity antagonist of human substance P/neurokinin 1 (NK1) receptors.	7.03	1	0	(trifluoromethyl)benzenes; cyclic acetal; morpholines; triazoles	antidepressant; antiemetic; neurokinin-1 receptor antagonist; peripheral nervous system drug; substance P receptor antagonist
db 766 [no description available]	2.1	1	0
antimony sodium gluconate Antimony Sodium Gluconate: Antimony complex where the metal may exist in either the pentavalent or trivalent states. The pentavalent gluconate is used in leishmaniasis. The trivalent gluconate is most frequently used in schistosomiasis.	2.66	3	0

Condition	Indicated	Relationship Strength	Studies	Trials
African Sleeping Sickness [description not available]	0	15.36	220	16
Trypanosomiasis, African A disease endemic among people and animals in Central Africa. It is caused by various species of trypanosomes, particularly T. gambiense and T. rhodesiense. Its second host is the TSETSE FLY. Involvement of the central nervous system produces African sleeping sickness. Nagana is a rapidly fatal trypanosomiasis of horses and other animals.	0	15.36	220	16
Infections, Plasmodium [description not available]	0	3.17	5	0
Malaria A protozoan disease caused in humans by four species of the PLASMODIUM genus: PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX; PLASMODIUM OVALE; and PLASMODIUM MALARIAE; and transmitted by the bite of an infected female mosquito of the genus ANOPHELES. Malaria is endemic in parts of Asia, Africa, Central and South America, Oceania, and certain Caribbean islands. It is characterized by extreme exhaustion associated with paroxysms of high FEVER; SWEATING; shaking CHILLS; and ANEMIA. Malaria in ANIMALS is caused by other species of plasmodia.	0	3.17	5	0
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	0	4.44	21	0
Trypanosomiasis Infection with protozoa of the genus TRYPANOSOMA.	1	8.17	33	1
Histomoniasis [description not available]	0	2.94	4	0
Plasmodium falciparum Malaria [description not available]	0	3.01	4	0
Malaria, Falciparum Malaria caused by PLASMODIUM FALCIPARUM. This is the severest form of malaria and is associated with the highest levels of parasites in the blood. This disease is characterized by irregularly recurring febrile paroxysms that in extreme cases occur with acute cerebral, renal, or gastrointestinal manifestations.	0	3.01	4	0
American Trypanosomiasis [description not available]	0	4.97	14	0
Chagas Disease Infection with the protozoan parasite TRYPANOSOMA CRUZI, a form of TRYPANOSOMIASIS endemic in Central and South America. It is named after the Brazilian physician Carlos Chagas, who discovered the parasite. Infection by the parasite (positive serologic result only) is distinguished from the clinical manifestations that develop years later, such as destruction of PARASYMPATHETIC GANGLIA; CHAGAS CARDIOMYOPATHY; and dysfunction of the ESOPHAGUS or COLON.	0	4.97	14	0
Acute Disease Disease having a short and relatively severe course.	0	2.07	1	0
Neglected Diseases Diseases that are underfunded and have low name recognition but are major burdens in less developed countries. The World Health Organization has designated six tropical infectious diseases as being neglected in industrialized countries that are endemic in many developing countries (HELMINTHIASIS; LEPROSY; LYMPHATIC FILARIASIS; ONCHOCERCIASIS; SCHISTOSOMIASIS; and TRACHOMA).	0	2.08	1	0
Black Fever [description not available]	0	2.83	3	0
Leishmaniasis, Visceral A chronic disease caused by LEISHMANIA DONOVANI and transmitted by the bite of several sandflies of the genera Phlebotomus and Lutzomyia. It is commonly characterized by fever, chills, vomiting, anemia, hepatosplenomegaly, leukopenia, hypergammaglobulinemia, emaciation, and an earth-gray color of the skin. The disease is classified into three main types according to geographic distribution: Indian, Mediterranean (or infantile), and African.	0	2.83	3	0
Parasitemia The presence of parasites (especially malarial parasites) in the blood. (Dorland, 27th ed)	0	3.3	6	0
Kahler Disease [description not available]	0	2.94	4	0
Multiple Myeloma A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY.	0	2.94	4	0
Cancer of Pancreas [description not available]	0	2.58	2	0
Pancreatic Neoplasms Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).	0	2.58	2	0
Anasarca [description not available]	0	2.48	2	0
Edema Abnormal fluid accumulation in TISSUES or body cavities. Most cases of edema are present under the SKIN in SUBCUTANEOUS TISSUE.	0	2.48	2	0
Hepatocellular Carcinoma [description not available]	0	7.6	1	0
Cancer of Liver [description not available]	0	2.6	1	0
Carcinoma, Hepatocellular A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.	0	2.6	1	0
Liver Neoplasms Tumors or cancer of the LIVER.	0	2.6	1	0
Benign Neoplasms, Brain [description not available]	0	2.52	2	0
Astrocytoma, Grade IV [description not available]	0	2.15	1	0
Brain Neoplasms Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain.	0	2.52	2	0
Glioblastoma A malignant form of astrocytoma histologically characterized by pleomorphism of cells, nuclear atypia, microhemorrhage, and necrosis. They may arise in any region of the central nervous system, with a predilection for the cerebral hemispheres, basal ganglia, and commissural pathways. Clinical presentation most frequently occurs in the fifth or sixth decade of life with focal neurologic signs or seizures.	0	7.15	1	0
Recrudescence [description not available]	0	9.83	27	4
Glial Cell Tumors [description not available]	0	2.08	1	0
Glioma Benign and malignant central nervous system neoplasms derived from glial cells (i.e., astrocytes, oligodendrocytes, and ependymocytes). Astrocytes may give rise to astrocytomas (ASTROCYTOMA) or glioblastoma multiforme (see GLIOBLASTOMA). Oligodendrocytes give rise to oligodendrogliomas (OLIGODENDROGLIOMA) and ependymocytes may undergo transformation to become EPENDYMOMA; CHOROID PLEXUS NEOPLASMS; or colloid cysts of the third ventricle. (From Escourolle et al., Manual of Basic Neuropathology, 2nd ed, p21)	0	2.08	1	0
Sensitivity and Specificity Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)	0	2.95	4	0
Insect Bites [description not available]	0	2.05	1	0
Insect Bites and Stings Bites and stings inflicted by insects.	0	2.05	1	0
Anemia, Macrocytic Anemia characterized by larger than normal erythrocytes, increased mean corpuscular volume (MCV) and increased mean corpuscular hemoglobin (MCH).	0	2.06	1	0
Thrombopenia [description not available]	0	2.06	1	0
Thrombocytopenia A subnormal level of BLOOD PLATELETS.	0	2.06	1	0
Arsenic Encephalopathy [description not available]	0	3.23	6	0
Long Sleeper Syndrome [description not available]	0	2.06	1	0
Sleep Wake Disorders Abnormal sleep-wake schedule or pattern associated with the CIRCADIAN RHYTHM which affect the length, timing, and/or rigidity of the sleep-wake cycle relative to the day-night cycle.	0	2.06	1	0
Behavior Disorders [description not available]	0	2.07	1	0
Dysesthesia [description not available]	0	2.45	2	0
Mental Disorders Psychiatric illness or diseases manifested by breakdowns in the adaptational process expressed primarily as abnormalities of thought, feeling, and behavior producing either distress or impairment of function.	0	2.07	1	0
Brain Disorders [description not available]	0	6.3	14	3
Brain Diseases Pathologic conditions affecting the BRAIN, which is composed of the intracranial components of the CENTRAL NERVOUS SYSTEM. This includes (but is not limited to) the CEREBRAL CORTEX; intracranial white matter; BASAL GANGLIA; THALAMUS; HYPOTHALAMUS; BRAIN STEM; and CEREBELLUM.	0	6.3	14	3
HIV Human immunodeficiency virus. A non-taxonomic and historical term referring to any of two species, specifically HIV-1 and/or HIV-2. Prior to 1986, this was called human T-lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV). From 1986-1990, it was an official species called HIV. Since 1991, HIV was no longer considered an official species name; the two species were designated HIV-1 and HIV-2.	0	2.93	1	0
Communicable Diseases, Emerging Infectious diseases that are novel in their outbreak ranges (geographic and host) or transmission mode.	0	3.8	2	0
Cerebromeningitis [description not available]	0	3.47	8	0
Brain Inflammation [description not available]	0	2.36	2	0
Infection [description not available]	0	1.93	1	0
Viral Diseases [description not available]	0	1.93	1	0
Coxsackie Virus Infections [description not available]	0	1.93	1	0
Encephalitis Inflammation of the BRAIN due to infection, autoimmune processes, toxins, and other conditions. Viral infections (see ENCEPHALITIS, VIRAL) are a relatively frequent cause of this condition.	0	2.36	2	0
Infections Invasion of the host organism by microorganisms or their toxins or by parasites that can cause pathological conditions or diseases.	0	1.93	1	0
Virus Diseases A general term for diseases caused by viruses.	0	1.93	1	0
Experimental Neoplasms [description not available]	0	2.02	1	0
Acanthamoeba Meningoencephalitis [description not available]	0	4.37	2	2
Bilateral Headache [description not available]	0	3.41	1	1
Lymphatic Diseases Diseases of LYMPH; LYMPH NODES; or LYMPHATIC VESSELS.	0	3.41	1	1
Itching [description not available]	0	3.41	1	1
Headache The symptom of PAIN in the cranial region. It may be an isolated benign occurrence or manifestation of a wide variety of HEADACHE DISORDERS.	0	3.41	1	1
Pruritus An intense itching sensation that produces the urge to rub or scratch the skin to obtain relief.	0	3.41	1	1
Innate Inflammatory Response [description not available]	0	2.03	1	0
Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.	0	2.03	1	0
Neuroblastoma A common neoplasm of early childhood arising from neural crest cells in the sympathetic nervous system, and characterized by diverse clinical behavior, ranging from spontaneous remission to rapid metastatic progression and death. This tumor is the most common intraabdominal malignancy of childhood, but it may also arise from thorax, neck, or rarely occur in the central nervous system. Histologic features include uniform round cells with hyperchromatic nuclei arranged in nests and separated by fibrovascular septa. Neuroblastomas may be associated with the opsoclonus-myoclonus syndrome. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2099-2101; Curr Opin Oncol 1998 Jan;10(1):43-51)	0	7.03	1	0
Nerve Root Avulsion [description not available]	0	2.03	1	0
Conus Medullaris Syndrome [description not available]	0	2.03	1	0
Demyelinative Myelitis [description not available]	0	2.03	1	0
Radiculopathy Disease involving a spinal nerve root (see SPINAL NERVE ROOTS) which may result from compression related to INTERVERTEBRAL DISK DISPLACEMENT; SPINAL CORD INJURIES; SPINAL DISEASES; and other conditions. Clinical manifestations include radicular pain, weakness, and sensory loss referable to structures innervated by the involved nerve root.	0	2.03	1	0
Exanthem [description not available]	0	2.03	1	0
Pyrexia [description not available]	0	2.68	3	0
Exanthema Diseases in which skin eruptions or rashes are a prominent manifestation. Classically, six such diseases were described with similar rashes; they were numbered in the order in which they were reported. Only the fourth (Duke's disease), fifth (ERYTHEMA INFECTIOSUM), and sixth (EXANTHEMA SUBITUM) numeric designations survive as occasional synonyms in current terminology.	0	2.03	1	0
Fever An abnormal elevation of body temperature, usually as a result of a pathologic process.	0	2.68	3	0
Disease Exacerbation [description not available]	0	2.03	1	0
As If Personality [description not available]	0	2.03	1	0
Cardiac Diseases [description not available]	0	3.77	2	1
Heart Diseases Pathological conditions involving the HEART including its structural and functional abnormalities.	0	3.77	2	1
Parasite Infections [description not available]	0	2.87	1	0
Anguilluliasis [description not available]	0	1.98	1	0
Strongyloidiasis Infection with nematodes of the genus STRONGYLOIDES. The presence of larvae may produce pneumonitis and the presence of adult worms in the intestine could lead to moderate to severe diarrhea.	0	1.98	1	0
Agitation, Psychomotor [description not available]	0	1.98	1	0
Psychomotor Agitation A feeling of restlessness associated with increased motor activity. This may occur as a manifestation of nervous system drug toxicity or other conditions.	0	1.98	1	0
Cerebellar Diseases Diseases that affect the structure or function of the cerebellum. Cardinal manifestations of cerebellar dysfunction include dysmetria, GAIT ATAXIA, and MUSCLE HYPOTONIA.	0	1.98	1	0
Benign Infantile Myoclonic Epilepsy [description not available]	0	1.98	1	0
Epilepsies, Myoclonic A clinically diverse group of epilepsy syndromes characterized either by myoclonic seizures or by myoclonus in association with other seizure types. Myoclonic epilepsy syndromes are divided into three subtypes based on etiology: familial, cryptogenic, and symptomatic.	0	1.98	1	0
Central Nervous System Disease [description not available]	0	3.99	5	0
Central Nervous System Diseases Diseases of any component of the brain (including the cerebral hemispheres, diencephalon, brain stem, and cerebellum) or the spinal cord.	0	3.99	5	0
Hypergonadotropic Hypogonadism [description not available]	0	1.98	1	0
Anemia A reduction in the number of circulating ERYTHROCYTES or in the quantity of HEMOGLOBIN.	0	1.98	1	0
Hypogonadism Condition resulting from deficient gonadal functions, such as GAMETOGENESIS and the production of GONADAL STEROID HORMONES. It is characterized by delay in GROWTH, germ cell maturation, and development of secondary sex characteristics. Hypogonadism can be due to a deficiency of GONADOTROPINS (hypogonadotropic hypogonadism) or due to primary gonadal failure (hypergonadotropic hypogonadism).	0	1.98	1	0
Enlarged Liver [description not available]	0	1.98	1	0
Idiopathic Inflammatory Myopathies [description not available]	0	1.98	1	0
Polyneuropathy, Acquired [description not available]	0	1.98	1	0
Enlarged Spleen [description not available]	0	1.98	1	0
Myositis Inflammation of a muscle or muscle tissue.	0	1.98	1	0
Polyneuropathies Diseases of multiple peripheral nerves simultaneously. Polyneuropathies usually are characterized by symmetrical, bilateral distal motor and sensory impairment with a graded increase in severity distally. The pathological processes affecting peripheral nerves include degeneration of the axon, myelin or both. The various forms of polyneuropathy are categorized by the type of nerve affected (e.g., sensory, motor, or autonomic), by the distribution of nerve injury (e.g., distal vs. proximal), by nerve component primarily affected (e.g., demyelinating vs. axonal), by etiology, or by pattern of inheritance.	0	1.98	1	0
Infectious Diseases [description not available]	0	1.98	1	0
Communicable Diseases An illness caused by an infectious agent or its toxins that occurs through the direct or indirect transmission of the infectious agent or its products from an infected individual or via an animal, vector or the inanimate environment to a susceptible animal or human host.	0	1.98	1	0
B-Cell Chronic Lymphocytic Leukemia [description not available]	0	3.79	2	1
Leukemia, Lymphocytic, Chronic, B-Cell A chronic leukemia characterized by abnormal B-lymphocytes and often generalized lymphadenopathy. In patients presenting predominately with blood and bone marrow involvement it is called chronic lymphocytic leukemia (CLL); in those predominately with enlarged lymph nodes it is called small lymphocytic lymphoma. These terms represent spectrums of the same disease.	0	3.79	2	1
Pachymeningitis [description not available]	0	1.99	1	0
Meningitis Inflammation of the coverings of the brain and/or spinal cord, which consist of the PIA MATER; ARACHNOID; and DURA MATER. Infections (viral, bacterial, and fungal) are the most common causes of this condition, but subarachnoid hemorrhage (HEMORRHAGES, SUBARACHNOID), chemical irritation (chemical MENINGITIS), granulomatous conditions, neoplastic conditions (CARCINOMATOUS MENINGITIS), and other inflammatory conditions may produce this syndrome. (From Joynt, Clinical Neurology, 1994, Ch24, p6)	0	1.99	1	0
Granulocytic Leukemia [description not available]	0	1.99	1	0
Acute Promyelocytic Leukemia [description not available]	0	3.32	2	0
Leukemia, Myeloid Form of leukemia characterized by an uncontrolled proliferation of the myeloid lineage and their precursors (MYELOID PROGENITOR CELLS) in the bone marrow and other sites.	0	1.99	1	0
Leukemia, Promyelocytic, Acute An acute myeloid leukemia in which abnormal PROMYELOCYTES predominate. It is frequently associated with DISSEMINATED INTRAVASCULAR COAGULATION.	0	3.32	2	0
Leucocythaemia [description not available]	0	3.38	1	1
Granulocytic Leukemia, Chronic [description not available]	0	3.38	1	1
Acute Myelogenous Leukemia [description not available]	0	3.38	1	1
Leukemia A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006)	0	8.38	1	1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive Clonal hematopoetic disorder caused by an acquired genetic defect in PLURIPOTENT STEM CELLS. It starts in MYELOID CELLS of the bone marrow, invades the blood and then other organs. The condition progresses from a stable, more indolent, chronic phase (LEUKEMIA, MYELOID, CHRONIC PHASE) lasting up to 7 years, to an advanced phase composed of an accelerated phase (LEUKEMIA, MYELOID, ACCELERATED PHASE) and BLAST CRISIS.	0	3.38	1	1
Leukemia, Myeloid, Acute Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES.	0	3.38	1	1
Breast Cancer [description not available]	0	2	1	0
Cancer of Prostate [description not available]	0	2	1	0
Breast Neoplasms Tumors or cancer of the human BREAST.	0	2	1	0
Prostatic Neoplasms Tumors or cancer of the PROSTATE.	0	2	1	0
Cholera Infantum [description not available]	0	2.91	1	0
Leukocytosis A transient increase in the number of leukocytes in a body fluid.	0	2.91	1	0
Benign Neoplasms [description not available]	0	2.91	1	0
Nervous System Disorders [description not available]	0	2.91	1	0
Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.	0	2.91	1	0
Nervous System Diseases Diseases of the central and peripheral nervous system. This includes disorders of the brain, spinal cord, cranial nerves, peripheral nerves, nerve roots, autonomic nervous system, neuromuscular junction, and muscle.	0	2.91	1	0
Symptom Cluster [description not available]	0	3.39	1	1
Syndrome A characteristic symptom complex.	0	8.39	1	1
Absence Seizure [description not available]	0	2.36	2	0
Diarrhea An increased liquidity or decreased consistency of FECES, such as running stool. Fecal consistency is related to the ratio of water-holding capacity of insoluble solids to total water, rather than the amount of water present. Diarrhea is not hyperdefecation or increased fecal weight.	0	3.28	2	0
Seizures Clinical or subclinical disturbances of cortical function due to a sudden, abnormal, excessive, and disorganized discharge of brain cells. Clinical manifestations include abnormal motor, sensory and psychic phenomena. Recurrent seizures are usually referred to as EPILEPSY or seizure disorder.	0	2.36	2	0
Trypanosomiasis, Bovine Infection in cattle caused by various species of trypanosomes.	0	2.87	1	0
A-V Dissociation [description not available]	0	2.36	2	0
Carditis [description not available]	0	1.95	1	0
Pleuropericarditis Inflammation of both the PERICARDIUM and the PLEURA.	0	1.95	1	0
Erythema Multiforme A skin and mucous membrane disease characterized by an eruption of macules, papules, nodules, vesicles, and/or bullae with characteristic bull's-eye lesions usually occurring on the dorsal aspect of the hands and forearms.	0	1.95	1	0
Myocarditis Inflammatory processes of the muscular walls of the heart (MYOCARDIUM) which result in injury to the cardiac muscle cells (MYOCYTES, CARDIAC). Manifestations range from subclinical to sudden death (DEATH, SUDDEN). Myocarditis in association with cardiac dysfunction is classified as inflammatory CARDIOMYOPATHY usually caused by INFECTION, autoimmune diseases, or responses to toxic substances. Myocarditis is also a common cause of DILATED CARDIOMYOPATHY and other cardiomyopathies.	0	1.95	1	0
Pericarditis Inflammation of the PERICARDIUM from various origins, such as infection, neoplasm, autoimmune process, injuries, or drug-induced. Pericarditis usually leads to PERICARDIAL EFFUSION, or CONSTRICTIVE PERICARDITIS.	0	1.95	1	0
Dirofilariasis Infection with nematodes of the genus DIROFILARIA, usually in animals, especially dogs, but occasionally in man.	0	1.95	1	0
Peripheral Nerve Diseases [description not available]	0	1.97	1	0
Autoimmune Demyelinating Disease, Peripheral [description not available]	0	2.37	2	0
Peripheral Nervous System Diseases Diseases of the peripheral nerves external to the brain and spinal cord, which includes diseases of the nerve roots, ganglia, plexi, autonomic nerves, sensory nerves, and motor nerves.	0	1.97	1	0
Elaeophoriasis [description not available]	0	1.97	1	0
Leishmania Infection [description not available]	0	1.97	1	0
Filariasis Infections with nematodes of the superfamily FILARIOIDEA. The presence of living worms in the body is mainly asymptomatic but the death of adult worms leads to granulomatous inflammation and permanent fibrosis. Organisms of the genus Elaeophora infect wild elk and domestic sheep causing ischemic necrosis of the brain, blindness, and dermatosis of the face.	0	1.97	1	0
Leishmaniasis A disease caused by any of a number of species of protozoa in the genus LEISHMANIA. There are four major clinical types of this infection: cutaneous (Old and New World) (LEISHMANIASIS, CUTANEOUS), diffuse cutaneous (LEISHMANIASIS, DIFFUSE CUTANEOUS), mucocutaneous (LEISHMANIASIS, MUCOCUTANEOUS), and visceral (LEISHMANIASIS, VISCERAL).	1	3.97	1	0
Coma A profound state of unconsciousness associated with depressed cerebral activity from which the individual cannot be aroused. Coma generally occurs when there is dysfunction or injury involving both cerebral hemispheres or the brain stem RETICULAR FORMATION.	0	3.36	1	1
Caprine Diseases [description not available]	0	1.97	1	0

melarsoprol

Description

Cross-References

Synonyms (34)

Research Excerpts

Overview

Effects

Treatment

Toxicity

Pharmacokinetics

Compound-Compound Interactions

Bioavailability

Dosage Studied

Drug Classes (1)

Bioassays (378)

Research

Studies (432)

Market Indicators

Research Demand Index: 57.02

Study Types

Clinical Trials (1)

Trial Overview

melarsoprol

Description

Cross-References

Synonyms (34)

Research Excerpts

Overview

Effects

Treatment

Toxicity

Pharmacokinetics

Compound-Compound Interactions

Bioavailability

Dosage Studied

Drug Classes (1)

Bioassays (378)

Research

Studies (432)

Market Indicators

Research Demand Index: 57.02

Study Types

Clinical Trials (1)

Trial Overview

Related Drugs (242)

Related Conditions (146)